

NEIGHBORHOOD DEVELOPMENT FUND
Not-for-Profit Transmittal and Approval Form

Applicant/Program: The Leukemia & Lymphoma Society/ Light the Night

Applicant Requested Amount: \$50,000

Appropriation Request Amount: \$5,950

Executive Summary of Request

Light the Night is the annual fundraising event for the Leukemia & Lymphoma Society. Funds raised from this event support lifesaving research and support for people battling cancer. Friends, families, co-workers and the public are invited to enjoy this free event on October 10, 2019 at Louisville Slugger Field featuring live music, booths, health and wellness fair, a non-denominational remembrance ceremony, and the evening walk.

Is this program/project a fundraiser?

☒ Yes

☐ No

Is this applicant a faith based organization?

☐ Yes

☒ No

Does this application include funding for sub-grantee(s)?

☐ Yes

☒ No

I have reviewed the attached Neighborhood Development Fund Application and have found it complete and within Metro Council guidelines and request approval of funding in the following amount(s). I have read the organization's statement of public purpose to be furthered by the funds requested and I agree that the public purpose is legitimate. I have also completed the disclosure section below, if required.

12
District #

Rail Bhargava
Primary Sponsor Signature

\$1500.00
Amount

1500.00 7/24/19
Date

Primary Sponsor Disclosure

List below any personal or business relationship you, your family or your legislative assistant have with this organization, its volunteers, its employees or members of its board of directors.

Approved by:

Appropriations Committee Chairman

Date

Final Appropriations Amount: _____

Applicant/Program:

Leukemia+Lymphoma Society / Light the Night

Additional Disclosure and Signatures

Additional Council Office Disclosure

List below any personal or business relationship you, your family or your legislative assistant have with this organization, its volunteers, its employees or members of its board of directors.

Council Member Signature and Amount

District 1		\$
District 2	Barbara Shoulkin	\$ 1,000
District 3		\$
District 4		\$
District 5		\$
District 6		\$
District 7		\$
District 8		\$
District 9		\$
District 10	Anna P. Malvick	\$ 1000
District 11		\$
District 12		\$
District 13		\$
District 14		\$
District 15	Jim Logan	\$ 500

Applicant/Program:

Leukemia+ Lymphoma Society/ Light the Night

Additional Disclosure and Signatures

Additional Council Office Disclosure

List below any personal or business relationship you, your family or your legislative assistant have with this organization, its volunteers, its employees or members of its board of directors.

District 16 _____ \$ _____

District 17  _____ \$ 250⁰⁰

District 18 _____ \$ _____


District 19 _____ \$ _____

District 20 _____ \$ _____

District 21  _____ \$ 200⁰⁰

District 22 _____ \$ _____

District 23 _____ \$ _____

District 24  _____ \$ 1500⁰⁰


District 25 _____ \$ _____

District 26 _____ \$ _____

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

Legal Name of Applicant Organization The Leukemia & Lymphoma Society

Program Name and Request Amount Light the Night - \$50,000

	Yes/No/NA
Is the NDF Transmittal Sheet Signed by all Council Member(s) Appropriating Funding?	<input checked="" type="checkbox"/> Yes
Is the funding proposed by Council Member(s) less than or equal to the request amount?	<input checked="" type="checkbox"/> Yes
Is the proposed public purpose of the program viable and well-documented?	<input checked="" type="checkbox"/> Yes
Will all of the funding go to programs specific to Louisville/Jefferson County?	<input checked="" type="checkbox"/> Yes
Has Council or Staff relationship to the Agency been adequately disclosed on the cover sheet?	<input checked="" type="checkbox"/> Yes
Has prior Metro Funds committed/granted been disclosed?	<input checked="" type="checkbox"/> Yes
Is the application properly signed and dated by authorized signatory?	<input checked="" type="checkbox"/> Yes
Is proof of Tax Exempt status of 501(c) 3, 4, 6, 19, 1120-H included?	<input checked="" type="checkbox"/> Yes
If Metro funding is for a separate taxing district is the funding appropriated for a program outside the legal responsibility of that taxing district?	<input type="checkbox"/> N/A
Is the entity in good standing with: <ul style="list-style-type: none"> ▸ Kentucky Secretary of State? ▸ Louisville Metro Revenue Commission? ▸ Louisville Metro Government? ▸ Internal Revenue Service? ▸ Louisville Metro Human Relations Commission? 	<input checked="" type="checkbox"/> Yes
Is the current Fiscal Year Budget included?	<input checked="" type="checkbox"/> Yes
Is the entity's board member list (with term length/term limits) included?	<input checked="" type="checkbox"/> Yes
Is recommended funding less than 33% of total agency operating budget?	<input checked="" type="checkbox"/> Yes
Does the application budget reflect only the revenue and expenses of the project/program?	<input checked="" type="checkbox"/> Yes
Is the cost estimate(s) from proposed vendor (if request is for capital expense) included?	<input type="checkbox"/> N/A
Is the most recent annual audit (if required by organization) included?	<input checked="" type="checkbox"/> Yes
Is a copy of Signed Lease (if rent costs are requested) included?	<input checked="" type="checkbox"/> Yes
Is the Supplemental Questionnaire for churches/religious organizations (if requesting organization is faith-based) included?	<input type="checkbox"/> N/A
Are the Articles of Incorporation of the Agency included?	<input checked="" type="checkbox"/> Yes
Is the IRS Form W-9 included?	<input checked="" type="checkbox"/> Yes
Is the IRS Form 990 included?	<input checked="" type="checkbox"/> Yes
Are the evaluation forms (if program participants are given evaluation forms) included?	<input type="checkbox"/> N/A
Affirmative Action/Equal Employment Opportunity plan and/or policy statement included (if required to do so)?	<input type="checkbox"/> N/A
Has the Agency agreed to participate in the BBB Charity review program? If so, has the applicant met the BBB Charity Review Standards?	<input checked="" type="checkbox"/> Yes
Prepared by: 	Date: 8/1/19

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 1 – APPLICANT INFORMATION			
Legal Name of Applicant Organization: The Leukemia & Lymphoma Society <i>(as listed on: http://www.sos.ky.gov/business/records)</i>			
Main Office Street & Mailing Address: 301 East Main Street, Suite 100, Louisville, KY 40202			
Website: www.lls.org/ky			
Applicant Contact:	Deanna Keal	Title:	Campaign Director
Phone:	502-719-0546	Email:	deanna.keal@lls.org
Financial Contact:	Deanna Keal	Title:	Campaign Director
Phone:	502-719-0546	Email:	deanna.keal@lls.org
Organization's Representative who attended NDF Training: Erika Furlong/Deanna Keal			
GEOGRAPHICAL AREA(S) WHERE PROGRAM ACTIVITIES ARE (WILL BE) PROVIDED			
Program Facility Location(s):	Louisville Slugger Field		
Council District(s):	4	Zip Code(s):	40202
SECTION 2 – PROGRAM REQUEST & FINANCIAL INFORMATION			
PROGRAM/PROJECT NAME: The Leukemia & Lymphoma Society - Light The Night			
Total Request: (\$)	50,000	Total Metro Award (this program) in previous year: (\$)	22,050
Purpose of Request (check all that apply):			
<input checked="" type="checkbox"/> Operating Funds (generally cannot exceed 33% of agency's total operating budget) <input checked="" type="checkbox"/> Programming/services/events for direct benefit to community or qualified individuals <input type="checkbox"/> Capital Project of the organization (equipment, furnishing, building, etc)			
The Following are Required Attachments:			
<input checked="" type="checkbox"/> IRS Exempt Status Determination Letter <input checked="" type="checkbox"/> Current year projected budget <input checked="" type="checkbox"/> Current financial statement <input checked="" type="checkbox"/> Most recent IRS Form 990 or 1120-H <input checked="" type="checkbox"/> Articles of Incorporation (current & signed) Cost estimates from proposed vendor if request is for capital expense		<input checked="" type="checkbox"/> Signed lease if rent costs are being requested <input checked="" type="checkbox"/> IRS Form W9 Evaluation forms if used in the proposed program Annual audit (if required by organization) Faith Based Organization Certification Form, if applicable	
For the current fiscal year ending June 30, list all funds appropriated and/or received from Louisville Metro Government for this or any other program or expense, including funds received through Metro Federal Grants, from any department or Metro Council Appropriation (Neighborhood Development Funds). Attach additional sheet if necessary.			
Source:		Amount: (\$)	
Source:		Amount: (\$)	
Source:		Amount: (\$)	
Has the applicant contacted the BBB Charity Review for participation? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Has the applicant met the BBB Charity Review Standards? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 3 – AGENCY DETAILS

Describe Agency's Vision, Mission and Services:

The mission of the Leukemia & lymphoma Society (LLS) is: to Cure leukemia, lymphoma, Hodgkin's disease and myeloma and improve the quality of life of patients and their families.

LLS is the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Our key priorities will ensure that: The Leukemia & Lymphoma Society helps blood cancer patients live better and longer lives.

Research

Advance the diagnosis and treatment of blood cancers through continues funding of academic research, the therapy acceleration program and other special initiatives. Protectively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma and myeloma. Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists.

Patient Services

Develop a services agenda for patients and their families to address their information and support needs. Inform blood cancer patients and improve access to the latest individual therapy options and blood cancer clinical trials. LLS is the key source of information and services for patients throughout their cancer journey.

Public Policy

Increase funding from non-LLS sources to accelerate the discovery and development of blood cancer therapies. Encourage an effective and science-driven regulatory system for efficient review of new blood cancer therapies. Ensure patients have insurance coverage for their treatments and well-coordinated and high quality cancer care.



LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 4 - BOARD OF DIRECTORS AND PAID STAFF

Board Member	Term End Date
John King- Board President	Jul 1, 2020
Jason Cox	Jul 1, 2020
Tom Bresnahan	Jul 1, 2020
Leslie Hurst	Jul 1, 2020
Dr. Geetha Joseph	Jul 1, 2020
Ben Keeton	Jul 1, 2020
Sony Steier	Jul 1, 2020
Aimee McCaa	Jul 1, 2020
Joe Peters	Jul 1, 2020
Dave Brown	Jul 1, 2020
Mindy Brown	Jul 1, 2020
Paul Resch	Jul 1, 2020
Dr. Robert Emmons	Jul 1, 2020
Jeff Peterman	Jul 1, 2020
Alex Martindale	Jul 1, 2020
Dr. Chandler Park	Jul 1, 2020
Jeff Peterman	Jul 1, 2020

Describe the Board term limit policy:

Trustees are elected at the annual meeting of the BOT. BOT Members shall serve a three-year term beginning July 1 of the year elected. A trustee is eligible for election for one additional consecutive three-year term. No trustee may serve more than two consecutive three-year terms without rotating off the BOT for one year. At the end of such one year period, such former trustee is then eligible to be considered for election to the BOT for a maximum of two three-year terms. For the purposes of this provision, the time served by a trustee elected to fill a vacancy until the next annual meeting of the BOT, as provided in

Three Highest Paid Staff Names	Annual Salary
attached	



LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 5 – PROGRAM/PROJECT NARRATIVE

A: Describe the program/project start and end dates, a description of the program/project and applicable data with regards to specific client population the program will address (attach related flyers, planning minutes, designs, event permits, proposals for services/goods, etc.):

Light The Night is The Leukemia & Lymphoma Society's annual event that funds lifesaving research and support for people battling cancer. Friends, families, co-workers and the public are able to come enjoy a inspirational, memorable evening walk.

The Louisville Light The Night Walk takes place at Louisville Slugger Field on October 10. The event draws 6,000 + in attendance and there is not charge to attend the event.

The event begins at 5PM with live music on the field and booths setup on the concourse, along with a health and wellness fair for everyone who attends.

Around 6PM we have a non-denominational remembrance ceremony. This ceremony is for individuals that has lost someone to any form of cancer.

At 6:45PM the main program beings. We have several speakers and 2-3 videos that play on the jumbo screen at Slugger Field.


7:30PM the walk begins along with the Light of the Lanterns. Individuals line up along the concourse and exit to Witherspoon exit of the park. They will cross the street and enter Waterfront Park make a lan around the Great Lawn.

B: Describe specifically how the funding will be spent including identification of funding to sub grantee(s):

The funds are used to offset The Leukemia & Lymphoma Society's operating expense & Light The Night staff expense. These expenses could include office rental, temporary staffing, phone expense, mailing expenses, fundraising incentives, music and much more. Your funds allow us to put on a great free event for the community and at the same time take the money that is raised and put it towards the mission of saving lives in this community. The event is open to the public and free of charge, but because of that there are some charges that we need to cover.

The more expenses we can offset, the more funds raised that evening will go directly to blood cancer research that will directly help save lives at the James Brown Cancer Center, Norton Cancer Institute and CBC at Baptist Health. The doctors at these institutions will tell you how valuable the research LLS does and how many lives we have saved in our community. Also, we will be able to personally touch and effect more families in our community through our countless programs and financial aids.

Items are paid with an American Express Card or through a check request from our National Office. The AMEX card is subdivided by category on a monthly basis.



LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

C: If this request is a fundraiser, please detail how the proceeds will be spent:

All funds will be credited to the King Team.

The King Team is led by John King, Vice President of King Southern Bank and our 2017 Corporate Walk Chair and current Board President. They walk in honor of Jim King former Metro Councilman and President.

Money will go to Leukemia & Lymphoma Society. The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.

D: For Expenditure Reimbursement Only – The grant award period begins with the Metro Council approval date and ends on June 30 of Metro fiscal year in which the grant is approved. If any part of this funding request is for funds to be spent before the grant award period, identify the applicable circumstances:

☒ The funding request is a reimbursement of the following expenditures that will probably be incurred after the application date, but prior to the execution of the grant agreement:

- ✓ If selecting this option, the invoice, receipt and payment documentation should not be available as of the date of this application.

The Grantee will be required to submit financial reporting in accordance with the reporting schedule provided in the grant agreement.

☐ Reimbursements should not be made before application date unless an emergency can be demonstrated by the primary council sponsor. The funding request is a reimbursement of the following expenditures (attach invoices or proof of payment):

- ✓ Attach a copy of invoices and/or receipts to provide proof of purchase of activities associated with the work plan identified in this application.
- ✓ Attach a copy of cancelled checks to provide proof of payment of the invoices or receipts associated with the work plan identified in this application.

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

E: Describe the program's benefits to those being served (measurable outcomes). Include the program's process for collecting data and the indicators that will be tracked to measure the benefits to those being served:
Because of the continued support of you and our partners and sponsors, in fiscal year 2018 we were able to:

- Invest \$49.3 million in research
- Support 268 research projects (and 22 Therapy Acceleration Program partnerships) in the United States, Canada and 7 other countries
- Provide co-pay assistance to patients
- Sponsor scientific conferences around the country
- Produce educational materials and videos
- Run dozens of Family Support Groups nationwide

Since 2017 LLS researchers have got FDA approval for 37 new treatments and countless others are in clinical trials. Locally the Kentucky Chapter provided \$970,000 in co-pay assistance and financial aid to area patients in the last fiscal year.

In Jefferson County, KY in this fiscal year LLS has provided \$1,250 in travel assistance, \$14,000 in patient aid and \$34,000 in co-pay assistance to help blood cancer patients right here in Metro Louisville. Nationally, LLS has given over \$800,000 in travel, co-pay, and patient aid assistance in 2018 alone.

F: Briefly describe any existing collaborative relationships the organization has with other community organizations. Describe what those partners are bringing to the relationship in general and to this program/project specifically.

The Leukemia & Lymphoma Society (LLS) has a great working relationship with Kindred Healthcare, our Presenting Sponsor, Norton Healthcare, KentuckyOne Health, Baptist Health, Signature Healthcare, Pharmerica, Onco360, Planet Fitness, Republic Bank, Walgreen's, ISCO, Hessig & Pohl, Galen College of Nursing, UPS, and WLKY. All these organizations have been long term partners of LLS and the Light The Night Walk. All these partners with the exception of WLKY are cash sponsors that range between \$5,000 - \$50,000. WLKY provided exposure through commercials and broadcast live from the event.



LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 6 – PROGRAM/PROJECT BUDGET SUMMARY

THE PROGRAM/PROJECT BUDGET SHOULD REALISTICALLY ESTIMATE WHAT AMOUNT IS NEEDED FROM METRO GOVERNMENT AND WHAT IS EXPECTED FROM OTHER SOURCES.

Program/Project Expenses	Column 1	Column 2	Column (1+2)=3
	Proposed Metro Funds	Non- Metro Funds	Total Funds
A: Personnel Costs Including Benefits	0	0	0
B: Rent/Utilities	10000	40000	50000
C: Office Supplies	0	0	0
D: Telephone	0	0	0
E: In-town Travel	0	0	0
F: Client Assistance (See Detailed List on Page 8)	0	0	0
G: Professional Service Contracts	0	0	0
H: Program Materials	0	0	0
I: Community Events & Festivals (See Detailed List on Page 8)	40000	0	40000
J: Machinery & Equipment	0	0	0
K: Capital Project	0	0	0
L: Other Expenses (See Detailed List on Page 8)	0	0	0
*TOTAL PROGRAM/PROJECT FUNDS	50000	40000	90000
% of Program Budget	55.5 %	44.5 %	100%

List funding sources for total program/project costs in Column 2, Non-Metro Funds:

Other State, Federal or Local Government	0
United Way	0
Private Contributions (do not include individual donor names)	400000
Fees Collected from Program Participants	0
Other (please specify)	0
Total Revenue for Columns 2 Expenses **	400000

*Total of Column 1 MUST match "Total Request on Page 1, Section 2"

**Must equal or exceed total in column 2.

mm

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

Detail for Client Assistance, Community Events & Festivals or Other Expenses shown on Page 7 (circle one and use multiple sheets if necessary)	Column 1	Column 2	Column (1 + 2)=3
	Proposed Metro Funds	Non- Metro Funds	Total Funds
T-shirts	7,000	0	7,000
Ball Park Rental	5,000	0	5,000
Fireworks	5,000	0	5,000
Lanterns	5,000	0	5,000
Food	3,000	0	3,000
Inflatable Arch	3,000	0	3,000
Awards Banquet	4,000	0	4,000
VIP Tent	5,000	0	5,000
Stage/Entertainment	3,000	0	3,000
Total	40,000		40,000

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

Detail of In-Kind Contributions for this PROGRAM only: Includes Volunteers, Space, Utilities, etc. (Include anything not bought with cash revenues of the agency).

Donor*/Type of Contribution	Value of Contribution	Method of Valuation
Papa Johns Pizza	\$3,000	Pizza
Coke/Water	\$5,000	Bottled soft drinks and water
Volunteer Hours	\$15,000	Number of volunteers through th
<i>Total Value of In-Kind</i> <i>(to match Program Budget Line Item.</i> <i>Volunteer Contribution & Other In Kind)</i>	\$23,000	

*** DONOR INFORMATION REFERS TO WHO MADE THE IN KIND CONTRIBUTION. VOLUNTEERS NEED NOT BE LISTED INDIVIDUALLY, BUT GROUPED TOGETHER ON ONE LINE AS A TOTAL NOTING HOW MANY HOURS PER PERSON PER WEEK**

Agency Fiscal Year Start Date: July 1

Does your Agency anticipate a significant increase or decrease in your budget from the current fiscal year to the budget projected for next fiscal year? NO ☒ YES ☐

If YES, please explain:

LOUISVILLE METRO COUNCIL NEIGHBORHOOD DEVELOPMENT FUND APPLICATION

SECTION 7 – CERTIFICATIONS & ASSURANCES

By signing Section 7 of the Grant Application, the authorized official signing for the applicant organization certifies and assures to the best of his or her knowledge and/or belief the following Assurances and Certifications. If there is any reason why one or more of the assurances or certifications listed cannot be certified or assured, please explain in writing and attach to this application.

Standard Assurances

1. Applicant understands this application and its attachments as well as any resulting grant agreement, reports and proof of expenditure is subject to Kentucky's open records law.
2. Applicant understands if the grant agreement is not returned to Louisville Metro within 90 days of its mailing to the applicant, the approval is automatically revoked and the funds will not be disbursed to our organization.
3. Applicant and any sub grantee will give Louisville Metro Government access to and the right to examine all paper or electronic records related to the awarded grant for up to five years of the grant agreement date.
4. Applicant assures compliance with the grant requirements and will monitor the performance of any third party (sub-grantee).
5. The Agency is in good standing with the Kentucky Secretary of State, Louisville Metro Government, the Jefferson County Revenue Commission, the Internal Revenue Service, and the Louisville Metro Human Relations Commission.
6. Applicant understands failure to provide the services, programs, or projects included in the agreement will result in funds being withheld or requested to be returned if previously disbursed.
7. Applicant understands they must return to Louisville Metro any unexpended funds by July 31 following the Metro Louisville's fiscal year end.
8. Applicant understands they must provide proof of all expenditures (canceled checks, receipts, paid invoices). The Applicant understands the failure to provide proof of expenditures as required in the grant agreement could result in funding being withheld or request to be returned if previously disbursed.
9. Applicant understands if this application is approved, the grant agreement will identify an award period that begins with the Metro Council approval date, and will end with June 30 of the fiscal year in which the grant is approved. Expenditures associated with this award expected to occur prior to the award period (approval date) must be disclosed in this application in order to be considered compliant with the grant agreement.
10. Applicant understands if we choose to incur expenditures prior to the approval of the application by the Metro Council, there is no guarantee that funding will be reimbursed, as the Council may choose not to award the application.
11. Applicant will establish safeguards to prohibit employees or any person that receives compensation from awarded funds from using their position for a purpose that constitutes or presents the appearance of personal or organizational conflict of interest, or personal gain.

Standard Certifications

1. The Agency certifies it will not use Louisville Metro Government funds for any religious, political or fraternal activities.
2. The Agency has a written Affirmative Action/Equal Opportunity Policy.
3. The Agency does not discriminate in employment or in provision of any service/program/activity/event based on age, color, disabled status, national origin, race, religion, sex, gender identity or sexual orientation, or Vietnam era veteran status.
4. The Agency certifies it will not require clients, recipients, or beneficiaries to participate in religious, political, fraternal or like activities in order to receive services/benefits provided with Louisville Metro Government funds.
5. The Agency understands the Americans with Disabilities Act (ADA) and makes reasonable accommodations.

Relationship Disclosure: List below any relationship you or any member of your Board of Directors or employees has with any Councilperson, Councilperson's family, Councilperson's staff or any Louisville Metro Government employee.

Deanna Keal

SECTION 8 – CERTIFICATIONS & ASSURANCES

I certify under the penalty of law the information in this application (including, without limitation, "Certifications and Assurances") is accurate to the best of my knowledge. I am aware my organization will not be eligible for funding if investigation at any time shows falsification. If falsification is shown after funding has been approved, any allocations already received and expended are subject to be repaid. I further certify that I am legally authorized to sign this application for the applying organization and have initialed each page of the application.

Signature of Legal Signatory:	Deanna Keal	Date:	Jun 25, 2019
Legal Signatory: (please print):	Deanna Keal	Title:	Campaign Director
Phone:	502-719-0546	Extension:	2397
Email:	deanna.keal@lls.org		



Louisville Metro Government
Office of Management and Budget

Neighborhood Development Fund Training Attestation

Grantee Organization Name: Luekemia & Lymphoma Society

Grantee Representative Name: Deanna Keal

I agree that I am an authorized representative and/or signatory of the organization named above and attest to having viewed the Neighborhood Development Fund training presentation. I understand the reporting requirements of the Neighborhood Development Fund grant. Additionally, after viewing the presentation, I have correctly answered the below questions.

Please check:



I viewed the NDF training material on the website

Answer the following questions before signing (Circle or write in the correct answer).

1. The NDF funding your agency received is a gift from LMG? True or False
2. Name the three budget categories that require a detail list.
Client Assistance, Community Events & Festivals and other expenses
3. If your agency charged gross pay to NDF, you are required to provide additional documentation to satisfy reporting requirements. True or False
4. Which four questions should your financial support documentation answer at all times?
who, what, when and where
5. Your agency is considered noncompliant if you do not account for funds received and/or your financial report is missing support documentation? True or False
6. Canceled check, bank statement, invoice and receipt are considered proof of payment. True or False.

Deanna Keal
Grantee Representative Signature

7/24/19
Date

NOTE: Please return to Roxanne Steele

E-mail address: Roxanne.Steele@louisvilleky.gov

Fax: 502-574-3219

Mailing Address: Louisville Metro Government
ATTN: NDF Coordinator
611 West Jefferson St.
Louisville, KY 40202

McQuillen, Liz

From: Furlong, Erika (Kentucky & S. Indiana) <Erika.Furlong@lls.org>
Sent: Wednesday, July 31, 2019 3:35 PM
To: McQuillen, Liz
Subject: LLS NDF Grant Application- Top 3 Local Staff Salaries (confidential information attached)

Importance: High

Follow Up Flag: Flag for follow up
Flag Status: Flagged

CAUTION: This email came from outside of Louisville Metro. Do not click links or open attachments unless you recognize the sender and know the content is safe

Hi Liz,

Deanna said you need our top 3 local staff salaries, not national level, correct? I am sending this rather than her as it is confidential information and not something she should have access to regarding her boss (me) and her peer.

Erika Furlong, Executive Director, \$140,000

Deanna Keal, Light the Night Campaign Director, \$65,000

Erin Schepman, Student Series Campaign Director, \$65,000

Thank you,
Erika

Erika Furlong | Executive Director

The Leukemia & Lymphoma Society | 301 East Main St., Suite 100, Louisville, KY 40202
502.719.0539 direct | 859.576.4787 mobile | www.lls.org/kentucky-southern-indiana | erika.furlong@lls.org



BEATING CANCER IS IN OUR BLOOD.

NOTICE: This message, including all attachments transmitted with it, is for the use of the addressee only. It may contain proprietary, confidential and/or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient, you must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message. If you believe you have received this message in error, please delete it and all copies of it from your system and notify the sender immediately by reply email. Thank you.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

General Information

Organization Number	0063800
Name	THE LEUKEMIA & LYMPHOMA SOCIETY, INC.
Profit or Non-Profit	N - Non-profit
Company Type	FCO - Foreign Corporation
Status	A - Active
Standing	G - Good
State	NY
File Date	7/17/1975
Authority Date	7/17/1975
Last Annual Report	4/30/2019
Principal Office	3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK, NY 10573
Registered Agent	HELEN OVERFIELD 301 EAST MAIN STREET SUITE 100 LOUISVILLE, KY 40202-1077

Current Officers

Chairman	<u>Jorge Benitez</u>
President	<u>Louis J DeGennaro</u>
Secretary	<u>Ralph Lawson</u>
Treasurer	<u>Ralph Lawson</u>
Director	<u>Jorge Benitez</u>
Director	<u>Peter Brock</u>
Director	<u>Ralph Lawson</u>
Director	<u>Bart Sichel</u>
Director	<u>William Behnke</u>
Director	<u>A. Dana Callow Jr</u>
Director	<u>Renzo Canetta</u>
Director	<u>Casey Cunningham</u>
Director	<u>Christopher Flowers</u>
Director	<u>Bernard Garil</u>
Director	<u>Francie Heller</u>
Director	<u>Janice Gabrilove</u>
Director	<u>John Greene</u>
Director	<u>Michele LeBeau</u>
Director	<u>Ruben Mesa</u>
Director	<u>Kathleen Meriwether</u>
Director	<u>Ted Moroz</u>

Director	<u>Lynne O'Brien</u>
Director	<u>Marla Persky</u>
Director	<u>Donald Proctor</u>
Director	<u>Robert Rosen</u>
Director	<u>Steven Rosen</u>
Director	<u>Jeff Sachs</u>
Director	<u>Kenneth Schwartz</u>
Director	<u>Keith White</u>
CFO	<u>Gordon Miller Jr.</u>

Individuals / Entities listed at time of formation

Director	<u>ANTAINETTE R DE VILLIER</u>
Director	<u>RUDOLPH ROESLER DE VILLE</u>
Director	<u>WM AVERELL BROWN</u>
Incorporator	<u>ANTOINETTE R DE VILLERS</u>
Incorporator	<u>RUDOLPH ROESLER DE VILLI</u>
Incorporator	<u>WM AVERELL BROWN</u>
Incorporator	<u>NORRIS DARRELL</u>
Incorporator	<u>FARNK L BABBOTT</u>

Images available online

Documents filed with the Office of the Secretary of State on September 15, 2004 or thereafter are available as scanned images or PDF documents. Documents filed prior to September 15, 2004 will become available as the images are created.

<u>Annual Report</u>	4/30/2019	1 page	<u>PDF</u>	
<u>Annual Report</u>	6/8/2018	1 page	<u>PDF</u>	
<u>Registered Agent name/address change</u>	2/27/2017 3:46:11 PM	1 page	<u>PDF</u>	
<u>Principal Office Address Change</u>	2/27/2017 3:41:22 PM	1 page	<u>PDF</u>	
<u>Annual Report</u>	2/27/2017	1 page	<u>PDF</u>	
<u>Annual Report</u>	4/1/2016	1 page	<u>PDF</u>	
<u>Annual Report</u>	6/15/2015	1 page	<u>PDF</u>	
<u>Registered Agent name/address change</u>	5/15/2015 11:29:57 AM	1 page	<u>PDF</u>	
<u>Annual Report Amendment</u>	6/6/2014	1 page	<u>PDF</u>	
<u>Annual Report</u>	6/5/2014	1 page	<u>PDF</u>	
<u>Annual Report</u>	6/25/2013	1 page	<u>PDF</u>	
<u>Registered Agent name/address change</u>	5/29/2013 2:18:09 PM	1 page	<u>PDF</u>	
<u>Annual Report</u>	5/31/2012	1 page	<u>PDF</u>	
<u>Annual Report</u>	6/6/2011	12 pages	<u>tiff</u>	<u>PDF</u>
<u>Annual Report</u>	6/3/2010	1 page	<u>tiff</u>	<u>PDF</u>
<u>Registered Agent name/address change</u>	6/3/2010	1 page	<u>tiff</u>	<u>PDF</u>
<u>Annual Report</u>	6/17/2009	15 pages	<u>tiff</u>	<u>PDF</u>
<u>Annual Report</u>	4/30/2008	1 page	<u>tiff</u>	<u>PDF</u>
<u>Annual Report</u>	2/16/2007	1 page	<u>tiff</u>	<u>PDF</u>
<u>Annual Report</u>	3/14/2006	17 pages	<u>tiff</u>	<u>PDF</u>

Statement of Change	7/21/2005	1 page	tiff	PDF
Annual Report	6/8/2005	1 page	tiff	PDF
Annual Report	7/17/2003	30 pages	tiff	PDF
Annual Report	9/30/2002	1 page	tiff	PDF
Annual Report	6/5/2001	1 page	tiff	PDF
Principal Office Address Change	4/16/2001	1 page	tiff	PDF
Annual Report	8/14/2000	18 pages	tiff	PDF
Amendment	3/7/2000	4 pages	tiff	PDF
Annual Report	6/21/1999	26 pages	tiff	PDF
Annual Report	4/29/1998	20 pages	tiff	PDF
Annual Report	7/1/1997	11 pages	tiff	PDF
Statement of Change	7/2/1996	1 page	tiff	PDF
Annual Report	7/1/1996	10 pages	tiff	PDF
Annual Report	7/1/1995	8 pages	tiff	PDF
Annual Report	7/1/1994	7 pages	tiff	PDF
Annual Report	7/1/1993	8 pages	tiff	PDF
Statement of Change	7/29/1992	1 page	tiff	PDF
Annual Report	7/1/1992	8 pages	tiff	PDF
Annual Report	7/1/1991	8 pages	tiff	PDF
Annual Report	7/1/1990	8 pages	tiff	PDF
Annual Report	7/1/1989	9 pages	tiff	PDF
Statement of Change	5/31/1988	1 page	tiff	PDF
Statement of Change	9/8/1986	1 page	tiff	PDF
Statement of Change	9/8/1986	1 page	tiff	PDF
Statement of Change	3/28/1984	2 pages	tiff	PDF
Statement of Change	7/25/1978	2 pages	tiff	PDF
Annual Report	7/1/1976	5 pages	tiff	PDF
Certificate of Authority	7/17/1975	64 pages	tiff	PDF
Statement of Change	7/17/1975	2 pages	tiff	PDF

Assumed Names

Activity History

Filing	File Date	Effective Date	Org. Referenced
Annual report	4/30/2019 4:30:52 PM	4/30/2019 4:30:52 PM	
Annual report	6/8/2018 12:14:21 PM	6/8/2018 12:14:21 PM	
Annual report	2/27/2017 3:55:43 PM	2/27/2017 3:55:43 PM	
Registered agent address change	2/27/2017 3:46:11 PM	2/27/2017 3:46:11 PM	
Principal office change	2/27/2017 3:41:22 PM	2/27/2017 3:41:22 PM	
Annual report	4/1/2016 1:59:39 PM	4/1/2016 1:59:39 PM	
Annual report	6/15/2015 2:08:51 PM	6/15/2015 2:08:51 PM	

Registered agent address change	5/15/2015 11:29:57 AM	5/15/2015 11:29:57 AM	
Amendment to annual report	6/6/2014 10:58:44 AM	6/6/2014 10:58:44 AM	
Annual report	6/5/2014 4:39:50 PM	6/5/2014 4:39:50 PM	
Annual report	6/25/2013 3:06:29 PM	6/25/2013 3:06:29 PM	
Registered agent address change	5/29/2013 2:18:09 PM	5/29/2013 2:18:09 PM	
Annual report	5/31/2012 11:16:41 AM	5/31/2012 11:16:41 AM	
Annual report	6/6/2011 9:49:18 AM	6/6/2011	
Registered agent address change	6/3/2010 8:07:13 AM	6/3/2010	
Annual report	6/3/2010 8:06:23 AM	6/3/2010	
Annual report	6/17/2009 11:57:09 AM	6/17/2009	
Annual report	4/30/2008 11:32:08 AM	4/30/2008	
Annual report	2/16/2007 9:56:09 AM	2/16/2007	
Annual report	3/14/2006 2:23:13 PM	3/14/2006	
Registered agent address change	7/21/2005 12:40:09 PM	7/21/2005	
Annual report	6/8/2005 12:37:15 PM	6/8/2005	
Annual report	5/3/2004 10:56:31 AM	5/3/2004	
Principal office change	5/2/2001 11:48:23 AM	5/2/2001	
Principal office change	4/16/2001 3:46:00 PM	4/16/2001	
Amendment - Change name	3/7/2000 12:05:38 PM	3/7/2000	<u>LEUKEMIA SOCIETY OF AMERICA, INC.</u>

Microfilmed Images

Microfilm images are not available online. They can be ordered by faxing a [Request For Corporate Documents](#) to the Corporate Records Branch at 502-564-5687.

Annual Report	6/7/2005	1 page
Annual Report	7/13/2004	28 pages
Annual Report	7/17/2003	30 pages
Annual Report	9/30/2002	1 page
Annual Report	6/5/2001	1 page
Principal Office Address Change	4/16/2001	1 page
Annual Report	8/14/2000	18 pages
Amendment	3/7/2000	2 pages



Department of the Treasury
Internal Revenue Service

P.O. Box 2508, Room 4010
Cincinnati OH 45201

In reply refer to: 4051050282
Apr. 07, 2017 LTR 4168C 0
13-5644916 000000 00
00043361
BODC: TE

LEUKEMIA & LYMPHOMA SOCIETY INC
3 INTERNATIONAL DRIVE STE 200
RYE BROOK NY 10573-7501



003139

Employer ID Number: 13-5644916
Form 990 required: Yes

Dear Taxpayer:

This is in response to your request dated Mar. 06, 2017, regarding your tax-exempt status.

We issued you a determination letter in January 2001, recognizing you as tax-exempt under Internal Revenue Code (IRC) Section 501(c)(03).

Our records also indicate you're not a private foundation as defined under IRC Section 509(a) because you're described in IRC Sections 509(a)(1) and 170(b)(1)(A)(vi).

Donors can deduct contributions they make to you as provided in IRC Section 170. You're also qualified to receive tax deductible bequests, legacies, devises, transfers, or gifts under IRC Sections 2055, 2106, and 2522.

In the heading of this letter, we indicated whether you must file an annual information return. If a return is required, you must file Form 990, 990-EZ, 990-N, or 990-PF by the 15th day of the fifth month after the end of your annual accounting period. IRC Section 6033(j) provides that, if you don't file a required annual information return or notice for three consecutive years, your exempt status will be automatically revoked on the filing due date of the third required return or notice.

For tax forms, instructions, and publications, visit www.irs.gov or call 1-800-TAX-FORM (1-800-829-3676).

If you have questions, call 1-877-829-5500 between 8 a.m. and 5 p.m., local time, Monday through Friday (Alaska and Hawaii follow Pacific Time).

		<u>FY2020</u>	<u>FY2019</u>	<u>FY2020</u>
		<u>Budget 2020</u>	<u>Full YR Actuals</u>	<u>New \$\$ Needed</u>
Product Line	Accounts			
Product Line (Rollup)				
Product Segments (Rollup)				
Campaign Segments (Rollup)				
TNT (Rollup)				
Total TNT (Rollup)	4000 - Revenue	70,000	75,171	(5,171)
	Gross Income	70,000	75,171	(5,171)
	Gross Margin %	100%	100%	0
Light The Night Louisville	4000 - Revenue	400,000	306,000	94,000
	5000 - DDB Expenses	(46,980)	(38,183)	(8,797)
	Gross Income	353,020	267,817	85,203
	Gross Margin %	87%	87%	0
Light The Night Lexington	4000 - Revenue	100,000	61,603	38,397
	5000 - DDB Expenses	(16,854)	(11,383)	(5,471)
	Gross Income	83,146	50,220	32,926
	Gross Margin %	87%	87%	0
Light The Night (Rollup)	4000 - Revenue	500,000	367,603	132,397
	5000 - DDB Expenses	(63,834)	(38,183)	(25,651)
	Gross Income	436,166	329,420	106,747
	Gross Margin %	87%	87%	0
Man Woman of the Year Louisville	4000 - Revenue	650,000	548,253	101,747
	5000 - DDB Expenses	(79,262)	(125,434)	46,172
	Gross Income	570,738	422,819	147,919
	Gross Margin %	88%	77%	0
Man Woman of the Year Lexington	4000 - Revenue	200,000	0	200,000
	5000 - DDB Expenses	(20,635)	0	(20,635)
	Gross Income	179,365		179,365
	Gross Margin %	88%	77%	0
Man Woman of the Year (Rollup)	4000 - Revenue	850,000	548,253	301,747
	5000 - DDB Expenses	(99,897)	(125,434)	25,537
	Gross Income	750,103	422,819	327,284
	Gross Margin %	88%	77%	0
Students of the Year Louisville	4000 - Revenue	200,000	58,630	141,370
	5000 - DDB Expenses	(20,593)	(12,423)	(8,170)
	Gross Income	179,407	46,207	133,200
	Gross Margin %	88%	77%	0
Students of the Year Lexington	4000 - Revenue	49,002	0	49,002
	5000 - DDB Expenses	(18,751)	0	(18,751)
	Gross Income	30,251	0	30,251
	Gross Margin %	88%	77%	0
Students of the Year (Rollup)	4000 - Revenue	249,004	58,630	190,374
	5000 - DDB Expenses	(39,344)	(12,423)	(26,922)
	Gross Income	209,660	46,207	163,453
	Gross Margin %	84%	79%	0
Student Series (Rollup)	4000 - Revenue	318,299	264,155	54,144
	5000 - DDB Expenses	(22,055)	(13,999)	(8,056)
	Gross Income	296,244	250,156	46,088
	Gross Margin %	93%	95%	(0)
All Other Campaigns (Rollup)				0
Clubs & Organizations	4000 - Revenue	1,000	902	98
	Gross Income	1,000	902	98
	Gross Margin %	100%	100%	0
Federated	4000 - Revenue	1,000	1,016	(16)
	Gross Income	1,000	1,016	(16)
	Gross Margin %	100%	100%	0
All Other Mkt Based	4000 - Revenue	0	475	(475)
	Gross Income	0	475	(475)
	Gross Margin %	0%	100%	(1)
Total All Other Campaigns (Rollup)	4000 - Revenue	2,000	2,393	(393)

	Gross Income	2,000	2,393	(393)
	Gross Margin %	100%	100%	0
Direct to Consumer (Rollup)	4000 - Revenue	40,593	41,745	(1,151)
	Gross Income	40,593	41,745	(1,151)
	Gross Margin %	100%	100%	0
Advancement (Rollup)	4000 - Revenue	60,050	44,631	15,419
	Gross Income	60,050	44,631	15,419
	Gross Margin %	100%	100%	0
Total Campaign Segments (Rollup)	4000 - Revenue	2,089,946	1,402,579	687,367
	5000 - DDB Expenses	(225,130)	(201,421)	(23,709)
	Gross Income	1,864,816	1,201,158	663,658
	Gross Margin %	89%	86%	0
Total Product Segments (Rollup)	4000 - Revenue	2,089,946	1,402,579	687,367
	5000 - DDB Expenses	(225,130)	(201,421)	(23,709)
	Gross Income	1,864,816	1,201,158	663,658
	Gross Margin %	89%	86%	0
Enterprise	4000 - Revenue	0	860	(860)
	5000 - DDB Expenses	(1,100)	(6,717)	5,617
	Gross Income	(1,100)	-5,858	4,758
	Gross Margin %	0%	-681%	7
Total Product Line (Rollup)	4000 - Revenue	2,089,946	1,403,439	686,507
	5000 - DDB Expenses	(226,230)	(208,138)	(18,092)
	Gross Income	1,863,716	1,195,300	668,416
	Gross Margin %	89%	85%	0
Accounts				
Expense				
6500 - Payroll				
6503 - Temporary Staffing (Agency)	(153,629)	(127,201)		0
6508 - Bonus	0	(6,000)		0
6509 - Overtime	0	(4,754)		0
Total 6500 - Payroll	(639,588)	(422,311)		0
6100 - Benefits	(78,102)	(35,475)		0
6750 - Payroll Taxes	(43,446)	(29,811)		0
6800 - Travel & Meetings	(29,154)	(15,319)		0
6650 - Professional Fees	(4,100)	(1,499)		0
6550 - Postage & Shipping	(10,320)	(8,534)		0
6600 - Printing	(26,939)	(15,737)		0
6700 - Stationery & Supplies	(7,262)	(5,375)		0
6050 - Advertising	(4,000)	(4,365)		0
6250 - Equipment	(20,950)	(9,624)		0
6400 - Occupancy	(78,640)	(82,639)		0
6900 - Telephony	(4,000)	(2,243)		0
6350 - Memberships	(2,250)	(1,805)		0
6200 - Depreciation	(4,162)	(866)		0
6450 - Other	(13,991)	(11,515)		0
Total Expense	(966,905)	(647,118)		0
	Net Income	896,811	548,182	0
	Net Margin %	43%	39%	0%

CERTIFICATE
OF
CHANGE OF NAME
OF
LEUKEMIA SOCIETY, INC.
TO
LEUKEMIA SOCIETY OF AMERICA, INC.

The name change was effected on May 3, 1967
State of New York, Department of State, Division of
Corporations and State Records, Albany, John P. Lomenzo,
Secretary of State - Film No. 616642-5.

CERTIFICATE OF INCORPORATION

(dated January 10, 1949)

and

Amendment Thereto

(dated August 1, 1955)

of

THE LEUKEMIA SOCIETY, INC.

A Membership Corporation pursuant to the

Laws of the State of New York

(formerly known as

ROBERT ROESLER DE VILLIERS FOUNDATION, INC.)

and

BY-LAWS

of

THE LEUKEMIA SOCIETY, INC.

Established in Memory

of

ROBERT ALEXANDER ROESLER DE VILLIERS,
who died of Leukemia, Sixteen and a half years old on

October 20, 1944,

Antoinette and Rudolph Roesler de Villiers'
only child and best friend.

* * * * *

Amendment Thereto

(dated May 3, 1967)

CERTIFICATE
OF
CHANGE OF NAME
OF
ROBERT ROESLER DE VILLIERS FOUNDATION, INC.
TO
LEUKEMIA SOCIETY, INC.

Pursuant to Section Forty of the
General Corporation Law

We, the undersigned, being a vice-president and the secretary, respectively, of ROBERT ROESLER DE VILLIERS FOUNDATION, INC., do hereby make, subscribe and acknowledge this certificate and do hereby state and certify as follows:

1. The name (unchanged since the date of incorporation) of the corporation is ROBERT ROESLER DE VILLIERS FOUNDATION, INC..

2. The date of filing of the certificate of incorporation in each state office where filed is:

In the office of the Secretary of State of the State of New York on January 31, 1949.

3. The new name to be assumed by the corporation is LEUKEMIA SOCIETY, INC.

IN WITNESS WHEREOF this undersigned have made,
subscribed and acknowledged this certificate this 29th day of July,
1955.

Frank L. Babbott
Vice-President

Benjamin H. Gaylord
Secretary

STATE OF NEW YORK)
COUNTY OF NEW YORK) SS.:

On this 29th day of July, 1955, before me personally came FRANK L. BABBOTT and BENJAMIN H. GAYLORD, to me known and known to me to be the persons described in and who executed the foregoing certificate as vice-president and secretary, respectively, of ROBERT ROESLER DE VILLIERS FOUNDATION, INC., the corporation described in the foregoing certificate, and they severally duly acknowledged to me that they executed the name.

Anthony J. Nostro
Notary Public

Anthony J. Nostro
Notary Public, State of New York
No. 41 2911200
Qualified and Residing
in Queens County
Certificates filed with Bronx,
Kings, N. Y. and Westchester
County Clerks'
Commission Expires March 31, 1957

STATE OF NEW YORK)
) SS.:
COUNTY OF NEW YORK)

FRANK L. BABBOTT AND BENJAMIN H. GAYLORD,
each being duly sworn, depose and say, and each individually deposes
and says, that the said FRANK L. BABBOTT is vice-president of
ROBERT ROESLER DE VILLIERS FOUNDATION, INC., and the
said BENJAMIN H. GAYLORD is secretary thereof; that they have
been duly authorized to execute and file the foregoing certificate by
the concurring votes cast in person or by proxy of a majority of the
members of record of the corporation who are entitled to vote; and
that such votes were cast at a meeting of the members called for the
purpose of considering and voting upon a change of name, upon like
notice as that required for the annual meetings of the corporation;
and that the date of such meeting was July 29, 1955.

ss Frank L. Babbott
Frank L. Babbott

ss Benjamin H. Gaylord
Benjamin H. Gaylord

Sworn to before me this
29th day of July, 1955

Anthony J. Nostro
Notary Public

Anthony J. Nostro
Notary Public, State of New York
No. 41 2911200
Qualified and Residing
in Queens County
Certificates filed with Bronx,
Kings, N. Y. and Westchester
County Clerks'
Commission Expires March 21, 1957

CERTIFICATE OF INCORPORATION

of

ROBERT ROESLER DE VILLIERS FOUNDATION, INC.

Pursuant to the Membership Corporation Law

The undersigned, desiring to form a corporation in accordance with the Membership Corporations Law: of the State of New York, make, sign, acknowledge and file this Certificate.

FIRST: The name of the proposed corporation is
ROBERT ROESLER DE VILLIERS FOUNDATION, INC.

SECOND: The purposes for which the Corporation is to be formed are;

1. To make grants of financial aid to hospitals and other institutions, and individuals, for the study of, and research into, the causes of leukemia, and its treatment and cure.

2. To assist and contribute to the support of exclusively charitable, scientific, literary and educational activities and projects, and to contribute to the support of exclusively charitable, scientific, literary and educational organizations and funds, of any and every kind, provided, however, that nothing herein contained shall authorize this Corporation to undertake or carry on any of the activities specified in Section II of the Membership Corporation Law of Section 35 of the Social Welfare Law.

3. In carrying out these purposes the Corporation shall have power -

- (a) to solicit contributions and to receive, acquire, hold, own, invest and reinvest any and all such cash securities, evidences of indebtedness or other property, real or personal, as may from time to time be given, sold, transferred, granted, conveyed or assigned to it by any person, estate, firm, committee, association or corporation; to take by devise or bequest, or otherwise subject to limitations, imposed by law, any and all property heretofore or hereafter devised or bequeathed by will or otherwise, or in any manner granted or conveyed to it; to exercise in respect to any and all such property any and all rights, powers, and privileges of ownership, and to collect any and all rents, profits and income therefrom; and
- (b) generally, to do any and all things which may be necessary or proper in connection with its objects and purposes which may not be contrary to law, either alone or in association with other corporations, firms, political subdivisions or individuals.

SEVENTH: All the subscribers to this Certificate are of full age; at least two-thirds of them are citizens of the United States; at least one of them is a resident of the State of New York; and of the persons named as directors or trustees at least one is a citizen of the United States and a resident of the State of New York.

IN WITNESS WHEREOF, we have made, subscribed and acknowledged this Certificate this 10th day of January, One Thousand nine hundred forty-nine.

(Signed) Antoinette R. de Villiers

Antoinette R. de Villiers

(Signed) Rudolph Roesler de Villiers

Rudolph Roesler de Villiers

(Signed) Wm. Averell Brown

Wm. Averell Brown

(Signed) Norris Darrell

Norris Darrell

(Signed) Frank L. Babbott

Frank L. Babbott

4. This Corporation shall be operated exclusively for charitable, scientific, literary or educational purposes, and no part of its property or net earnings thereof shall inure to the benefit of any private member or individual, firm or corporation and no substantial part of its activities shall consist in carrying on propaganda or otherwise attempting to influence legislation. Upon dissolution of the Corporation, its property, after the payment of all debts, shall be disposed of or applied only for the purposes for which the Corporation is organized, in accordance with the provisions of the Membership Corporations Law.

THIRD: The territory in which the operations of the Corporation are principally to be conducted is the United States of America.

FOURTH: The principal office of the Corporation is to be located in the City of New York, County and State of New York.

FIFTH: The number of directors or trustees shall be not less than three nor more than fifteen.

SIXTH: The names and residences of the persons who are to be directors or trustees until the first annual meeting and until their successors are elected are:

<u>NAME</u>	<u>RESIDENCE</u>
Antoinette R. de Villiers	417 Park Avenue, New York 22, N. Y.
Rudolph Roesler de Villiers	417 Park Avenue, New York 22, N. Y.
Wm. Averell Brown	129 East 95th Street, N. Y. 28, N. Y.

I, Louis A. Valente, one of the Justices of the Supreme Court of the State of New York, First Judicial District, hereby approve the foregoing Certificate of Incorporation of Robert Roesler de Villiers Foundation, Inc.

Dated, New York City, New York this 27th day of January 1949.

(Signed) Louis A. Valente

Justice of the Supreme Court
of the State of New York

CERTIFICATE OF AMENOMENT

Dated October 19, 1968

CERTIFICATE OF AMENDMENT CHANGING THE POWERS OF

LEUKEMIA SOCIETY OF AMERICA, INC.

PURSUANT TO SECTION 30 OF THE MEMBERSHIP CORPORATION LAW

WE, THE UNDERSIGNED, JOHN J. KENNY, President, and JULES OSTROFF, Secretary, of the LEUKEMIA SOCIETY OF AMERICA, INC., a membership corporation, duly organized and existing under the Membership Corporation Law of the State of New York, for the purpose of eliminating one of the powers of said corporation and increasing the authorized number of directors, pursuant to section 30 of the Membership Corporations Law, do hereby make, sign and acknowledge this certificate and do certify as follows:

1. The name of the corporation is LEUKEMIA SOCIETY OF AMERICA, INC.
2. The Certificate of Incorporation was filed in the office of the Secretary of State of the State of New York on the 29th day of January, 1949, at which time the corporation was known as ROBERT ROESLER DE VILLIERS FOUNDATION, INC.

That thereafter and on the 29th day of July, 1955, the said corporate name was amended to the LEUKEMIA SOCIETY, INC., pursuant to section 40 of the General Corporation Law.

That thereafter on the 3rd day of May, 1967, the name of the corporation was again amended and changed to be the LEUKEMIA SOCIETY OF AMERICA, INC., pursuant to section 30 of the Membership Corporation Law.

3. The particular objects for which the above named corporation was organized are as follows:

- a) To make grants of financial aid to hospitals and other institutions, and individuals, for the study of, and research into, the causes of leukemia, and its treatment and cure.
- b) To assist and contribute to the support of exclusively charitable, scientific, literary and educational activities and projects, and to contribute to the support of exclusively charitable, scientific,

literary and educational organizations and funds, of any and every kind, provided, however, that nothing herein contained shall authorize this corporation to undertake or carry on any of the activities specified in Section II of the Membership Corporation Law of Section 35 of the Social Welfare Law.

c) In carrying out these purposes the Corporation shall have power -

1. to solicit contributions and to receive, acquire, hold, own, invest and reinvest any and all such cash securities, evidences of indebtedness or other property, real or personal, as may from time to time be given, sold, transferred, granted, conveyed or assigned to it by any person, estate, firm, committee, association or corporation; to take by devise or bequest, or otherwise subject to limitations, imposed by law, any and all property heretofore or hereafter devised or bequeathed by will or otherwise, or in any manner granted or conveyed to it; to exercise in respect to any and all such property any and all rights, powers, and privileges of ownership, and to collect any and all rents, profits and income therefrom; and

2. generally, to do any and all things which may be necessary or proper in connection with its objects and purposes which may not be contrary to law, either alone or in association with other corporations, firms, political subdivisions or individuals.

d) This Corporation shall be operated exclusively for charitable, scientific, literary or educational purposes, and no part of its property or net earnings thereof shall inure to the benefit of any private member or individual, firm or corporation and no substantial part of its activities shall consist in carrying on propaganda or otherwise attempting to influence legislation. Upon dissolution of the Corporation, its property, after the pay-

purposes for which the Corporation is organized, in accordance with the provisions of the Membership Corporations Law.

4. The alterations proposed and intended to be effected by the execution and filing of this certificate consist of a limitation of the power of the corporation so as to preclude the corporation from engaging in any literary activities, and further to provide that the corporation shall have no less than three (3) directors or trustees and no more than sixty (60), and the corporation shall have the power as follows:

a) To make grants of financial aid to hospitals and other institutions, and individuals, for the study of, and research into, the causes of leukemia, and its treatment and cure.

b) To assist and contribute to the support of exclusively charitable, scientific, education activities and projects, and to contribute to the support of exclusively charitable, scientific educational organizations and funds, or any and every kind, provided, however, that nothing herein contained shall authorize this Corporation to undertake or carry on any of the activities specified in Section II of the Membership Corporation Law of Section 35 of the Social Welfare Law.

c) In carrying out these purposes the Corporation shall have power -

1. to solicit contributions and to receive, acquire, hold, own, invest and reinvest any and all such cash securities, evidences of indebtedness or other property, real or personal, as may from time to time be given, sold, transferred, granted, conveyed or assigned to it by any person, estate, firm, committee, association or corporation; to take by devise or bequest, or otherwise subject to limitations, imposed by law, any and all property heretofore or hereafter devised or bequeathed by will or otherwise, or in any manner granted or conveyed to it; to exercise in respect to any and all such

erty any and all rights, powers, . . . privileges of ownership, and to collect any and all rents, profits and income therefrom; and

2. generally, to do any and all things which may be necessary or proper in connection with its objects and purposes which may not be contrary to law, either alone or in association with other corporations, firms, political subdivisions or individuals.

d) This Corporation shall be operated exclusively for charitable, scientific, educational purposes, and no part of its property or net earnings thereof shall inure to the benefit of any private member or individual, firm or corporation and no substantial part of its activities shall consist in carrying on propaganda or otherwise attempting to influence legislation. Upon dissolution of the Corporation, its property, after the payment of all debts, shall be disposed of or applied only for the purposes for which the Corporation is organized, in accordance with the provisions of the Membership Corporations Law.

The manner in which this amendment to the Certificate of Incorporation of LEUKEMIA SOCIETY OF AMERICA, INC. was authorized was by the affirmation vote of the majority of the members of the corporation present at the annual corporation membership meeting held upon due notice pursuant to section 43 of the Membership Corporations Law on the 19th day of October, 1968.

The number of directors or trustees shall be not less than 3, nor more than 60.

IN WITNESS WHEREOF, we have made, signed, and acknowledged this Certificate, this 19th day of October, 1968.

S/ John J. Kenny, M.D.
President

S/ Julius Ostroff
Secretary

I, Hon. Leonard J. Supple J.S.C., hereby approve the foregoing Certificate of Amendment or Powers and consent to the filing of same.

Dated: October 29, 1968

S/ Leonard J. Supple

STATE OF NEW YORK
SS:
COUNTY OF NEW YORK

On the 19th day of October, 1968, before me personally came
JOHN J. KENNY, to me known, and known to me to be the person described
in and who executed the foregoing certificate, and he duly acknowledged
to me that he executed the same.

S/ Steven I. Schechtman
Notary Public

Steven I. Schechtman
Notary Public, State of New York
No. 41-8795780
Qualified in Queens County
Commission expires March 30, 1970

STATE OF NEW YORK
SS:
COUNTY OF NEW YORK

JOHN J. KENNY, being duly sworn, deposes and says that he is the
president of LEUKEMIA SOCIETY OF AMERICA, INC., that he has been authorized
to execute and file the foregoing certificate by the concurring vote of a
majority of the members of the corporation present at an annual meeting held
on the 19th day of October 1968 upon notice pursuant to section 43 of the
Membership Corporations Law.

S/ John J. Kenny, M.D.
JOHN J. KENNY

Subscribed and sworn to
before me this 19th day
of October, 1968.

S/ Steven I. Schechtman
Notary Public

Steven I. Schechtman
Notary Public, State of New York
No. 41-8795780
Qualified in Queens County
Commission expires March 30, 1970

10/25/74

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION
OF

LEUKEMIA SOCIETY OF AMERICA, INC.

UNDER SECTION 503 OF THE
NOT-FOR-PROFIT CORPORATION
LAW

We, the undersigned, being the President and Secretary of Leukemia Society of America, Inc., do hereby certify:

(1) The name of the corporation is Leukemia Society of America, Inc. The name under which the corporation was formed is Robert Roesler De Villiers Foundation, Inc.

(2) The certificate of incorporation of Robert Roesler De Villiers Foundation, Inc. was filed by the Department of State on the 29th day of January, 1949. The said corporation was formed under the Membership Corporation Law of the State of New York. This name was changed to Leukemia Society, Inc. by an amendment dated July 29, 1955 pursuant to section 40 of the General Corporation Law. Thereafter, and on the 3rd day of May, 1967, the name of the corporation was again amended and changed to be Leukemia Society of America, Inc., pursuant to section 30 of the Membership Corporation Law.

(3) The Leukemia Society of America, Inc. is a corporation as defined in subparagraph (a) (5) of section 101 of the Not-For-Profit Corporation Law and is a Type B corporation under section 101 of said law.

(4) The post-office address within the state to which the secretary or state shall mail a copy of any notice required by law is: 211 East 43rd Street, New York, N.Y. 100


(5) The certificate of incorporation is hereby amended to effect the deletion therefrom of a provision restrictive of the powers of the Board of Directors pursuant to section 301 (b) (3) of the Not-For-Profit Corporation Law. The certificate of incorporation is hereby amended by striking out the following statement from Paragraph Fifth, to wit:


"The number of directors or trustees shall be not less than three nor more than fifteen."

(6) The manner in which this amendment to the certificate of incorporation of Leukemia Society of America, Inc. was authorized was by the affirmative vote of a majority of the members entitled to vote thereon at a meeting of the members duly called and held on the 29th day of June, 1974, the affirmative vote being at least equal to the quorum.

(7) No approvals or consents are required by the Not-for-profit Corporation Law or by any other statute of the State of New York.

IN WITNESS WHEREOF, the undersigned have executed and signed this certificate this 25 day of October, 1974.


Rudolph F. Farnham,
President


Robert H. Farnham,
Secretary

STATE OF NEW YORK)
COUNTY OF NEW YORK) ss.:

RUDOLPH F. BADUN and ROBERT M. YAGOURI, being duly sworn, depose and say that deponents are the President and Secretary respectively of LEUKEMIA SOCIETY OF AMERICA, INC. the corporation named in the within action; that deponents have read the foregoing Certificate of Amendment of the Certificate of Incorporation of Leukemia Society of America Inc., Under Section 803 of the Not-For-Profit Corporation Law and know the contents thereof; and that the same is true to deponents' own knowledge, except as to the matters therein stated to be alleged upon information and belief, and as to these matters deponents believe it to be true. This verification is made by deponents because LEUKEMIA SOCIETY OF AMERICA, INC. is a domestic corporation. Deponents are officers thereof, to-wit its President and Secretary respectively. The grounds of deponents' belief as to all matters not stated upon deponents' knowledge are as follows: Books and records in the possession of the corporation.

Rudolph F. Badun
Rudolph F. Badun

Robert M. Yagouri
Robert M. Yagouri

Sworn to before me

this 25 day of October 1974

[Signature]

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION
OF
LEUKEMIA SOCIETY OF AMERICA, INC.

CLINE, HALLISSEY & HAUSMAN
Attorneys At Law
585 Stewart Avenue
Garden City, New York 11530

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION
OF
LEUKEMIA SOCIETY OF AMERICA, INC.
Under Section 803 of the Not-For-Profit
CORPORATION LAW

The undersigned, being the President and Secretary,
respectively, of the LEUKEMIA SOCIETY OF AMERICA, INC., hereby
certify that:

1. The name of the Corporation is LEUKEMIA SOCIETY OF AMERICA, INC. It was incorporated under the name of ROBERT ROESLER DE VILLIERS FOUNDATION, INC. On or about July 29, 1955, its name was changed to LEUKEMIA SOCIETY, INC. and on or about March 15, 1967 to its present name, LEUKEMIA SOCIETY OF AMERICA, INC.
2. The Certificate of Incorporation of said Robert Roesler Devilliers Foundation, Inc., now known as LEUKEMIA SOCIETY OF AMERICA, INC. was filed in the office of the Department of State, State of New York, on January 31, 1949. Said corporation was formed under the Membership Corporation Law.
3. LEUKEMIA SOCIETY OF AMERICA, INC. is a corporation as defined in subparagraph (a) (5) of section 102 of the Not-For-Profit Corporation Law and is a Type B corporation pursuant to section 201 of said law. The corporate purposes are not

enlarged, limited or in any way changed by this certificate of amendment and it shall continue to be a type B corporation thereafter.

4. The post-office address within the state to which the Secretary of State shall mail a copy of any notice required by law is LEUKEMIA SOCIETY OF AMERICA, INC., 800 Second Avenue, New York, New York 10017.

5. The Certificate of Incorporation of LEUKEMIA SOCIETY OF AMERICA, INC. as amended on or about October 19, 1968 is hereby further amended at the request of the Internal Revenue Service, to change the wording of said certificate relating to the distribution of the assets of the corporation upon dissolution. Paragraph "SECOND: 6" of the Certificate of Incorporation as amended by paragraph "3.d)" of the aforesaid Certificate of Amendment of October 19, 1968, which is to be eliminated by the execution and filing of this Certificate of Amendment, reads as follows:

"d) This Corporation shall be operated exclusively for charitable, scientific, educational purposes, and no part of its property or net earnings thereof shall enure to the benefit of any private member or individual, firm or corporation and no substantial part of its activities shall consist in carrying on propaganda or otherwise attempting to influence legislation. Upon dissolution of the Corporation, its property, after payment of all debts, shall be

disposed of or applied only for the purposes for which the Corporation is organized, in accordance with the provisions of the Membership Corporations Law and with the approval of a Justice of the Supreme Court."

6. The new Paragraph "SECOND: 6" to be substituted for the foregoing upon the execution and filing of this certificate of amendment, will read as follows:

"(i) This Corporation shall be operated exclusively for charitable, scientific and/or educational purposes, and no part of its property or net earnings thereof shall enure to the benefit of any private member or individual, firm or corporation and no substantial part of its activities shall consist in carrying on propaganda or otherwise attempting to influence legislation.


(ii) Upon dissolution of this Corporation, its assets, after the payment of all debts, shall be transferred, subject to the approval of a Justice of the Supreme Court of the State of New York, to any other Corporation(s) and/or organization(s) exempt under section 501(c) (3) of the Internal Revenue Code and engaged in activities substantially similar to those of the dissolved corporation, or to the Federal Government,

or to a state or local government for a public purpose."


7. The manner in which this Amendment to the Certificate of Incorporation was authorized was by the consent of a majority vote of the Members of LEUKEMIA SOCIETY OF AMERICA, INC. at the annual corporation membership meeting held at Houston, Texas on October 25, 1980 upon due notice pursuant to section 605 of the Not-For-Profit Corporation Law.

8. No approvals or consents are required pursuant to 102(a) (3).

IN WITNESS WHEREOF, the undersigned have executed this certificate this 25th day of October, 1980.





President



Secretary

STATE OF NEW YORK)
COUNTY OF NEW YORK) ss.:

ROBERT M. YACOBI and ROBERT H. NEWMAN, being severally duly sworn, depose and say: that ROBERT M. YACOBI is the President of LEUKEMIA SOCIETY OF AMERICA, INC. and ROBERT H. NEWMAN is the Secretary thereof; that they were authorized to execute the foregoing Certificate of Amendment of the Certificate of Incorporation of LEUKEMIA SOCIETY OF AMERICA, INC., pursuant to Section 803 of the Not-for-Profit Corporations Law, by the concurring vote of a majority of the members of the corporation present at an annual meeting held on the 25th day of October, 1980, upon notice pursuant to Section 605 of the Not-for-Profit Corporations Law, and they subscribe such certificate by virtue of such authority.

Sworn to before me this
25th day of October, 1980.



— RITA HICKS —
Notary Public, State of New York
No. 41-4314148
Qualified in Queens County
Commission Expires March 30, 1981

As Approved By:

The National Board of Trustees
June 28, 1980

As Approved By:

The Annual Meeting of the Corporate Members
October 25, 1980

*State of New York } ss:
Department of State }*

I hereby certify that the annexed copy has been compared with the original document in the custody of the Secretary of State and that the same is a true copy of said original.

Witness my hand and seal of the Department of State on **FEB 01 2000**



A handwritten signature in dark ink, appearing to read "J. L. L. L.", followed by a long horizontal line.

Special Deputy Secretary of State

FILING RECEIPT

F000201000512

ENTITY NAME: THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

DOCUMENT TYPE: NAME RESERVATION (NCH) (DOM. NFP)

SERVICE COMPANY: DELANEY CORPORATE SERVICES LTD.


SERVICE CODE: 30

APPLICANT NAME : LEUKEMIA SOCIETY OF AMERICA, INC.

FILED:12/14/1999 DURATION:02/14/2000 CASH#:991214000712 FILM #:991214000684

ADDRESS FOR PROCESS

REGISTERED AGENT



** SUBMIT RECEIPT WHEN FILING CERTIFICATE **

FILER	FEES		PAYMENTS	
		35.00		35.00
LEUKEMIA SOCIETY OF AMERICA, INC.	FILING	10.00	CASH	0.00
600 THIRD AVENUE	TAX	0.00	CHECK	0.00
NEW YORK, NY 10022	CERT	0.00	CHARGE	0.00
	COPIES	0.00	DRAWDOWN	35.00
	HANDLING	25.00	BILLED	0.00
			REFUND	0.00

DOS-1025 (11/89)

FILING RECEIPT

ENTITY NAME: THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

DOCUMENT TYPE: AMENDMENT (DOMESTIC NFP)
PROCESS NAME

COUNTY: NEWY

SERVICE COMPANY: DELANEY CORPORATE SERVICES LTD.

SERVICE CODE: 30

FILED:02/01/2000 DURATION:***** CASH#:000201000531 FILM #:000201000513

ADDRESS FOR PROCESS

THE CORPORATION
600 THIRD AVENUE
NEW YORK, NY 10016

REGISTERED AGENT



FILER	FEES		PAYMENTS	
		140.00		140.00
GILBERT SEGALL AND YOUNG LLP	FILING	30.00	CASH	0.00
430 PARK AVENUE	TAX	0.00	CHECK	0.00
	CERT	0.00	CHARGE	0.00
NEW YORK, NY 10022-3592	COPIES	10.00	DRAWDOWN	140.00
	HANDLING	100.00	BILLED	0.00
			REFUND	0.00

DOS-1025 (11/89)

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION
OF
LEUKEMIA SOCIETY OF AMERICA, INC.

Under Section 803 of the Not-For-Profit Corporation Law

I, the undersigned President of Leukemia Society of America, Inc., (the Corporation), hereby certify that:

1. The name of the Corporation is Leukemia Society of America, Inc. (the "Corporation"). The Corporation was formed under the name of Robert Roesler de Villiers Foundation, Inc.
2. The Certificate of Incorporation of the Corporation was filed by the Department of State of the State of New York on January 31, 1949. The Corporation was formed under the New York State Membership Corporations Law.
3. A Certificate of Change of Name of the Corporation amending the Corporation's name to Leukemia Society, Inc. was filed by the Department of State of

the State of New York on August 1, 1955. A Certificate of Change of Name of the Corporation changing the Corporation's name to Leukemia Society of America, Inc. was filed by the Department of State of the State of New York on May 3, 1967.

4. The Corporation is a corporation as defined in Section 102(a)(5) of the Not-For-Profit Corporation Law ("NPCL"); the Corporation is a Type B corporation under Section 201 of the NPCL.

5. The Certificate of Incorporation of the Corporation is hereby amended to change the name of the Corporation to The Leukemia & Lymphoma Society, Inc.

6. To effect the foregoing amendment, Paragraph FIRST of the Certificate of Incorporation, which was previously amended on August 1, 1955 and again on May 3, 1967, is now amended to read as follows:

"FIRST: The name of the Corporation is The Leukemia & Lymphoma Society, Inc."

7. The above amendment was authorized by a majority vote of the members of the Corporation present at a meeting of the members duly called and held on June 26, 1999 and the affirmative votes cast in favor of such amendment were at least equal to a quorum of members.

8. The Secretary of State is hereby designated as agent of the Corporation upon whom process against the Corporation may be served. The post office address to

which the Secretary of State shall mail a copy of any process against the Corporation served upon him is:

The Leukemia & Lymphoma Society, Inc.
600 Third Avenue
New York, New York 10016

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment and, under penalties of perjury, affirms the truth of the statements made herein this 6th day of January, 2000.

Dwayne Howell

Dwayne Howell
President

424652

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION
OF

LEUKEMIA SOCIETY OF AMERICA, INC.

Under Section 803 of the Not-For-Profit Corporation Law

**DRAWDOWN
DELANEY - 30**

GILBERT, SEGALL AND YOUNG LLP
430 PARK AVENUE
NEW YORK, N.Y. 10022-3592

RSU

1CC
STATE OF NEW YORK
DEPARTMENT OF STATE
FILED FEB 01 2000
TAXS
BY: *RSU*
NY

5

00020100053

BYLAWS
OF
The Leukemia & Lymphoma Society, Inc.
a New York Not-for-Profit Corporation

(Amended and Restated through January 25, 2014)



TABLE OF CONTENTS

	<u>Page</u>
ARTICLE I NAME; PURPOSES; BASIS OF OPERATION	1
Section 1. Name	1
Section 2. Purposes	1
Section 3. Basis of Operation	1
ARTICLE II OFFICES	1
Section 1. Principal Office	1
Section 2. Other Offices	2
ARTICLE III MEMBERSHIP	2
Section 1. Members	2
Section 2. Class A Members	2
Section 3. Class B Members	2
Section 4. Transfer of Membership	2
ARTICLE IV CLASS A MEMBERS	2
Section 1. Voting Rights of Class A Members	2
Section 2. Chapter Chair Assembly	2
Section 3. Composition of the CCA	2
Section 4. Term	2
Section 5. Meetings of the CCA	3
Section 6. Notice of Meetings of the CCA	3
Section 7. Quorum	3
Section 8. Voting	3
Section 9. Action Without a Meeting	3
Section 10. Vacancies	3
Section 11. Annual Forum with BOD	3
Section 12. Deprivation or Suspension of Class A Membership	4
ARTICLE V CLASS B MEMBERS	4
Section 1. Voting Rights of Class B Members	4
Section 2. Term	4
Section 3. Meetings of Class B Members	4
Section 4. Notice of Class B Member Meetings	4
Section 5. Quorum	4
Section 6. Voting	4
Section 7. Action without a Meeting	4
ARTICLE VI BOARD OF DIRECTORS	5
Section 1. Powers	5
Section 2. Composition of BOD	5
Section 3. Number and Term of Elected Directors	5
Section 4. Qualification Criteria for Elected Directors	6
Section 5. Nominations of Elected Directors; Notice	6
Section 6. Additional Nominations; Notice	6
Section 7. Ballots	6
Section 8. Voting	6
Section 9. Resignations	6
Section 10. Removal	7
Section 11. Meetings of the BOD	7

Section 12.	Waiver of Notice	7
Section 13.	Quorum	7
Section 14.	Action by BOD.....	7
Section 15.	Meetings by Telephone, Etc.	7
Section 16.	Action Without a Meeting.....	7
Section 17.	Vacancies.....	7
Section 18.	President; Other Employed Officers	8
ARTICLE VII COMMITTEES.....		8
Section 1.	Standing Committees of the BOD.....	8
Section 2.	Other Standing Committees of the BOD.....	12
Section 3.	Operating Committees, Advisory Committees and Task Forces	12
Section 4.	Quorum	12
Section 5.	Committee Charters	12
ARTICLE VIII OFFICERS		13
Section 1.	Election of Officers	13
Section 2.	Removal and Resignation	13
Section 3.	Vacancies.....	14
Section 4.	Chairperson.....	14
Section 5.	Vice Chairperson.....	14
Section 6.	Secretary/Treasurer	14
ARTICLE IX CHAPTERS		14
Section 1.	Establishment.....	14
Section 2.	Rules and Regulations	14
Section 3.	Suspension and Revocation	14
Section 4.	Funds, Moneys and Contributions	15
Section 5.	Employees	16
ARTICLE X OTHER PROVISIONS		15
Section 1.	Endorsement of Documents; Contracts	15
Section 2.	Representation of Shares of Other Corporations	16
Section 3.	Fiscal Year, Books and Records	16
Section 4.	Notice.....	16
Section 5.	Corporate Seal	16
Section 6.	Procedure at Meetings	16
Section 7.	Annual Report	17
Section 8.	Amendment.....	17
Section 9.	Severability.....	17
Section 10.	Effective Date	17
Section 11.	Use of Electronic Communications for Corporate Action	17
ARTICLE XI INDEMNIFICATION.....		17
Section 1.	Indemnification of Directors, Members, Officers and Others	17
Section 2.	Indemnification of Others.....	18
Section 3.	Advances or Reimbursement of Expenses	18
Section 4.	Interpretation	18
Section 5.	Indemnification Right.....	18
Section 6.	Limitation.....	18

BYLAWS

OF

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. a New York Not-for-Profit Corporation

(as Amended and Restated through January 25, 2014)

ARTICLE I

NAME: PURPOSES: BASIS OF OPERATION

Section 1. Name. This Corporation shall be known as The Leukemia & Lymphoma Society, Inc. ("*Corporation*").

Section 2. Purposes. The Corporation shall have the following purposes:

A. To support research into the causes, treatments, and cure of blood cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma;

B. to organize and conduct educational programs and disseminate information to and for the medical and scientific community and the public at large as to the continuing developments in the prevention, diagnosis and treatment of blood cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma;

C. to provide financial assistance to patients suffering from blood cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma;

D. to support community service programs for patients suffering from blood cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma, and their families; and

E. to solicit contributions and to advocate for government funding to carry out the Corporation's stated purposes.

Section 3. Basis of Operation. The Corporation is formed under the New York Not-for-Profit Corporation Law (the "NPCL"). No part of its earnings, dividends or other profits shall inure to the benefit of any Member of the Corporation (as defined in Article III, Sections 1 through 3) or individual and no substantial part of the activities of the Corporation shall be devoted to carrying on propaganda or otherwise attempting to influence legislation.

ARTICLE II

OFFICES

Section 1. Principal Office. The Corporation's principal office ("*Home Office*") shall be fixed and located at such place as the Board of Directors (the "*BOD*") shall determine from time to time. The BOD is granted full power and authority to change the principal office from one location to another.

Section 2. Other Offices. Other offices may be established at any time by the BOD at any place or places.

ARTICLE III

MEMBERSHIP

Section 1. Members. The Corporation shall have two classes of "*Members*," which shall include Class A Members and Class B Members.

Section 2. Class A Members. The Class A Members of the Corporation shall consist of each "Chapter" (which term excludes a provisional chapter) of the Corporation.

Section 3. Class B Members. The Class B Members shall consist of the Directors of the Corporation, as that term is defined in Article VI, Section 2, of these Bylaws.

Section 4. Transfer of Membership. Membership in the Corporation shall not be transferable.

ARTICLE IV

CLASS A MEMBERS

Section 1. Voting Rights of Class A Members. The Class A Members of the Corporation shall be entitled to vote on all proposed Bylaw amendments that would affect the "Field" as that term is defined in Section 2 of this Article IV of the Bylaws. The Class A Members shall not have any other voting rights afforded to members under the NPCL.

Section 2. Chapter Chair Assembly. In recognition that the Corporation's roots are in its volunteer network, organized through its Chapters, and that its success has been and will be the result of united efforts of its local and national volunteers and staff in furtherance of its mission, and to ensure a constantly strong commitment to significantly involving, utilizing and integrating its local volunteer leaders into the Corporation's plans, programs and leadership at the national level, the Chapter Chair Assembly of the Corporation (the "CCA") shall be the representative body of the Corporation's Class A Members to the BOD. The CCA shall represent the perspective and concerns of the programs and activities of the Corporation at the Chapter level (i.e., the "Field"), to the BOD and shall, through the members of the CCA, be a liaison from the BOD to the Field.

Section 3. Composition of the CCA. Each Class A Member shall have one representative on the CCA, which shall be the chair of the Class A Member's Boards of Trustees (the "Chapter Chair"). The Chapter Chair from each Class A Member must be an experienced leader of such Chapter and must reside within, be employed within or be physically present for a significant period of time within the geographical boundaries of such Chapter at the time of his or her election as Chapter Chair. Should a Chapter Chair, during his or her term, no longer satisfy the geographic eligibility requirement, he or she shall be deemed to have resigned from the CCA unless the Class A Member's Board of Trustees determines to retain him or her as the Chapter's representative on the CCA for the balance of his or her term as Chapter Chair. No person may be a Chapter Chair and a member of the BOD simultaneously.

Section 4. Term. Chapter Chairs serve on the CCA by virtue of their office as Chapter Chair and, accordingly, a Chapter Chair's service on the CCA shall coincide with his or

her service as the Chair of the Board of Trustees of his or her respective Chapter. No person shall continue to be a member of the CCA after ceasing to be a Chapter Chair.

Section 5. Meetings of the CCA. There shall be an annual meeting of the CCA to be held on the date and at such time and place in April, or such other month, fixed by the BOD Chairperson (the "Chairperson"). A special meeting of the CCA may be called at any time by the Chairperson, the BOD or upon the written request of at least 10% of all of the Chapter Chairs. The members of the CCA shall appoint from among the members of the CCA a chairperson (the "CCA Chair") to conduct meetings of the CCA.

Section 6. Notice of Meetings of the CCA. The Chairperson shall cause written notice of each meeting of the CCA, stating the place, date and time of the meeting, to be given personally or by mail to all Class A Members and Chapter Chairs. If such notice is given personally or by first-class mail, notice shall be given at least ten but not more than 50 days before the meeting. If such notice is given by any other class of mail, notice shall be given at least 30 but not more than 60 days before the meeting. In the case of a special meeting of the CCA, such notice shall also state the purpose or purposes of the meeting.

Section 7. Quorum. The presence in person or by proxy of a majority of the Chapter Chairs shall constitute a quorum for the transaction of all business at meetings of the CCA. A majority of the Chapter Chairs present in person or by proxy may adjourn any meeting to another time or place, whether or not a quorum is present. At such adjourned meeting, at which a quorum is present, any business may be transacted that might have been transacted on the original date of the meeting.

Section 8. Voting. Each Class A Member is entitled to one vote at all CCA meetings. Such vote may be cast by the Chapter Chair in person or by written proxy duly executed by the Chapter Chair or, in his or her absence, another duly authorized officer of the Chapter Member. Only a member of the CCA, BOD or Chapter Chair's Chapter Board of Trustees may be authorized to act by proxy for a Chapter Chair. Except as otherwise expressly required by applicable law, by the Certificate of Incorporation of the Corporation, as amended ("Articles"), or by these Bylaws, the act of a majority of the Chapter Chairs present in person or by proxy at a meeting at which a quorum is present shall be the act of the Class A Members.

Section 9. Action Without a Meeting. Any action required or permitted to be taken at a meeting of the Class A Members may be taken without a meeting, without prior notice, if a consent in writing, setting forth the action so taken, is signed by the Chapter Chairs or other authorized representatives of all of the Class A Members.

Section 10. Vacancies. A vacancy occurring in any Class A Member's representative office on the CCA, from whatever cause arising, shall be filled by that Class A Member. The Chapter Chair chosen by the Class A Member to fill the vacancy on the CCA shall serve for the unexpired term of the Chapter Chair replaced.

Section 11. Annual Forum with BOD. The CCA may meet with the BOD in an annual forum, which may be held at the same place as and in conjunction with the BOD and CCA annual meetings. In such forum, the CCA may ask questions, express viewpoints, concerns and recommendations, introduce proposals, advocate changes, and engage the BOD in discussions, with respect to any aspects of the Corporation's operations, affairs, initiatives, strategic policies, plans and direction.

Section 12. Deprivation or Suspension of Class A Membership. Any Class A Member may be deprived of membership in the Corporation or may be suspended or reinstated as a Class A Member by the BOD with or without cause. All rights, powers and privileges of any Class A Member shall cease upon the revocation or suspension of the Class A Member's membership.

ARTICLE V

CLASS B MEMBERS

Section 1. Voting Rights of Class B Members. Except as otherwise provided in Article X, Section 8, of these Bylaws, the Class B Members of the Corporation shall have all of the voting rights afforded to members under the NPCL.

Section 2. Term. The election of a person as a Director of the Corporation shall likewise be an admission to the class of Class B Members. No person shall continue to be a Class B Member of the Corporation after ceasing to be a Director.

Section 3. Meetings of Class B Members. There shall be an annual meeting of the Class B Members for the election of Elected Directors and the conduct of such other business as may come before the meeting, to be held on the date, and at such time and place, fixed by the Chairperson. A special meeting of Class B Members may be called at any time by the Chairperson, the BOD or upon the written request of at least 10% of all of the Class B Members.

Section 4. Notice of Class B Member Meetings. The Chairperson shall cause written notice of each meeting of the Class B Members, stating the place, date and time of the meeting, to be given personally or by mail to all Class B Members. If such notice is given personally or by first-class mail to Class B Members, notice shall be given at least ten but not more than 50 days before the meeting. If such notice is given to Class B Members by any other class of mail, notice shall be given at least 30 but not more than 60 days before the meeting. In the case of a special meeting of the Class B Members, such notice shall also state the purpose or purposes of the meeting.

Section 5. Quorum. Except as otherwise required by applicable law or these Bylaws, the presence in person or by proxy of a majority of the Class B Members shall constitute a quorum for the transaction of all business at meetings of the Class B Members. A majority of the Class B Members present in person or by proxy may adjourn any meeting to another time or place, whether or not a quorum is present. At such adjourned meeting, at which a quorum is present, any business may be transacted that might have been transacted on the original date of the meeting.

Section 6. Voting. Each Class B Member is entitled to one vote at all meetings of Class B Members. Except as otherwise expressly required by applicable law, by the Articles or by these Bylaws, the act of a majority of the Class B Members present in person or by proxy at a meeting at which a quorum is present shall be the act of the Class B Members. Only another Class B member may be authorized to act by proxy for a Class B Member.

Section 7. Action without a Meeting. Any action required or permitted to be taken at a meeting of Class B Members may be taken without a meeting, without prior notice, if a consent in writing, setting forth the action so taken, is signed by all of the Class B Members.

ARTICLE VI
BOARD OF DIRECTORS

Section 1. Powers. The business and affairs of the Corporation shall be conducted under the direction of, and the control and disposal of the Corporation's properties and funds shall be vested in, the BOD, *except* as otherwise provided by the NPCL, the Articles or these Bylaws. The BOD, to the extent permitted by law, may delegate the management of the activities of the Corporation to any person or persons, or committees however composed, *provided* that the activities and affairs of the Corporation shall be managed and all corporate powers shall be exercised under the ultimate direction of the BOD. The BOD shall have all powers as are necessary, appropriate or incidental to conduct and manage the affairs of the Corporation, including all powers granted to the Corporation by any law applicable to it.

Section 2. Composition of BOD. The BOD shall be composed of Elected Directors, as provided in Sections 3A and 3B of this Article VI and Life Member Directors.¹ The term "Directors" as used in these Bylaws includes Elected Directors and Life Member Directors.

Section 3. Number and Term of Elected Directors.

A Number. There shall be no less than 20 and no more than 30 Directors, the exact number constituting the entire BOD to be fixed, from time to time, by the BOD pursuant to a resolution adopted by a majority of the entire BOD, provided that in doing so the BOD may not shorten the term of any incumbent Director. "Entire BOD" means the total number of Directors entitled to vote which the Corporation would have if there were no vacancies on the BOD.

B Classes, Terms. At each annual meeting of the Class B Members, the successors of those Elected Directors whose term expires in that year shall be elected to serve a three-year term beginning July 1 of that year, except as expressly provided otherwise in these Bylaws. The Elected Directors with terms ending June 30, 2009 and each subsequent third anniversary of that date shall be designated in the records of the Corporation as being in Class I. The Elected Directors with terms ending June 30, 2010 and each subsequent third anniversary of that date shall be designated in the records of the Corporation as being in Class II. The Elected Directors with terms ending June 30, 2011 and each subsequent third anniversary of that date shall be designated in the records of the Corporation as being in Class III. Anyone elected to fill a vacancy in any Class of the Elected Directors, from whatever cause arising, shall be designated in the records of the Corporation as being in that Class. Any newly created directorships or any decrease in directorships shall be so apportioned among the classes as to make all classes as nearly equal in number as possible.

C BOD Officers as Elected Directors. A BOD Officer is an Elected Director by virtue of being a BOD Officer. No person shall be elected to serve for a term as a BOD Officer if service for such term would cause that person to exceed the term limits for serving as an Elected Director set forth in subsection E below.

¹ Life Member Directors are those individuals who, as of January 1, 2005, were Life Members of the Corporation's then governing Board.

D Definition of "Term" for Term Limitation Purposes. For purposes of the following term limitations for Elected Directors, the word "Term" does not include the period of time served by anyone elected to fill a vacancy in any Class of Elected Director if such period is 18 months or less.

E Term Limitations. No person shall hold the office of Elected Director for more than three consecutive Terms, but such person shall again be eligible to be elected as an Elected Director for a Term commencing at least three years after the end of his or her last Term.

Section 4. Qualification Criteria for Elected Directors. From time to time, the Board Development Committee shall present to the BOD "Board Composition Guiding Principles" and a "Board Capabilities Framework" ("BOD Criteria") for adoption by the BOD to assist the BOD and the Board Development Committee in evaluating suitable candidates for positions as Elected Directors and BOD Officers.

Section 5. Nominations of Elected Directors: Notice. All nominations of Elected Directors shall be in accordance with Sections 5 and 6 of this Article VI. There shall be no nominations of Elected Directors from the floor at any meeting of the Class B Members.

Applying the BOD Criteria, the Board Development Committee shall nominate for the election of Elected Directors at the next annual meeting of the Class B Members one nominee for any Elected Director position to be filled. The Board Development Committee shall complete such nominations and give written notice of all such nominees to all Class B Members at least 40 days before the annual meeting of the Class B Members. Such notice shall (i) specify how the nominee satisfies the BOD Criteria in Section 4 of this Article VI and (ii) be accompanied by the nominee's biographical data.

Section 6. Additional Nominations: Notice. Applying the BOD Criteria, additional nominations for any Elected Director position may be made by written petition signed by at least 15% of all of the Class B Members, which petition must be received at the Home Office (addressed to the attention of the Chairperson) at least 20 days before the annual meeting of the Class B Members and which must bear the signature of the nominee consenting to such nomination by petition. Each petition shall (i) carry the name of only one nominee, (ii) be accompanied by the nominee's biographical data, and (iii) specify how the nominee satisfies the BOD criteria provided for in Section 4 of this Article VI. The Chairperson shall cause written notice of the receipt of such petition, accompanied by such biographical data, to be given within two Business Days after the deadline for such petitions to all Class B Members.

Section 7. Ballots. This Section 7 applies solely if an election of Elected Directors at an annual meeting of the Class B Members involves anyone who was nominated by petition. In that event, voting ballots shall be prepared for use at the meeting. Such ballots shall designate the names of all nominees and shall specify who was nominated by the Board Development Committee. When there is more than one nominee for an Elected Director position, the nominee for that position receiving the highest number of votes shall be elected.

Section 8. Voting. Each Director is entitled to one vote at all BOD meetings.

Section 9. Resignations. Any Director may resign at any time by delivering a written resignation to the BOD or to the Chairperson or the Secretary/Treasurer. Any resignation shall take effect on the date of the Corporation's receipt of such resignation unless a

later time is specified therein, and the acceptance of the resignation shall not be necessary to make the resignation effective.

Section 10. Removal. Any Director may be removed for cause by the BOD after giving notice of the reasons for removal to each Director, and after a hearing and a vote for removal by two-thirds of the Directors present at a meeting, *provided* there is a quorum of not less than a majority present at the BOD meeting at which such action is taken.

Section 11. Meetings of the BOD. The annual meeting of the BOD to elect BOD Officers and to transact such other business as may properly come before the meeting shall be held at the place, date and time fixed by the Chairperson. The Chairperson shall cause written notice of the BOD annual meeting to be provided to all BOD Members not less than 15 days prior to the date of the meeting.

Regular or special meetings of the BOD shall be held at such times and in such places as may be determined by the BOD. Special meetings of the BOD shall also be held at the Home Office upon the request of the Chairperson or at the written request of at least 20% of the Directors. Not less than three meetings of the BOD shall be held every year. Notice of a BOD meeting shall be given to all BOD Members not less than 10 days prior to the date of any regular meeting and not less than 72 hours prior to any special meeting.

Section 12. Waiver of Notice. Notice of any BOD meeting need not be given to any Director who submits a signed waiver of notice whether before or after the meeting, nor to any Director who attends the meeting without protesting, prior thereto or at its commencement, the lack of notice to him or her.

Section 13. Quorum. The presence of a majority of the Directors then in office shall constitute a quorum, provided that in no instance shall the quorum be less than five Directors plus one Director for every ten Directors or fraction thereof over 15. A majority of the Directors present may adjourn any meeting to another time and place, whether or not a quorum is present.

Section 14. Action by BOD. *Except* as otherwise expressly required by applicable law, by the Articles or by these Bylaws, the vote of a majority of the Directors present at the time of the vote, if a quorum is present at such time, shall be sufficient to take any action.

Section 15. Meetings by Telephone, Etc. Any one or more Directors or any committee thereof may participate in a meeting of the BOD or a committee by means of a conference telephone or similar communication equipment allowing all persons participating in the meeting to hear each other at the same time. Participation by such means shall constitute presence in person at a meeting.

Section 16. Action Without a Meeting. Whenever the Directors are required or permitted to take any action by vote at a meeting, such action may be taken without a meeting on unanimous written consent, setting forth the action so taken, signed by all of the Directors.

Section 17. Vacancies. The BOD, at any meeting of the BOD, may fill a vacancy occurring in an Elected Director position, from whatever cause arising, including, but not limited to, newly created directorships. Should the BOD decide to fill a vacancy, the Board Development Committee, applying the BOD Criteria, shall nominate a nominee to fill such vacancy.

No reduction of the authorized number of Elected Directors shall have the effect of removing any Elected Director prior to the expiration of the Elected Director's current term of office.

Section 18. President; Other Employed Officers. The BOD shall engage a President and Chief Executive Officer of the Corporation ("*President*"), whose duties and powers shall be determined by the BOD. The President shall be an employee of the Corporation and may not be a Director, Chapter Chair or trustee of a Chapter or provisional chapter. The President may designate one or more executive vice presidents, senior vice presidents, vice presidents or other titled officers, each of whom shall be an employee of the Corporation and may not be a Director, Chapter Chair or trustee of a Chapter or provisional chapter. No officer designated by the President shall have any authority to sign any document described in Article X, Section 1 without the consent of the BOD.

ARTICLE VII

COMMITTEES

Section 1. Standing Committees of the BOD. The Corporation shall have the following standing committees of the BOD, each of which must have at least three members. Only Directors can be members of standing committees. *Except* as specifically provided to the contrary in this Section 1, their members and chairpersons shall be appointed by the Chairperson with the consent of the BOD by resolution adopted by a majority of the entire BOD. As of July 1, 2014, the effective date of the New York Non-Profit Revitalization Act of 2013 (the "Act"), all committees of the BOD authorized pursuant to Sections 1 and 2 of this Article VII, whether currently in existence or subsequently established shall be known as "committees of the BOD" and any reference in these Bylaws to a "standing committee" shall be deemed to be a reference to a "committee of the BOD."

A Audit Committee. The Audit Committee shall be composed of Independent Directors (as defined below) and shall:

(a) recommend the firm to be employed as the Corporation's independent auditor, and review and approve the discharge of any such firm; review and approve the independent auditor's compensation and the terms of its engagement by the Corporation, and annually review the performance and the independence of such auditor;

(b) review, in consultation with the independent auditor, the scope and planning of the audit prior to the audit's commencement; the result of each independent audit of the Corporation, the report of the independent auditor, any related management letter, management's responses to the recommendations made by the independent auditor in connection with the audit, the adequacy of the Corporation's accounting and financial reporting processes, any material risks and weakness in internal controls identified with by the independent auditor, any restrictions on the scope of the independent auditor's activities or access to requested information and any significant disagreements between the auditor and management;

(c) review, in consultation with the independent auditor and management, the Corporation's annual financial statements, any report or

opinion rendered by the independent auditor in connection with those financial statements, and any dispute between management and the independent auditor that arose in connection with the preparation of those financial statements; and review and report to the BOD with respect to the financial portions of the Corporation's annual report;

(d) review, before or after publication, the Corporation's periodic interim unaudited financial statements;

(e) consider, in consultation with the independent auditor, the scope and plan of forthcoming external audits;

(f) consider, in consultation with the independent auditor and the chief internal auditor, if any, the adequacy of the Corporation's internal accounting controls;

(g) consider, when presented by the independent auditor or otherwise, material questions of choice with respect to the choice of appropriate accounting principles and practices to be used in the preparation of the Corporation's financial statements;

(h) review the expense accounts and perquisites of officers and senior staff and the Corporation's compliance with its conflict of interest policy and code of ethical conduct;

(i) review the Society's annual report to the Internal Revenue Service (Form 990) prior to filing with the Service and present the annual report by the BOD;

(j) oversee the Corporation's administration of and compliance with its whistleblower policy;

(k) have power to inquire into any financial matters in addition to those set forth in clauses (a) through (h) above;

(l) report to the BOD on the Audit Committee's activities; and

(m) perform such other functions as may be assigned to it by applicable law, these Bylaws or the BOD.

In order to be considered an "Independent Director," a Director may not (i) be or have been within the last three years an employee of the Corporation or any affiliate, or have a relative who is or has been within the last three years a key employee of the Corporation or any affiliate; (ii) have received or have a relative who received more than \$10,000 in direct compensation from the Corporation or any affiliate within any of the last three fiscal years; or (iii) be an employee of or have a substantial financial interest in any entity that has made payments to or received them from the Corporation or any affiliate for property or services which, in any of the last three fiscal years, exceeds the lesser of \$25,000 or 2 percent of such entity's consolidated gross revenues, or have a relative who is an officer of or has a substantial financial interest in any such entity. A "relative"

shall include a Director's spouse, brothers and sisters (whether by whole or half-blood), children (whether natural or adopted), grandchildren, great-grandchildren and the spouses or domestic partners of brothers, sisters, children, grandchildren and great-grandchildren. For the purposes of the definition of "Independent Director," the term "payments" does not include charitable contributions made to the Corporation.

At least one member of the Audit Committee (who may be its chairperson) shall qualify as an audit committee financial expert (defined as a person who has the following attributes: (i) an understanding of generally accepted accounting principles and financial statements; (ii) the ability to assess the general application of such principles in connection with the accounting for estimates, accruals and reserves; (iii) experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Corporation's financial statements, or experience actively supervising one or more persons engaged in such activities; (iv) an understanding of internal controls and procedures for financial reporting; and (v) an understanding of audit committee functions).

B Finance Committee. The Finance Committee recommends strategic policy and direction; provides oversight, evaluation and support for all significant financial matters affecting the Corporation; recommends and monitors the Corporation's annual budget and financial procedures, records, and internal reports; recommends funding parameters for program and non-program expenditures; and provides guidance and support to professional staff and Chapters and provisional chapters on financial management.

C Board Development Committee.

(a) The Board Development Committee recommends strategic policy and direction, provides oversight and evaluation, and recommends candidates to the Class B Members for election as Elected Directors and to the BOD for election as BOD Officers and Board Development Committee members, based on the BOD Criteria and the candidates' potential for "value added" in time, talent and treasury to the advancement of the Corporation's mission and the achievement of its goals. The Board Development Committee's primary role is to ensure that the BOD has the right mix of capabilities to ensure mission and governance effectiveness. The Board Development Committee shall appoint its own chairperson.

(b) The Board Development Committee shall consist of six members, four of whom are elected and two of whom are appointed. The four elected members of the Board Development Committee shall be elected by the affirmative vote of a majority of the entire BOD to serve a two year term. The two appointed members of Board Development Committee shall be appointed to serve a two year term by the Chairperson with the consent of the BOD by resolution adopted by a majority of the entire BOD. The members of the Board Development Committee shall be divided into two classes. For the purposes of so classifying the Board Development Committee membership, the three elected Board Development Committee members serving as of [January 1, 2014] shall have their terms extended so that their terms end on June 30, 2015,

and the terms of the two appointed Board Development Committee members appointed by the Chairperson whose term begins on July 1, 2014 and the one elected Board Development Committee member whose term begins on July 1, 2014 shall end on June 30, 2016. The Board Development Committee members with terms ending on June 30, 2015 and their successors having terms ending each subsequent second anniversary of that date shall be designated in the records of the Corporation as being in Class 1. The Board Development Committee members with terms ending on June 30, 2016 and their successors having terms ending each subsequent second anniversary of that date shall be designated in the records of the Corporation as being in Class 2. The terms of both Class 1 and Class 2 Board Development Committee members shall begin on July 1. No person shall hold the office of Board Development Committee member for more than two consecutive two year terms. Anyone elected to fill a vacancy in any Class of the Board Development Committee members, from whatever cause arising, shall be designated in the records of the Corporation as being in that Class. Any increase or decrease in the number of Board Development Committee members shall be so apportioned among the classes as to make all classes as nearly equal in number as possible.

(c) All Board Development Committee members shall be Independent Directors, as that term is defined in subsection 1A of this Article VII.

(d) A vacancy on the Board Development Committee may be filled by appointment by the Chairperson with the consent of the BOD by resolution adopted by a majority of the entire BOD. A vacancy shall exist if a Board Development Committee member is no longer a Director. The Board Development Committee member appointed to fill the vacancy on the Committee shall serve for the unexpired term of the member replaced.

(e) Rules, regulations and procedures governing the composition, activities and operations of the Board Development Committee, in addition to those set forth in these Bylaws, shall be set forth in the Board Development Committee charter and the Board Development Committee shall be governed by such additional rules, regulations and procedures as they are amended from time to time by the BOD. Should any such additional rules, regulations or procedures set forth in the Board Development Committee charter conflict with a provision of these Bylaws, the provision in the Bylaws shall prevail.

D Executive Committee. There shall be an Executive Committee, consisting of the BOD Officers and one At-Large Director, to conduct the business of the Corporation between regular meetings of the BOD, but only when deemed necessary in the good faith judgment of the Executive Committee. The At-Large Director shall be appointed by the Chairperson with the consent of the BOD by resolution adopted by a majority of the entire BOD. The Executive Committee also shall review the performance of the Corporation's Chief Executive Officer and make recommendations to the BOD about his or her compensation, including bonuses and benefits, if any, and about his or her termination, if deemed appropriate by the Executive Committee.

E Mission Oversight Committee. There shall be a Mission Oversight Committee which shall be responsible for safeguarding and overseeing the

Corporation's substantive mission including, without limitation, with respect to its research, Therapy Acceleration Program, patient services, advocacy, outcomes assessments, and the priorities and integration of the Therapy Acceleration Program and research agendas.

Section 2. Other Standing Committees of the BOD. The BOD, by resolution adopted by a majority of the entire BOD, may designate one or more other standing committees of the BOD, each of which must be comprised of at least three members and all members of such standing committees must be Directors. The members and chairperson of each such standing committee shall be appointed by the Chairperson with the consent of the BOD by resolution adopted by a majority of the entire BOD. Such other standing committees of the BOD shall have only the specific powers delegated to them by the BOD.

Section 3. Operating Committees, Advisory Committees and Task Forces.

A *Membership.* The Corporation shall have Operating Committees as the BOD may create from time to time. Except as specifically provided to the contrary in this Section 3, their members may, but need not, be Directors and their members shall be appointed by the Chairperson with the consent of the BOD. The Chairperson of the BOD shall appoint from among the members of each operating committee a committee chairperson. Such Operating Committees shall be committees of the corporation under the NPCL. The BOD may establish and disband committees as needed to support its work.

B *Composition.* The BOD or the Chairperson with the consent of the BOD may (i) appoint Operating Committees of the Corporation as the BOD or the Chairperson determines for the furtherance of the objectives and purposes of the Corporation and (ii) delegate to such Operating Committees those powers which, in the BOD's or the Chairperson's judgment, are necessary and desirable provided that no such Operating Committee shall have the power to bind the BOD. Such committees shall have only the specific powers delegated to them by the BOD or the Chairperson with the consent of the BOD and report to the BOD as requested by the BOD.

C *Advisory Committees and Task Forces.* The Corporation, from time to time, may have such Advisory Committees and Task Forces as deemed advisable by the BOD or BOR.

Section 4. Quorum. Except as otherwise specifically provided in these Bylaws, the presence of one-third or more of the members (but in no event fewer than two members, except for committees of one) of any committee or task force shall constitute a quorum of that committee or task force. A majority of the committee or task force members present may adjourn any meeting to another time and place, whether or not a quorum is present.

Section 5. Committee Charters. Additional rules and regulations governing the composition and operations of the standing, operating and advisory committees of the Corporation may be set forth in committee charters adopted and amended from time to time by the BOD.

ARTICLE VIII

OFFICERS

Section 1. Election of Officers.

A *Number and Qualifications.* The officers of the Corporation shall consist of a Chairperson ("Chairperson"), a Vice Chairperson, and a Secretary/Treasurer (collectively, "BOD Officers"), all of whom shall be voting members of the BOD. The officers of the Corporation also shall include a President and Chief Executive Officer and others, all of whom shall be employees of the Corporation and shall not be members of the BOD, as provided in Article VI, Section 18. No more than one Office may be held simultaneously by the same person. No employee of the Corporation may serve as Chairperson or Vice Chairperson.

B *Election and Term of Office.* Pursuant to nominations as provided in subsection C below, at the 2010 BOD annual meeting and the BOD annual meeting every even-numbered year thereafter, the BOD shall elect a Chairperson, a Vice Chairperson and a Secretary/Treasurer, each for a two-year term beginning July 1 of that year. No one elected as Chairperson at or after the 2008 BOD annual meeting may serve more than a single two year term. Any other BOD Officer who has served two consecutive terms in the same BOD office, whether such term be one or two years, may not be elected again to that office until two years have elapsed from the end of his or her last term.

C *Nominations of Officers.*

(a) All nominations of BOD Officers shall be in accordance with this subsection C. There shall be no nominations of BOD Officers from the floor at the BOD meeting. The Board Development Committee shall nominate for election at the 2010 BOD annual meeting and the BOD annual meeting every even-numbered year thereafter one nominee for each of these Offices: Chairperson, Vice Chairperson and Secretary/Treasurer. The Board Development Committee shall complete such nominations and give written notice of all such nominees to all BOD members at least 40 days before the BOD annual meeting, accompanied by the nominees' biographical data.

(b) Additional nominations for any Office for which the Board Development Committee has presented a nominee may be made by written petition signed by at least 15% of all Directors, which petition must be received at the Home Office (addressed to the attention of the Chairperson) at least 20 days before the BOD annual meeting and which must bear the signature of the nominee consenting to such nomination by petition. Each petition shall carry the name of only one nominee and be accompanied by the nominee's biographical data. The Chairperson shall cause written notice of the receipt of such petition, accompanied by such biographical data, to be given within two Business Days after the deadline for such petitions to all BOD members.

Section 2. Removal and Resignation. Any BOD Officer may be removed for cause by the BOD after giving notice of the reasons for removal to the BOD Officer and to each Director, and after a hearing and a vote of two-thirds of the Directors present at a meeting.

Any BOD Officer may resign at any time by delivering a written resignation to the Chairperson or Secretary/Treasurer or to the Corporation's President. Any resignation shall take effect on the date of the Corporation's receipt of such resignation unless a later time is specified therein, and the acceptance of such resignation shall not be necessary to make it effective.

Section 3. Vacancies. A vacancy in any Office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in these Bylaws for regular election or appointment to such Office, provided that such vacancies may be filled as they occur.

Section 4. Chairperson. This person shall preside at all BOD meetings. Except as specifically provided to the contrary in these Bylaws, the Chairperson shall have the power to call special meetings, to appoint chairpersons and members of committees as set forth in these Bylaws and to make such other appointments as he or she may deem necessary. The Chairperson is a nonvoting ex officio member of every committee with the exception of the Board Development Committee.

Section 5. Vice Chairperson. The Vice Chairperson of the Board shall, if present at any time when the Chairperson of the Board is absent, preside at the meetings of the BOD and shall perform such other duties as may from time to time be assigned to him or her by these Bylaws or by the BOD or by the Chairperson of the BOD.

Section 6. Secretary/Treasurer. The Secretary/Treasurer shall keep the minutes of the BOD meetings, and shall have control of the seal of the Corporation and shall affix same to documents when authorized to do so. The Secretary/Treasurer shall oversee the care and custody of the funds and securities of the Corporation and the general supervision of the books of account. The Secretary/Treasurer shall also be a member of the Finance Committee. The Secretary/Treasurer shall perform all of the other duties usual to the office of a secretary and a treasurer of a corporation.

ARTICLE IX

CHAPTERS

Section 1. Establishment. Chapters of the Corporation are established by the issuance of a charter. The BOD may establish such Chapters or provisional chapters of the Corporation and shall promulgate such rules and regulations governing Chapters and provisional chapters as may be determined from time to time. No Chapter or provisional chapter shall incorporate.

Section 2. Rules and Regulations. All Chapters and provisional chapters must abide by the Corporation's Chapter Policies and Procedures, the Corporation's Bylaws to the extent that the Bylaws do not conflict with the Chapter Policies and Procedures and any other applicable policies and procedures, as each may be amended from time to time. The Chairperson is a nonvoting ex officio member of the board and the executive committee of each Chapter and provisional chapter.

Section 3. Suspension and Revocation. The BOD may suspend or revoke the charter issued to a Chapter or provisional chapter, with or without cause, and vest all its powers and functions in the Chairperson.

Section 4. Funds, Moneys and Contributions.

A *Remittances.* All funds, moneys, contributions and other property received, held, given to or in the custody or control of any Chapter or provisional chapter are the funds and property of the Corporation. The net receipts of such funds and property of each Chapter and provisional chapter must be remitted to the Corporation at the Home Office. Each Chapter and provisional chapter shall receive, at least monthly, detailed reports from the Home Office, as to all income and expenditures. Failure of any Chapter or provisional chapter to remit funds as aforesaid shall subject such Chapter or provisional chapter to sanctions which may be invoked by the BOD, including, but not limited to, revocation of the charter, notification of local authorities, institution of suit, and such other measures as deemed necessary by the BOD. The purpose of this subsection A is to insure the maximum use of and general benefit from donated public and private funds for the objectives and purposes of the Corporation, and the general public.

B *Bank Resolutions, Etc.* For or with respect to each Chapter and provisional chapter, bank resolutions for the opening and closing of accounts, investment accounts, state registrations and filings, and other documents that encumber the Corporation or its property are required to contain the signatures of two individuals. The individuals authorized to sign such documents on behalf of the Corporation shall be determined by resolution adopted from time to time by the BOD.

C *Loans.* No Chapter or provisional chapter shall have the power to borrow money in the name of the Corporation.

D *Signatures.* All checks, drafts or orders for the payment of money of each Chapter and provisional chapter shall be signed by Directors or other agents as the BOD may from time to time designate, but no less than two signatures shall be required at all times.

E *Contracts.* Except in accordance with Corporation policy or as provided by the BOD from time to time by resolution of the BOD, no Chapter or provisional chapter shall bind the Corporation in any contractual relationship without prior written approval of the Corporation.

Section 5. Employees. Employees receiving financial compensation on the Chapter or provisional chapter level, or from the Corporation's Home Office, are subject to and controlled by the Corporation's personnel policies, rules and regulations. Among other things, these pertain to hiring, promotion and transfers, performance standards and reviews, salary increases and termination of employment.

ARTICLE X

OTHER PROVISIONS

Section 1. Endorsement of Documents; Contracts. Subject to the provisions of applicable law, any note, mortgage, evidence of indebtedness, contract, conveyance, instrument or other document in writing and any assignment or endorsement thereof executed or entered into between the Corporation and any other person, when signed by the Chairperson, the President, the Vice Chairperson or the Secretary/Treasurer, shall be valid and

binding on the Corporation in the absence of actual knowledge on the part of the other person that the signing officers had no authority to execute the same. Any such documents may be signed by any other person or persons and in such manner as from time to time shall be determined by the BOD, and unless so authorized by the BOD, no officer, agent, or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or amount.

Section 2. Representation of Shares of Other Corporations. The Chairperson or any other officer or officers authorized by the BOD or by the Chairperson each are authorized to vote, represent, and exercise on behalf of the Corporation all rights incident to any and all shares of any other corporation or corporations standing in the name of the Corporation. The authority herein granted may be exercised either by any such officer in person or by any other person authorized so to do by proxy or power of attorney duly executed by such officer.

Section 3. Fiscal Year, Books and Records. The fiscal year of the Corporation shall end on June 30. The books and records of the Corporation shall be kept on the basis of such fiscal year and shall reflect all the transactions of the Corporation and be appropriate and adequate for the Corporation's business.

Section 4. Notice. Whenever any notice is authorized or required by these Bylaws to be given, it shall be in writing and shall be delivered personally, by fax or e-mail or by mail, express mail or similar private service at least 15 days prior to the event requiring such notice, unless a different period or method for notice is required by these Bylaws. Means other than e-mail will be used for anyone who so requests in writing mailed to the Home Office (addressed to the attention of the Chairperson). If notice is given by mail, it shall be deemed to be sufficient if mailed by first class mail addressed to the person or entity entitled to notice at the last known post office address on the records of the Corporation, and such notice shall be deemed to have been given on the day of such mailing. Any notice may be waived in writing by the person or entity entitled to notice. Any notice authorized or required by these Bylaws to be given to a Class A Member shall be given to the Class A Member's executive director and Chapter Chair. Any notice of a CCA meeting shall be given personally or by mail to each Class A Member and Chapter Chair: (i) at least ten but not more than 50 days before the meeting if given personally or by first class mail, and (ii) if mailed by any other class of mail, at least 30 but not more than 60 days before the meeting. Any notice of a meeting of Class B Members shall be given personally or by mail to each Class B Member: (i) at least ten but not more than 50 days before the meeting if given personally or by first class mail, and (ii) if mailed by any other class of mail, at least 30 but not more than 60 days before the meeting.

Section 5. Corporate Seal. The Corporate Seal shall be in such form as shall be adopted from time to time by the BOD.

Section 6. Procedure at Meetings.

A. Procedure and debate shall be in accordance with these Bylaws and rules of parliamentary law known as Robert's Rules of Order as most recently revised.

B. Whenever there is an election involving anyone who was nominated by petition, voting ballots shall be prepared for use at the meeting, designating the names of all nominees and specifying who was nominated by the Board Development Committee.

Section 7. Annual Report. The Directors shall present at a meeting of each of the Class A Members and the Class B Members a report, certified by a certified public accountant, showing all matters customarily reported in an annual report; which report shall be filed with the records of the Corporation and an abstract thereof entered in the minutes of the proceedings of such meeting.

Section 8. Amendment. These Bylaws may be amended, in whole or in part, at any meeting of either the Class B Members or the BOD, provided that at least 30 days' prior written notice of the proposed amendment has been given to each Class B Member or BOD Member, as applicable; and *provided, further*, that no amendment of the Bylaws by the Class B Members or the BOD Members which affects the Field shall become effective unless and until it has been ratified by the CCA, and the Class B Members or BOD Members shall declare, in their respective resolution approving any amendment of the Bylaws, whether in their judgment such amendment does or does not affect the Field.

Section 9. Severability. If any provision, section, subsection, subdivision, rule or regulation contained in these Bylaws is deemed to be invalid, such invalidity shall not affect the validity of the remaining portions of these Bylaws.

Section 10. Effective Date. The effective date of these Bylaws and any amendment to them shall be the date of adoption or a subsequent date specified therein or in the resolution adopting or ratifying same.

Section 11. Use of Electronic Communications for Corporate Action. As of July 1, 2014, the effective date of the New York Non-Profit Revitalization Act of 2013, actions that may be taken by electronic means under the Act, including the giving of board and member meeting notices, waivers of notice, member proxies and votes requiring board or member unanimous consent, as well as participation in board meetings by videoconference, may be taken by such electronic means in accordance with the Act notwithstanding a provision to the contrary in these Bylaws.

ARTICLE XI

INDEMNIFICATION

Section 1. Indemnification of Directors, Members, Officers and Others. The Corporation shall, to the fullest extent permitted by applicable law, indemnify any person who is or was a Director, a Class B Member, Chapter Chair, officer and/or trustee of the Corporation (and its Chapters and provisional chapters) and any person who is or was serving at the request of the Corporation in any capacity in any other entity or corporation (individually and collectively, "*Indemnified Persons*") from any liability by reason of serving or having served in such capacity.

This indemnification shall apply when such person was or is made, or threatened to be made, a party to any proceeding, whether civil, criminal, administrative or investigative, whether involving any actual or alleged breach of duty, neglect or error, any accountability, or any actual or alleged misstatement, misleading statement or other act or omission and whether brought or threatened in any court or administrative or legislative body or agency.

Indemnification shall cover, to the fullest extent permitted by applicable law, the amount of the judgment(s), fine(s), amount(s) paid in settlement, costs, charges, reasonable expenses

(including without limitation attorneys' fees) incurred in connection with any proceeding or any threatened proceeding mentioned in this Section 1 and/or any appeals.

Section 2. Indemnification of Others. The Corporation shall indemnify other persons and reimburse the reasonable expenses thereof, to the extent required by applicable law, and may indemnify any other person to whom the Corporation is permitted to provide indemnification or the advancement of reasonable expenses as permitted by applicable law.

Section 3. Advances or Reimbursement of Expenses. The Corporation may from time to time reimburse or advance to any Indemnified Person the funds necessary for payment of reasonable expenses, including attorneys' fees, incurred in connection with any proceeding or any threatened proceeding referred to in Section 1 of this Article XI, upon receipt of a written undertaking by or on behalf of such person to repay such amount(s) if a judgment or other final adjudication adverse to the Indemnified Person establishes that (i) such person's acts were committed in bad faith or were the result of active and deliberate dishonesty and, in either case, were material to the cause of action so adjudicated, (ii) such person personally gained in fact a financial profit or other advantage to which such person was not legally entitled, or (iii) such person's conduct was otherwise of a character such that the applicable law would require that such amount(s) be repaid.

Section 4. Interpretation. Any person entitled to be indemnified as a matter of right pursuant to this Article XI may elect to have the right to indemnification (or advancement of reasonable expenses) interpreted on the basis of the applicable law in effect at the time of the occurrence of the event or events giving rise to the proceeding or threatened proceeding, to the extent permitted by applicable law, or on the basis of the applicable law in effect at the time indemnification is sought. The term "Corporation" as used in this Article XI shall include but not be limited to The Leukemia & Lymphoma Society, Inc. or any Chapter or provisional chapter thereof, or any affiliate organization(s). All references to person(s) in this Article XI shall include the heirs, executors and administrators of such person(s).

Section 5. Indemnification Right. The right to be indemnified pursuant to this Article XI: (i) is a contract right pursuant to which the person entitled thereto may bring suit as if the provisions hereof were set forth in a separate written contract between the Corporation and such person, (ii) is intended to be retroactive and shall be available with respect to events occurring prior to the adoption hereof, and (iii) shall continue to exist after any rescission or restrictive modification hereof, with respect to events occurring prior thereto.

Section 6. Limitation. It is expressly provided that no indemnification shall be made to or on behalf of any person if a judgment or other final adjudication adverse to such person establishes that (i) such person's acts were committed in bad faith or were the result of active and deliberate dishonesty and, in either case, were material to the cause of action so adjudicated, (ii) such person personally gained in fact a financial profit or other advantage to which such person was not legally entitled, or (iii) such person's conduct was otherwise of a character such that the applicable law would not permit indemnification.



October 27, 2009

The Leukemia & Lymphoma Society
1311 Mamaroneck Avenue, Suite 130
White Plains, N.Y. 10605

Gentlemen:

Cobalt 301 East Main, LLC is excited to have The Leukemia & Lymphoma Society as a key tenant in our building at 301 East Main Street, Louisville, Kentucky. We look forward to a long and mutually satisfying relationship with the Society.

As a further demonstration of our support for the fine work done by your organization, we commit to making a \$10,000 cash donation to The Leukemia & Lymphoma Society, to be made by one of our affiliates, upon your move to our facility.

Thank you for selecting Cobalt for your office requirements in Louisville.

Sincerely,

Douglas C. Smith
Sr. Vice President

CHECK NO.	CHECK DATE	CHECK AMOUNT	CHECK TYPE	CHECK DATE
281318	Cobalt 301 East Main, LLC	00225784	11/16/09	Stub 1 of 1
11/13/09	111309	3,832.00		3,832.00
		3,832.00		3,832.00

REMOVE DOCUMENT ALONG THIS PERFORATION

The Leukemia & Lymphoma Society
Fighting Blood Cancers

1311 MAMARONECK AVENUE, WHITE PLAINS, NY 10605
GENERAL DISBURSEMENT'S INCOME ACCOUNT

Wells Fargo Bank, N.A.
118 Hospital Drive
Van Wert, OH 45891

CHEK NO. 00225784

VENDOR 281318 DATE 11/16/09 AMOUNT \$3,832.00

PAY TO THE ORDER OF THREE THOUSAND EIGHT HUNDRED THIRTY TWO AND 00/100

Cobalt 301 East Main, LLC
445 East Market Street, Suite 320
Louisville KY 40202

[Signature]

The Leukemia & Lymphoma Society
Fighting Blood Cancers
1311 MAMARONECK AVENUE, SUITE 310
WHITE PLAINS NY 10605

Cobalt 301 East Main, LLC
445 East Market Street, Suite 320
Louisville KY 40202

Lease Extension and Modification Agreement

This Lease Extension and Modification Agreement (the "Agreement") is made this ____ day of ~~August 2014~~ by and between The Leukemia & Lymphoma Society, Inc., a New York not-for-profit corporation with an address of 1311 Mamaroneck Ave, White Plains, N.Y. 10605 ("Tenant") and Cobalt 301 East Main, LLC, a Kentucky limited liability company with an address of 301 E. Main Street, Louisville, KY 40202 ("Landlord").

WHEREAS, Landlord and Tenant entered into a Lease Agreement dated January 1, 2010 (the "Original Lease") for the premises described therein; and

WHEREAS, Landlord and Tenant desire to amend the Original Lease to modify the Original Lease to include a renewal term;

NOW, THEREFORE, in consideration of the rights and duties contained in the Original Lease as modified in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:

1. Paragraph C of the Original Lease shall be amended to read as follows:

(5) "Renewal Term"One (1) Five year period upon expiration of the Initial Term, commencing at 12:00:01 am on January 1st, 2015 and ending at 11:59:59 pm on December 31, 2019.

2. Paragraph D-1 of the Original Lease shall be amended to read as follows:

During the renewal term.... Fixed Annual Rent due and payable with respect to the first 12 months of the Renewal Term shall be \$53,648, payable \$4,470.67 per month on the first day of the month.

Thereafter, Fixed Annual Rent shall increase by 1.5% annually as follows:

Year #2 (7)	\$54,452.72	payable \$4,537.73/Mo.
Year #3 (8)	\$55,269.51	payable \$4,605.79/Mo.
Year #4 (9)	\$56,098.55	payable \$4,674.88/Mo.
Year #5 (10)	\$56,940.03	payable \$4,745.00/Mo.

3. Tenant advises Landlord that Tenant is a not-for-profit corporation, exempt from state and federal taxation, whose mission and purpose, among other things, is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. In furtherance of Tenant's mission and purpose, Landlord agrees that Landlord shall make a \$15,000.00 donation to Tenant no later than ~~November 15, 2014~~ Landlord further agrees that if Landlord does not make the donation as set forth herein, Tenant shall have the right to offset the \$15,000.00 donation against the rent Tenant is obligated to pay under the Original Lease or this Agreement, as applicable.


Upon the \$15,000.00 donation being made by Landlord or applied by Tenant, as the case may be, Tenant agrees to furnish Landlord with a letter reflecting that the \$15,000.00 donation was so made by Landlord and received by Tenant.

4. All other provisions of the Original Lease shall remain unchanged and are in full force and effect.

IN WITNESS WHEREOF, the Landlord and Tenant hereby execute this Agreement on the date given below:

Tenant:


The Leukemia & Lymphoma Society, Inc.

By: 

Date: 11/13/14

Landlord:

Cobalt 301 East Main, LLC

By: 

Todd Blue, Manager

Date: 11-24-14



THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Consolidated Financial Statements

June 30, 2018

(With Independent Auditors' Report Thereon)

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Balance Sheet	3
Consolidated Statement of Activities	4
Consolidated Statement of Functional Expenses	5
Consolidated Statement of Cash Flows	6
Notes to Consolidated Financial Statements	7–19



KPMG LLP
345 Park Avenue
New York, NY 10154-0102

Independent Auditors' Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2018, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2018, and the changes in its net assets and its cash flows for the year then ended, in accordance with U.S. generally accepted accounting principles.



Report on Summarized Comparative Information

We have previously audited LLS's 2017 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated October 27, 2017. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2017 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

November 7, 2018

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Consolidated Balance Sheet

June 30, 2018

(with comparative amounts at June 30, 2017)

(In thousands)

Assets	2018	2017
Cash and cash equivalents	\$ 27,628	41,401
Prepaid expenses and other assets	2,767	3,613
Contributions and other receivables, net (note 6)	32,255	17,785
Investments (note 4)	319,662	209,421
Fixed assets, net (note 9)	8,614	10,119
Total assets	\$ 390,926	282,339
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 21,907	21,711
Deferred revenue (note 7)	16,243	14,028
Awards and grants payable (note 2)	51,673	64,052
Co-Pay assistance payable (note 3)	54,696	20,071
Other long-term liabilities (note 10)	3,835	3,167
Total liabilities	148,354	123,029
Commitments and contingencies (notes 2, 3 and 11)		
Net assets (note 5):		
Unrestricted	149,199	126,993
Temporarily restricted	90,221	29,161
Permanently restricted	3,152	3,156
Total net assets	242,572	159,310
Total liabilities and net assets	\$ 390,926	282,339

See accompanying notes to consolidated financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Consolidated Statement of Activities

Year ended June 30, 2018

(with summarized totals for the year ended June 30, 2017)

(In thousands)

	Unrestricted	Temporarily restricted	Permanently restricted	Total	
				2018	2017
Operating revenue:					
Contributions	\$ 251,770	30,338	—	282,108	258,525
Less direct donor benefit costs	(29,198)	—	—	(29,198)	(25,955)
Net campaign contributions	222,572	30,338	—	252,910	232,570
Co-Pay contributions (note 3)	—	159,851	—	159,851	77,779
Therapy acceleration program contractual return (note 2)	3,792	63	—	3,855	29,548
Service revenue	9,230	—	—	9,230	3,847
Donated services, goods and media (note 8)	7,715	—	—	7,715	14,594
Legacies and other revenue	9,645	1,373	—	11,018	5,291
Net interest and dividend income	3,895	421	—	4,316	2,866
Net assets released from restrictions (note 3):					
Co-Pay assistance	115,797	(115,797)	—	—	—
Satisfaction of other donor restrictions	15,530	(15,530)	—	—	—
Total operating revenue	388,176	60,719	—	448,895	366,495
Operating expenses (note 8):					
Program services:					
Research	69,752	—	—	69,752	65,067
Patient and community service	165,496	—	—	165,496	125,677
Public health education	42,940	—	—	42,940	48,138
Professional education	18,388	—	—	18,388	21,698
Total program services	296,576	—	—	296,576	260,580
Supporting services:					
Management and general	31,831	—	—	31,831	29,049
Fundraising	44,468	—	—	44,468	47,656
Total supporting services	76,299	—	—	76,299	76,705
Total operating expenses	372,875	—	—	372,875	337,285
Change in net assets from operating activities	15,301	60,719	—	76,020	29,210
Foreign currency translation adjustment	267	(362)	(4)	(99)	(184)
Net increase in fair value of investments (note 4)	6,638	703	—	7,341	8,428
Change in net assets	22,206	61,060	(4)	83,262	37,454
Net assets:					
Beginning of period	126,993	29,161	3,156	159,310	121,856
End of period	\$ 149,199	90,221	3,152	242,572	159,310

See accompanying notes to consolidated financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Consolidated Statement of Functional Expenses

Year ended June 30, 2018
(with comparative totals for the year ended June 30, 2017)
(in thousands)

	Program services				Management and general		Supporting services		Year ended		Direct donor benefit costs	
	Research	Patient and community service	Public health education	Professional education	Total	Total	Fundraising	Total	June 30, 2018	June 30, 2017	2018	2017
Awards and grants (note 2)	\$ 44,517	—	—	—	44,517	—	—	—	44,517	42,219	—	—
Therapy acceleration program (note 2)	5,834	—	—	—	5,834	—	—	—	5,834	4,711	—	—
Clinical Trial	5,899	—	—	—	5,899	—	—	—	5,899	2,142	—	—
Financial aid to patients	—	2,007	—	—	2,007	—	—	—	2,007	1,703	—	—
Co-Pay assistance (note 3)	—	108,442	—	—	108,442	—	—	—	108,442	72,969	—	—
Co-Pay processing fees	—	6,571	—	—	6,571	—	—	—	6,571	4,585	—	—
Donated services, goods, and media (note 8)	645	2,636	1,510	290	5,081	417	2,217	2,634	7,715	14,594	—	—
Salaries and employee benefits and taxes (note 10)	6,660	27,371	22,372	10,714	67,117	19,390	21,843	41,233	108,350	101,702	—	—
Professional fees	3,179	4,429	4,961	2,431	15,000	3,613	4,945	8,558	23,558	22,707	4,395	3,305
Printing, advertising, and supplies	80	3,571	4,661	1,070	9,382	2,224	6,910	9,134	18,516	17,581	6,286	5,090
Occupancy, telephone, and insurance (note 11)	391	3,279	2,925	1,126	7,721	1,729	2,281	4,010	11,731	11,912	—	—
Travel and meetings	583	1,757	1,579	1,041	4,960	1,163	1,144	2,307	7,267	10,165	16,043	14,877
Equipment rentals and maintenance	1,187	946	782	406	3,321	1,177	944	2,121	5,442	6,316	—	—
Postage and shipping	24	1,815	1,920	318	4,077	542	2,421	2,963	7,040	6,580	—	—
Miscellaneous	239	1,328	950	485	3,002	678	807	1,485	4,487	4,374	2,474	2,683
Impairment of fixed asset (note 9)	—	—	—	—	—	—	—	—	—	5,434	—	—
Depreciation and amortization	514	1,344	1,280	507	3,645	898	956	1,854	5,499	7,580	—	—
Total expenses	\$ 69,752	165,496	42,940	18,388	296,576	31,831	44,468	76,299	372,875	337,285	29,196	25,855

See accompanying notes to consolidated financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Consolidated Statement of Cash Flows

Year ended June 30, 2018

(with comparative amounts for the year ended June 30, 2017)

(In thousands)

	<u>2018</u>	<u>2017</u>
Cash flows from operating activities:		
Change in net assets	\$ 83,262	37,454
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net increase in fair value of investments	(7,341)	(8,428)
Impairment of fixed asset	—	5,434
Depreciation and amortization	5,499	7,580
Provision for uncollectible accounts	(630)	188
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	846	(707)
Contributions and other receivables	(13,840)	(729)
Accounts payable and accrued expenses	196	8,056
Other long-term liability	668	1,529
Deferred revenue	2,215	1,112
Awards and grants payable	(12,379)	3,601
Co-Pay assistance payable	34,625	6,602
Net cash provided by operating activities	<u>93,121</u>	<u>61,692</u>
Cash flows from investing activities:		
Purchases of fixed assets	(3,994)	(6,187)
Purchases of investments	(150,533)	(117,279)
Sales of investments	47,633	84,579
Net cash used in investing activities	<u>(106,894)</u>	<u>(38,887)</u>
Net (decrease) increase in cash and cash equivalents	(13,773)	22,805
Cash and cash equivalents at beginning of period	41,401	18,596
Cash and cash equivalents at end of period	\$ <u>27,628</u>	<u>41,401</u>

See accompanying notes to consolidated financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

(1) Organization and Summary of Significant Accounting Policies

(a) Organization

The Leukemia & Lymphoma Society, Inc. (LLS) is the world's largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today's most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

(b) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-six chapters in the United States, and LLS's not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. As part of the assumption of control, LLS recognized a transfer of net assets of \$552 in 2016. Effective February 8, 2018, PPCS was dissolved. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

(c) Tax-Exempt Status

LLS, LLSRP, LLSRF, and PPCS qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, as these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS and its related entities recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2018 and 2017.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

(d) Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS's management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the allowance for uncollectible accounts, allocation of functional expenses, and valuation of donated services, goods, and media. Actual results could differ from those estimates.

(e) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks, such as interest rate risks, market risk, political risks, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS's principal source of revenue is contributions by the general public. Accordingly, LLS's operations are dependent upon individual contributions that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co-Pay program in 2018 and 2017 was funded by six and eight donors, respectively. In addition, the Beat AML Master Trial was primarily funded by seven and five donors in 2018 and 2017, respectively.

(f) Summarized Financial Information

The consolidated financial statements are presented with 2017 summarized for comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2017 expenses by natural classification are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS's 2017 consolidated financial statements from which the summarized information was derived.

(g) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2018 through November 7, 2018, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

(h) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS's Board of Directors, for LLS to utilize for its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds is recorded as temporarily restricted net assets and is released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 5).

(i) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

(j) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) Topic 820, *Fair Value Measurement*, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

(k) Contributions, Grants, and Deferred Revenue

Contributions are recorded as revenue, at fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(l) Service Revenue

Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(m) Donated Services and Goods

LLS has determined that certain of the donated services and goods it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 8).

(n) Donated Media

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSAs (note 8).

(o) Cash Equivalents

Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

(p) Investments

Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments, which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC Topic 820. These values are reviewed and evaluated by management.

(q) Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years, furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

(r) Other Long-Term Liabilities

Other long-term liabilities represent LLS's liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 10) and straight-line rent of office leases (note 11).

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

(s) Professional Fees

Professional fees included in the consolidated financial statements principally include professional fundraising fees, contracted software development, and legal and auditing fees.

(t) New Authoritative Accounting Pronouncements

The FASB issued Accounting Standards Update (ASU) 2016-14, Presentation of Financial Statements of Not-for-Profit Entities, which among other things, changes how not-for-profit entities report net asset classes, expenses and liquidity in their financial statements. The significant requirements of the new ASU include the reduction of the number of net asset classes from three to two: with donor restrictions and without donor restrictions; the presentation of expenses by their function and their natural classification in one location; quantitative and qualitative information about the management of liquid resources and availability of financial assets to meet cash needs within one year of the date of the Consolidated Balance Sheet; and retaining the option to present operating cash flows in the Consolidated Statement of Cash Flows using either the direct or indirect method. LLS plans to adopt ASU 2016-14 for the year ending June 30, 2019.

The FASB is issuing Accounting Standards Update (ASU) 2018-08, to clarify and improve the scope and the accounting guidance for contributions received and contributions made. The amendments in this Update should assist entities in (1) evaluating whether transactions should be accounted for as contributions (nonreciprocal transactions) within the scope of Topic 958, Not-for-Profit Entities, or as exchange (reciprocal) transactions subject to other guidance and (2) determining whether a contribution is conditional. LLS plans to adopt ASU 2018-08 for the year ending June 30, 2020. LLS is continuing to evaluate the impact of adopting this guidance on its financial statements.

(2) Research

LLS has various activities that are utilized to carry out its mission as presented below:

Research

Awards and Grants: Awards and grants for research are approved by LLS's Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multiyear grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS's Board of Directors. LLS has multiyear grant commitments of \$52,216 at June 30, 2018, that are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of \$51,673 and \$64,052 at June 30, 2018 and 2017, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately \$984 and \$923 as of June 30, 2018 and 2017, respectively, have been netted against awards and grants expense.

TAP: Therapy Acceleration Program (TAP) is LLS's strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology, pharmaceutical companies, and universities. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multiyear contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS. LLS has contract commitments of \$12,745 and \$9,144 at June 30, 2018 and 2017, respectively, that are conditioned upon

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

future events and, accordingly, are not recorded. Grant refunds of approximately \$591 as of June 30, 2018 have been netted against therapy acceleration program contractual return.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

Year ending June 30:		
2019	\$	31,328
2020		19,710
2021		11,354
2022		<u>2,569</u>
Total	\$	<u>64,961</u>

TAP Contractual Return: In January 2009, as part of its TAP, LLS entered into an agreement with Celator Pharmaceuticals, Inc. (Celator) through which LLS provided funding of approximately \$4,100 to Celator in support of the Phase 2 study of Celator's lead compound Vyxeos™ (daunorubicin and cytarabine liposome for injection) for the treatment of Acute Myeloid Leukemia (AML). From 2012 through 2016, LLS provided funding of an additional \$5,000 for the Phase 3 clinical study of Vyxeos™. LLS provisions of funding to Celator were based on clinical milestones.

As part of the agreement, Celator was obligated to make payments to LLS relative to the timing of the product commercialization and other liquidity events. In July 2016, Jazz Pharmaceuticals (Jazz) completed the purchase of Celator, triggering a payment of \$13,716 to LLS. In late 2016, Jazz terminated the agreement with LLS triggering a one-time contract termination fee of \$11,612 to eliminate potential future royalty payments related to Vyxeos™. The total amount of the return to LLS from its TAP contract in Celator was \$25,328. The remaining \$4,220 of TAP contractual return for the year ended June 30, 2017 comes from various other TAP contracts.

For the year ended June 30, 2018, LLS received \$3,855 of TAP contractual returns from various TAP contracts.

(3) Co-Pay Assistance Program

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance Co-Pay obligations for prescription medications or private/public health insurance premiums. Revenue is recognized when donations are received while expenses are recognized as patient applications are approved for participation according to program criteria and on availability of funding. The Co-Pay Assistance payable of \$54,696 and \$20,071 has been established based on approved patient applications received through June 30, 2018 and 2017, respectively. At June 30, 2018, temporarily restricted net assets include \$52,528 received in 2018, which are available for expenditure and are intended to be awarded in fiscal year 2019.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

The following summarizes the activities of the Co-Pay Assistance program in 2018 and 2017.

	<u>2018</u>	<u>2017</u>
Beginning balance	\$ 8,148	8,960
Co-Pay contributions	159,851	77,779
Investments gains	326	—
Amount expended during the year:		
Direct assistance to patients	(108,442)	(72,969)
Other expenses incurred and reimbursed under the contract	<u>(7,355)</u>	<u>(5,622)</u>
Amounts available for expenditures in the next year	\$ <u>52,528</u>	<u>8,148</u>

(4) Investments

The following tables present LLS's fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2018 and 2017:

	<u>2018</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Money market funds and cash	\$ 158,371	158,371	—	—
Fixed income:				
Corporate bonds	56,758	56,758	—	—
Government securities and other	849	849	—	—
Equities:				
Large cap equity	35,644	35,644	—	—
International equity	33,437	33,437	—	—
Small/mid-cap equity	22,872	22,872	—	—
Commodities	<u>3,665</u>	<u>3,665</u>	—	—
	<u>311,596</u>	\$ <u>311,596</u>	<u>—</u>	<u>—</u>
Investments reported at net asset value:				
Multi strategy hedge funds	<u>8,066</u>			
Total investments reported at net asset value	<u>8,066</u>			
	\$ <u>319,662</u>			

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

	<u>2017</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Money market funds and cash	\$ 63,155	63,155	—	—
Fixed income:				
Corporate bonds	49,312	49,312	—	—
Government securities and other	2,098	2,098	—	—
Equities:				
Large cap equity	32,356	32,356	—	—
International equity	30,261	30,261	—	—
Small/mid-cap equity	20,813	20,813	—	—
Commodities	3,566	3,566	—	—
	<u>201,561</u>	<u>\$ 201,561</u>	<u>—</u>	<u>—</u>
Investments reported at net asset value:				
Multi strategy hedge funds	<u>7,860</u>			
Total investments reported at net asset value	<u>7,860</u>			
	<u>\$ 209,421</u>			

Investment expenses totaled \$318 and \$376 for the years ended June 30, 2018 and 2017, respectively. The unrealized gains were \$1,802 and \$4,504 for the years ended June 30, 2018 and 2017, respectively.

LLS's alternative investments strategy is as follows:

Multi strategy hedge funds – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event-driven strategies, distressed debt, merger and other arbitrage, and value investing.

The strategy creates indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS's risk with respect to such transactions is limited to its capital balance in each investment.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

LLS's alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS's nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2018 and 2017, the following table summarizes the redemption provisions for those investments reported at NAV:

	June 30	
	2018	2017
Redemption period:		
Quarterly	\$ 6,380	6,265
Annual	1,686	1,595
Total	<u>\$ 8,066</u>	<u>7,860</u>

As of June 30, 2018 and 2017, LLS had no unfunded commitments on its alternative investments.

(5) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2018 and 2017:

	2018		2017	
	Temporarily restricted	Permanently restricted	Temporarily restricted	Permanently restricted
Time restrictions	\$ 13,702	—	6,297	—
Research	13,209	3,100	7,097	3,035
Patient service	10,025	—	7,533	—
Co-Pay assistance	52,528	—	8,148	—
Other	757	52	86	121
Total	<u>\$ 90,221</u>	<u>3,152</u>	<u>29,161</u>	<u>3,156</u>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2018 and 2017 was 4% of ending balance at June 30, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS's overall investment strategy.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2018:

	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,126	3,156	6,282
Investment income	551	—	551
Foreign currency translation adjustment	(3)	(4)	(7)
Appropriation for expenditure	(249)	—	(249)
Endowment net assets at June 30	<u>\$ 3,425</u>	<u>3,152</u>	<u>6,577</u>

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2017:

	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 2,962	3,437	6,399
Investment income	428	—	428
Foreign currency translation adjustment	335	—	335
Contributions	—	5	5
Reclassifications	(347)	(286)	(633)
Appropriation for expenditure	(252)	—	(252)
Endowment net assets at June 30	<u>\$ 3,126</u>	<u>3,156</u>	<u>6,282</u>

(6) Contribution and Other Receivables

LLS's contribution and other receivables at June 30, 2018 and 2017 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions and other receivables consist of the following:

	2018	2017
Contributions	\$ 1,539	2,749
Co-Pay contributions	15,100	6,000
Other restricted contributions	15,266	8,080
Service revenue and other	350	956
	<u>\$ 32,255</u>	<u>17,785</u>

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

Contributions receivables are originally recorded based on discounted cash flows using a risk-adjusted discount rate. Amounts are scheduled to be received as follows:

	<u>2018</u>	<u>2017</u>
Less than 1 year	\$ 24,400	13,688
1 to 5 years	10,076	5,186
After 5 years	<u>—</u>	<u>25</u>
Subtotal	34,476	18,899
Less:		
Allowance for uncollectible accounts	(987)	(357)
Discount to present value (1.5% to 5.0%)	<u>(1,234)</u>	<u>(757)</u>
Total	\$ <u>32,255</u>	<u>17,785</u>

As of June 30, 2018 and 2017, 77% and 53% of gross legacies and contributions receivable were from two funding sources, respectively.

(7) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end. Deferred revenue as of June 30, 2018 and 2017 consists of the following:

	<u>2018</u>	<u>2017</u>
Grants	\$ —	45
Service revenue	3,857	2,100
Special events	<u>12,386</u>	<u>11,883</u>
	\$ <u>16,243</u>	<u>14,028</u>

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

(8) Donated Services, Goods, and Media

The value of donated goods for the Beat AML Master Trial and campaign supplies, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

	<u>2018</u>	<u>2017</u>
Donated goods	\$ 1,483	3,552
Donated services	2,950	2,430
Donated media	<u>3,282</u>	<u>8,612</u>
Total	\$ <u>7,715</u>	<u>14,594</u>

(9) Fixed Assets, Net

Fixed assets at June 30, 2018 and 2017 consist of the following:

	<u>2018</u>	<u>2017</u>
Leasehold improvements	\$ 2,079	1,795
Furnitures, fixtures, and other office equipment	4,154	3,547
Computer equipment and software	<u>39,231</u>	<u>36,350</u>
Total	45,464	41,692
Less accumulated depreciation and amortization	<u>(36,850)</u>	<u>(31,573)</u>
Fixed assets, net	\$ <u>8,614</u>	<u>10,119</u>

In 2017, an impairment of fixed assets of \$5,434 was recorded for the write-off of a fundraising platform that will no longer be utilized by LLS. There was no such impairment in 2018.

(10) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated \$2,336 and \$2,149 for the years ended June 30, 2018 and 2017, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2018 and 2017. The assets and liabilities of the 457 Plans are included in investments and other long-term liabilities in the accompanying consolidated balance sheet and amounted to approximately \$1,586 and \$1,574 at June 30, 2018 and 2017, respectively.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Notes to Consolidated Financial Statements

June 30, 2018

(In thousands)

(11) Lease Commitments

The leases for premises, which LLS's National Office and chapters occupy, expire on various dates through March 31, 2031 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

Year ending June 30:	
2019	\$ 7,450
2020	7,037
2021	6,632
2022	5,855
2023	4,191
Thereafter	<u>10,780</u>
Total	\$ <u>41,945</u>

(12) Joint Costs Allocation

For the years ended June 30, 2018 and 2017, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coin boards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

	<u>2018</u>	<u>2017</u>
Fundraising	\$ 7,463	12,832
Patient and community services	3,496	2,666
Public health education	<u>4,884</u>	<u>5,002</u>
Total	\$ <u>15,843</u>	<u>20,500</u>

Request for Taxpayer Identification Number and Certification

► Go to www.irs.gov/FormW9 for instructions and the latest information.

Give Form to the
requester. Do not
send to the IRS.

Print or type.
See specific instructions on page 3.

1 Name (as shown on your income tax return). Name is required on this line; do not leave this line blank. Leukemia & Lymphoma Society	
2 Business name/disregarded entity name, if different from above	
3 Check appropriate box for federal tax classification of the person whose name is entered on line 1. Check only one of the following seven boxes. <input type="checkbox"/> Individual/sole proprietor or single-member LLC <input type="checkbox"/> Limited liability company. Enter the tax classification (C=C corporation, S=S corporation, P=Partnership) ► Note: Check the appropriate box in the line above for the tax classification of the single-member owner. Do not check LLC if the LLC is classified as a single-member LLC that is disregarded from the owner unless the owner of the LLC is another LLC that is not disregarded from the owner for U.S. federal tax purposes. Otherwise, a single-member LLC that is disregarded from the owner should check the appropriate box for the tax classification of its owner. <input checked="" type="checkbox"/> Other (see instructions) ► Non Profit Orgnaization	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3): Exempt payee code (if any) _____ Exemption from FATCA reporting code (if any) _____ <i>(Applies to accounts maintained outside the U.S.)</i>
5 Address (number, street, and apt. or suite no.) See instructions. 301 E Main Street, Suite 100	Requester's name and address (optional)
6 City, state, and ZIP code Louisville, KY 40202	
7 List account number(s) here (optional)	

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Note: If the account is in more than one name, see the instructions for line 1. Also see *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number								
			-					
or								
Employer identification number								
1	3		-	5	6	4	4	9 1 6

Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here Signature of U.S. person ► *Danana Keel*

Date ► *8/13/19*

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS must obtain your correct taxpayer identification number (TIN) which may be your social security number (SSN), individual taxpayer identification number (ITIN), adoption taxpayer identification number (ATIN), or employer identification number (EIN), to report on an information return the amount paid to you, or other amount reportable on an information return. Examples of information returns include, but are not limited to, the following.

- Form 1099-INT (interest earned or paid)

- Form 1099-DIV (dividends, including those from stocks or mutual funds)
- Form 1099-MISC (various types of income, prizes, awards, or gross proceeds)
- Form 1099-B (stock or mutual fund sales and certain other transactions by brokers)
- Form 1099-S (proceeds from real estate transactions)
- Form 1099-K (merchant card and third party network transactions)
- Form 1098 (home mortgage interest), 1098-E (student loan interest), 1098-T (tuition)
- Form 1099-C (canceled debt)
- Form 1099-A (acquisition or abandonment of secured property)

Use Form W-9 only if you are a U.S. person (including a resident alien), to provide your correct TIN.

If you do not return Form W-9 to the requester with a TIN, you might be subject to backup withholding. See What is backup withholding, later.

Form **990**Department of the Treasury
Internal Revenue Service**Return of Organization Exempt From Income Tax**

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

▶ Do not enter social security numbers on this form as it may be made public.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017
Open to Public
Inspection**A** For the 2017 calendar year, or tax year beginning **07/01/17**, and ending **06/30/18****B** Check if applicable:☐ Address change☐ Name change☐ Initial return☐ Final return/terminated☐ Amended return☐ Application pending**C** Name of organization**THE LEUKEMIA & LYMPHOMA SOCIETY, INC**

Doing business as

Number and street (or P.O. box if mail is not delivered to street address)

3 INTERNATIONAL DRIVE

Room/suite

City or town, state or province, country, and ZIP or foreign postal code

RYE BROOK**NY 10573****F** Name and address of principal officer**LOUIS J. DEGENNARO****3 INTERNATIONAL DRIVE, SUITE 200****RYE BROOK****NY 10573****D** Employer identification number**13-5644916****E** Telephone number**914-949-5213****G** Gross receipts \$ **509,256,601****H(a)** Is this a group return for subordinates? ☐ Yes ☒ No**H(b)** Are all subordinates included? ☐ Yes ☐ No

If "No," attach a list (see instructions)

H(c) Group exemption number ▶**I** Tax-exempt status ☒ 501(c)(3) ☐ 501(c) () (insert no) ☐ 4947(a)(1) or ☐ 527**J** Website: **WWW.LLS.ORG****K** Form of organization: ☒ Corporation ☐ Trust ☐ Association ☐ Other ▶**L** Year of formation: **1949****M** State of legal domicile: **NY****Part I Summary**

Activities & Governance	1 Briefly describe the organization's mission or most significant activities: OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.		
	2 Check this box <input type="checkbox"/> if the organization discontinued its operations or disposed of more than 25% of its net assets.		
	3 Number of voting members of the governing body (Part VI, line 1a)	3	24
	4 Number of independent voting members of the governing body (Part VI, line 1b)	4	23
	5 Total number of individuals employed in calendar year 2017 (Part V, line 2a)	5	1291
	6 Total number of volunteers (estimate if necessary)	6	3000000
Revenue	7a Total unrelated business revenue from Part VIII, column (C), line 12	7a	0
	b Net unrelated business taxable income from Form 990-T, line 34	7b	0
	8 Contributions and grants (Part VIII, line 1h)	Prior Year	Current Year
	9 Program service revenue (Part VIII, line 2g)	314,912,814	419,570,497
	10 Investment income (Part VIII, column (A), lines 3, 4, and 7d)	3,847,456	9,230,125
	11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	1,121,864	9,920,211
Expenses	12 Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	25,416,466	133,928
	13 Grants and similar amounts paid (Part IX, column (A), lines 1-3)	345,298,600	438,854,761
	14 Benefits paid to or for members (Part IX, column (A), line 4)	122,873,965	157,849,965
	15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	0	0
	16a Professional fundraising fees (Part IX, column (A), line 11e)	97,808,057	104,079,229
	b Total fundraising expenses (Part IX, column (D), line 25) ▶ 45,741,999	4,046,893	5,748,936
Net Assets or Fund Balances	17 Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	90,757,098	88,772,222
	18 Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	315,486,013	356,450,352
	19 Revenue less expenses. Subtract line 18 from line 12	29,812,587	82,404,409
	20 Total assets (Part X, line 16)	Beginning of Current Year	End of Year
	21 Total liabilities (Part X, line 26)	272,265,949	382,344,839
	22 Net assets or fund balances. Subtract line 21 from line 20	119,978,224	146,112,465
	152,287,725	236,232,374	

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign
Here

Signature of officer

GORDON MILLER, JR

Type or print name and title

SVP FINANCE**2/4/2019**

Date

Paid

Preparer
Use Only

Print/Type preparer's name

DAVID M. HIGEFILL

Preparer's signature

David M. Higefill

Date

02/01/19Check ☐ if

self-employed

PTIN

P01517891Firm's name ▶ **KPMG LLP**

Firm's EIN ▶

13-5565207Firm's address ▶ **345 Park Avenue
New York, NY 10154-0102**

Phone no

212-758-9700

May the IRS discuss this return with the preparer shown above? (see instructions)

☒ Yes ☐ No

For Paperwork Reduction Act Notice, see the separate instructions.

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III

☒

1 Briefly describe the organization's mission:

OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ?

☐ Yes ☒ No

If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services?

☐ Yes ☒ No

If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses \$ **64,124,010** including grants of \$ **47,400,064**) (Revenue \$ **9,230,125**)**A) RESEARCH PROGRAMS:**

With advisory input from recognized biomedical research experts, LLS funds exemplary projects across the entire research continuum relevant to improve outcomes for blood cancer patients, from basic laboratory science through clinical trials, and from investigator-initiated research to private-sector drug development alliances. LLS is deliberate and purposeful in finding and supporting research that is most likely to help patients as soon as possible.

To date, LLS has invested over \$1.2 billion in research aimed at helping all blood cancer patients live better, longer lives.
(continued on Schedule O)

4b (Code:) (Expenses \$ **160,694,033** including grants of \$ **110,449,901**) (Revenue \$)**B) PATIENT & COMMUNITY SERVICES:**

An estimated 1.3 million people across the United States (US) currently battle leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society (LLS) offers an array of free, comprehensive resources to blood cancer patients, caregivers, families and friends of patients, advocates, healthcare professionals and the public. LLS is committed to providing the most accurate and up-to-date blood cancer information. Professional volunteer clinical advisors work with LLS staff to review all of the information LLS provides through healthcare professional and patient education programs, publications and the LLS website. Support services are
(continued on Schedule O)

4c (Code:) (Expenses \$ **39,795,810** including grants of \$) (Revenue \$)**C) PUBLIC HEALTH EDUCATION:**

Information and Education.

Paying for medical care, making treatment choices, communicating with healthcare providers, family members and friends-these are some of the stresses that come with a cancer diagnosis. LLS's Information Specialists are Master's level oncology social workers, nurses and health educators who provide help with disease, treatment and clinical trial information and support. Information Specialists may also refer patients and caregivers to a nurse in the Clinical Trial Support Center. The nurses in this Center have expertise in the blood cancers and provide patients and their
(continued on Schedule O)

4d Other program services (Describe in Schedule O.)

(Expenses \$ **17,206,016** including grants of \$) (Revenue \$)4e Total program service expenses **281,819,869**

Form 990 (2017) **THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916**Page **4****Part IV Checklist of Required Schedules (continued)**

	Yes	No
20a Did the organization operate one or more hospital facilities? If "Yes," complete Schedule H		X
b If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?		
21 Did the organization report more than \$5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? If "Yes," complete Schedule I, Parts I and II	X	
22 Did the organization report more than \$5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? If "Yes," complete Schedule I, Parts I and III	X	
23 Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5 about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? If "Yes," complete Schedule J	X	
24a Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the last day of the year, that was issued after December 31, 2002? If "Yes," answer lines 24b through 24d and complete Schedule K. If "No," go to line 25a		X
b Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?		
c Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?		
d Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?		
25a Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit transaction with a disqualified person during the year? If "Yes," complete Schedule L, Part I		X
b Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? If "Yes," complete Schedule L, Part I		X
26 Did the organization report any amount on Part X, line 5, 6, or 22 for receivables from or payables to any current or former officers, directors, trustees, key employees, highest compensated employees, or disqualified persons? If "Yes," complete Schedule L, Part II		X
27 Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity or family member of any of these persons? If "Yes," complete Schedule L, Part III		X
28 Was the organization a party to a business transaction with one of the following parties (see Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions):		
a A current or former officer, director, trustee, or key employee? If "Yes," complete Schedule L, Part IV		X
b A family member of a current or former officer, director, trustee, or key employee? If "Yes," complete Schedule L, Part IV	X	
c An entity of which a current or former officer, director, trustee, or key employee (or a family member thereof) was an officer, director, trustee, or direct or indirect owner? If "Yes," complete Schedule L, Part IV		X
29 Did the organization receive more than \$25,000 in non-cash contributions? If "Yes," complete Schedule M	X	
30 Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? If "Yes," complete Schedule M		X
31 Did the organization liquidate, terminate, or dissolve and cease operations? If "Yes," complete Schedule N, Part I		X
32 Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? If "Yes," complete Schedule N, Part II		X
33 Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Schedule R, Part I	X	
34 Was the organization related to any tax-exempt or taxable entity? If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1	X	
35a Did the organization have a controlled entity within the meaning of section 512(b)(13)?	X	
b If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? If "Yes," complete Schedule R, Part V, line 2	X	
36 Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization? If "Yes," complete Schedule R, Part V, line 2		X
37 Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? If "Yes," complete Schedule R, Part VI		X
38 Did the organization complete Schedule O and provide explanations in Schedule O for Part VI, lines 11b and 19? Note. All Form 990 filers are required to complete Schedule O.	X	

Form **990** (2017)

Part VI Governance, Management, and Disclosure For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions. Check if Schedule O contains a response or note to any line in this Part VI ☒

Section A. Governing Body and Management

	Yes	No
1a Enter the number of voting members of the governing body at the end of the tax year If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.	24	
b Enter the number of voting members included in line 1a, above, who are independent	23	
2 Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?	2	X
3 Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, or trustees, or key employees to a management company or other person?	3	X
4 Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4	X
5 Did the organization become aware during the year of a significant diversion of the organization's assets?	5	X
6 Did the organization have members or stockholders?	6	X
7a Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?	7a	X
b Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?	7b	X
8 Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:		
a The governing body?	8a	X
b Each committee with authority to act on behalf of the governing body?	8b	X
9 Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses in Schedule O	9	X

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

	Yes	No
10a Did the organization have local chapters, branches, or affiliates?	10a	X
b If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?	10b	X
11a Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	X
b Describe in Schedule O the process, if any, used by the organization to review this Form 990.		
12a Did the organization have a written conflict of interest policy? If "No," go to line 13	12a	X
b Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	X
c Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe in Schedule O how this was done	12c	X
13 Did the organization have a written whistleblower policy?	13	X
14 Did the organization have a written document retention and destruction policy?	14	X
15 Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?		
a The organization's CEO, Executive Director, or top management official	15a	X
b Other officers or key employees of the organization	15b	X
If "Yes" to line 15a or 15b, describe the process in Schedule O (see instructions).		
16a Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?	16a	X
b If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?	16b	

Section C. Disclosure

17 List the states with which a copy of this Form 990 is required to be filed ► **AK, AL, AR, AZ, CA, CO, CT, DE, DC, FL, GA, HI, ID**

18 Section 6104 requires an organization to make its Forms 1023 (or 1024 if applicable), 990, and 990-T (Section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
☒ Own website ☐ Another's website ☒ Upon request ☐ Other (explain in Schedule O)

19 Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.

20 State the name, address, and telephone number of the person who possesses the organization's books and records: ►
GORDON MILLER, JR
RYE BROOK
3 International Drive
NY 10573
914-821-8935

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(12) CARSON JACOB	40.00									
SVP, HEALTHCARE PART	0.00				X			251,004	0	31,039
(13) PETER B. BROCK	6.00									
CHAIR	2.00	X		X				0	0	0
(14) JORGE L. BENITEZ	4.00									
VICE CHAIR	2.00	X		X				0	0	0
(15) RALPH E. LAWSON	4.00									
SECRETARY/TREASURER	2.00	X		X				0	0	0
(16) BART SICHEL	4.00									
At Large	2.00	X		X				0	0	0
(17) WILLIAM G. BEHNKE	4.00									
BOD MEMBER	0.00	X						0	0	0
(18) A. DANA CALLOW, JR.	4.00									
BOD MEMBER	0.00	X						0	0	0
(19) RENZO CANETTA, M.D.	4.00									
BOD MEMBER	0.00	X						0	0	0
1b Sub-total								4,155,769		378,593
c Total from continuation sheets to Part VII, Section A										
d Total (add lines 1b and 1c)								4,155,769		378,593

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization **187**

	Yes	No
3 Did the organization list any former officer, director, or trustee, key employee, or highest compensated employee on line 1a? If "Yes," complete Schedule J for such individual		X
4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? If "Yes," complete Schedule J for such individual	X	
5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? If "Yes," complete Schedule J for such person		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
INC Research, LLC Chicago	75 Remittance Drive, Suite 3160 IL 60675-3160 Clinical Trial	7,600,357
PATIENT ADVOCACY FOUNDATION HAMPTON	421 BUTLER FARM RD VA 23666 PAT ASSIST PROC	6,567,690
RESOURCE ONE TULSA	2900 EAST APACHE STREET OK 74110 DIRECT MARKETIN	6,070,357
TARGETCW SAN DIEGO	9475 Chesapeake Drive CA 92123 TEMP STAFFING	3,867,319
Northgate Digital Corporation Newtown	301 South State Street, Suite N-200 PA 18940-1956 Software Develo	2,906,258

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 of compensation from the organization **146**

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX ☐

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	40,792,965	40,792,965		
2 Grants and other assistance to domestic individuals. See Part IV, line 22	110,449,901	110,449,901		
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	6,607,099	6,607,099		
4 Benefits paid to or for members				
5 Compensation of current officers, directors, trustees, and key employees	2,710,622	1,681,862	485,583	543,177
6 Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7 Other salaries and wages	82,813,099	51,395,278	14,893,616	16,524,205
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	2,267,194	1,402,356	385,162	479,676
9 Other employee benefits	10,397,109	6,431,056	1,766,311	2,199,742
10 Payroll taxes	5,891,205	3,643,962	1,000,826	1,246,417
11 Fees for services (non-employees):				
a Management				
b Legal	1,084,438	777,839	129,137	177,462
c Accounting	358,738	257,313	42,719	58,706
d Lobbying	686,929	492,716	81,801	112,412
e Professional fundraising services. See Part IV, line 17	5,748,936			5,748,936
f Investment management fees	318,629	196,795	61,210	60,624
g Other. (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O.)	19,806,356	14,206,574	2,358,584	3,241,198
12 Advertising and promotion	7,220,365	3,668,782	824,733	2,726,850
13 Office expenses	18,634,663	10,151,479	1,917,567	6,565,617
14 Information technology	7,321,496	5,251,515	871,860	1,198,121
15 Royalties				
16 Occupancy	9,096,024	6,022,346	1,269,131	1,804,547
17 Travel	7,034,959	4,839,364	1,114,311	1,081,284
18 Payments of travel or entertainment expenses for any federal, state, or local public officials				
19 Conferences, conventions, and meetings				
20 Interest				
21 Payments to affiliates				
22 Depreciation, depletion, and amortization	5,401,215	3,579,240	882,566	939,409
23 Insurance	720,360	514,432	99,631	106,297
24 Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)				
a RESEARCH AND DEVELOPMENT	5,898,507	5,898,507		
b MISCELLANEOUS	5,189,543	3,558,488	703,736	927,319
c				
d				
e All other expenses				
25 Total functional expenses. Add lines 1 through 24e	356,450,352	281,819,869	28,888,484	45,741,999
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here <input checked="" type="checkbox"/> if following SOP 98-2 (ASC 958-720)	12,830,983	7,313,910		5,517,073

Part XI Reconciliation of Net AssetsCheck if Schedule O contains a response or note to any line in this Part XI ☐

1	Total revenue (must equal Part VIII, column (A), line 12)	1	438,854,761
2	Total expenses (must equal Part IX, column (A), line 25)	2	356,450,352
3	Revenue less expenses. Subtract line 2 from line 1	3	82,404,409
4	Net assets or fund balances at beginning of year (must equal Part X, line 33, column (A))	4	152,287,725
5	Net unrealized gains (losses) on investments	5	1,802,359
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain in Schedule O)	9	-262,119
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 33, column (B))	10	236,232,374

Part XII Financial Statements and ReportingCheck if Schedule O contains a response or note to any line in this Part XII ☐

	Yes	No
1 Accounting method used to prepare the Form 990: <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain in Schedule O.		
2a Were the organization's financial statements compiled or reviewed by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis		X
b Were the organization's financial statements audited by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input checked="" type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis	X	
c If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.	X	
3a As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?		X
b If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.		

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(28) KATHLEEN MERIWETHER	4.00									
BOD MEMBER	0.00	X						0	0	0
(29) TED MOROZ	4.00									
BOD MEMBER	0.00	X						0	0	0
(30) LYNNE O'BRIEN	4.00									
BOD MEMBER	0.00	X						0	0	0
(31) MARLA PERSKY	4.00									
BOD MEMBER	0.00	X						0	0	0
(32) DONALD PROCTOR	4.00									
BOD MEMBER	0.00	X						0	0	0
(33) ROBERT ROSEN	4.00									
BOD MEMBER	0.00	X						0	0	0
(34) STEVEN T. ROSEN	4.00									
BOD MEMBER	0.00	X						0	0	0
(35) JEFF SACHS	4.00									
BOD MEMBER	0.00	X						0	0	0
1b Sub-total										
c Total from continuation sheets to Part VII, Section A										
d Total (add lines 1b and 1c)										

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization

- 3 Did the organization list any former officer, director, or trustee, key employee, or highest compensated employee on line 1a? If "Yes," complete Schedule J for such individual
- 4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? If "Yes," complete Schedule J for such individual
- 5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? If "Yes," complete Schedule J for such person

	Yes	No
3		
4		
5		

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 of compensation from the organization

SCHEDULE A
(Form 990 or 990-EZ)Department of the Treasury
Internal Revenue Service**Public Charity Status and Public Support**

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection**

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Employer identification number

13-5644916**Part I Reason for Public Charity Status** (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

- 1 ☐ A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
- 2 ☐ A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990 or 990-EZ))
- 3 ☐ A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
- 4 ☐ A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state:
- 5 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
- 6 ☐ A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
- 7 ☒ An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 8 ☐ A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 9 ☐ An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land grant college of agriculture (see instructions). Enter the name, city, and state of the college or university:
- 10 ☐ An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
- 11 ☐ An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
- 12 ☐ An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2).** See **section 509(a)(3).** Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.
- a ☐ **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete **Part IV, Sections A and B.**
- b ☐ **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete **Part IV, Sections A and C.**
- c ☐ **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete **Part IV, Sections A, D, and E.**
- d ☐ **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete **Part IV, Sections A and D, and Part V.**
- e ☐ Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
- f Enter the number of supported organizations:
- g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1–10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
(A)						
(B)						
(C)						
(D)						
(E)						
Total						

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule A (Form 990 or 990-EZ) 2017

Schedule A (Form 990 or 990-EZ) 2017

THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916

Page 3

Part III Support Schedule for Organizations Described in Section 509(a)(2)(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II.
If the organization fails to qualify under the tests listed below, please complete Part II.)**Section A. Public Support**

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 Total. Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b						
8 Public support. (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 Total support. (Add lines 9, 10c, 11, and 12.)						
14 First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here <input type="checkbox"/>						

Section C. Computation of Public Support Percentage

15 Public support percentage for 2017 (line 8, column (f) divided by line 13, column (f))	15	%
16 Public support percentage from 2016 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for 2017 (line 10c, column (f) divided by line 13, column (f))	17	%
18 Investment income percentage from 2016 Schedule A, Part III, line 17	18	%

19a 33 1/3% support tests—2017. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ☐

b 33 1/3% support tests—2016. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ☐

20 Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ☐

Part IV Supporting Organizations (continued)

- 11 Has the organization accepted a gift or contribution from any of the following persons?
- a A person who directly or indirectly controls, either alone or together with persons described in (b) and (c) below, the governing body of a supported organization?
- b A family member of a person described in (a) above?
- c A 35% controlled entity of a person described in (a) or (b) above? If "Yes" to a, b, or c, provide detail in Part VI.

	Yes	No
11a		
11b		
11c		

Section B. Type I Supporting Organizations

- 1 Did the directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's directors or trustees at all times during the tax year? If "No," describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.
- 2 Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If "Yes," explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.

	Yes	No
1		
2		

Section C. Type II Supporting Organizations

- 1 Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? If "No," describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

	Yes	No
1		

Section D. All Type III Supporting Organizations

- 1 Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?
- 2 Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).
- 3 By reason of the relationship described in (2), did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization's supported organizations played in this regard.

	Yes	No
1		
2		
3		

Section E. Type III Functionally-Integrated Supporting Organizations

- 1 Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions).
- a ☐ The organization satisfied the Activities Test. Complete line 2 below.
- b ☐ The organization is the parent of each of its supported organizations. Complete line 3 below.
- c ☐ The organization supported a governmental entity. Describe in Part VI how you supported a governmental entity (see instructions).

2 Activities Test. Answer (a) and (b) below.

- a Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.
- b Did the activities described in (a) constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.
- 3 Parent of Supported Organizations. Answer (a) and (b) below.
- a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? Provide details in Part VI.
- b Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? If "Yes," describe in Part VI the role played by the organization in this regard.

	Yes	No
2a		
2b		
3a		
3b		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations (continued)

Section D - Distributions		Current Year		
1	Amounts paid to supported organizations to accomplish exempt purposes			
2	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity			
3	Administrative expenses paid to accomplish exempt purposes of supported organizations			
4	Amounts paid to acquire exempt-use assets			
5	Qualified set-aside amounts (prior IRS approval required)			
6	Other distributions (describe in Part VI). See instructions.			
7	Total annual distributions. Add lines 1 through 6.			
8	Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions.			
9	Distributable amount for 2017 from Section C, line 6			
10	Line 8 amount divided by line 9 amount			

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2017	(iii) Distributable Amount for 2017
1	Distributable amount for 2017 from Section C, line 6			
2	Underdistributions, if any, for years prior to 2017 (reasonable cause required-explain in Part VI). See instructions.			
3	Excess distributions carryover, if any, to 2017:			
a				
b	From 2013			
c	From 2014			
d	From 2015			
e	From 2016			
f	Total of lines 3a through e			
g	Applied to underdistributions of prior years			
h	Applied to 2017 distributable amount			
i	Carryover from 2012 not applied (see instructions)			
j	Remainder. Subtract lines 3g, 3h, and 3i from 3f.			
4	Distributions for 2017 from Section D, line 7: \$			
a	Applied to underdistributions of prior years			
b	Applied to 2017 distributable amount			
c	Remainder. Subtract lines 4a and 4b from 4.			
5	Remaining underdistributions for years prior to 2017, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, explain in Part VI. See instructions.			
6	Remaining underdistributions for 2017. Subtract lines 3h and 4b from line 1. For result greater than zero, explain in Part VI. See instructions.			
7	Excess distributions carryover to 2018. Add lines 3j and 4c.			
8	Breakdown of line 7:			
a	Excess from 2013			
b	Excess from 2014			
c	Excess from 2015			
d	Excess from 2016			
e	Excess from 2017			

SCHEDULE C
(Form 990 or 990-EZ)Department of the Treasury
Internal Revenue Service**Political Campaign and Lobbying Activities****For Organizations Exempt From Income Tax Under section 501(c) and section 527**

OMB No. 1545-0047

2017**Open to Public
Inspection**

▶ Complete if the organization is described below.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

If the organization answered "Yes," on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes," on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes," on Form 990, Part IV, line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Employer identification number

13-5644916**Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.**

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV. (see instructions for definition of "political campaign activities")

2 Political campaign activity expenditures (see instructions)

▶ \$

3 Volunteer hours for political campaign activities (see instructions)

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955

▶ \$

2 Enter the amount of any excise tax incurred by organization managers under section 4955

▶ \$

3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year?

☐ Yes ☐ No
☐ Yes ☐ No

4a Was a correction made?

☐ Yes ☐ No

b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities

▶ \$

2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities

▶ \$

3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b

▶ \$

4 Did the filing organization file Form 1120-POL for this year?

☐ Yes ☐ No

5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule C (Form 990 or 990-EZ) 2017

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes," response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

	(a)		(b)
	Yes	No	Amount
1 During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:			
a Volunteers?	X		
b Paid staff or management (include compensation in expenses reported on lines 1c through 1i)?	X		
c Media advertisements?		X	
d Mailings to members, legislators, or the public?		X	
e Publications, or published or broadcast statements?	X		196,761
f Grants to other organizations for lobbying purposes?		X	
g Direct contact with legislators, their staffs, government officials, or a legislative body?	X		296,800
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?	X		233,151
i Other activities?	X		398,846
j Total. Add lines 1c through 1i			1,125,558
2a Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?		X	
b If "Yes," enter the amount of any tax incurred under section 4912			
c If "Yes," enter the amount of any tax incurred by organization managers under section 4912			
d If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?			

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

	Yes	No
1 Were substantially all (90% or more) dues received nondeductible by members?		
2 Did the organization make only in-house lobbying expenditures of \$2,000 or less?		
3 Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?		

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No," OR (b) Part III-A, line 3, is answered "Yes."

1 Dues, assessments and similar amounts from members	1	
2 Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).		
a Current year	2a	
b Carryover from last year	2b	
c Total	2c	
3 Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues	3	
4 If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year?	4	
5 Taxable amount of lobbying and political expenditures (see instructions)	5	

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions); and Part II-B, line 1. Also, complete this part for any additional information.

Schedule C, Part II-B, Line 1

LLS is a member of a number of coalitions and memberships including Friends of Cancer Research, One Voice Against Cancer, National Health Council, The Cancer Leadership Council, American Childhood Cancer Organization, Public Affairs Council, Patient Quality of Life Coalition, Defense Health Research Consortium, and The State Access to Innovative Medicines Coalition.

**SCHEDULE D
(Form 990)**Department of the Treasury
Internal Revenue Service**Supplemental Financial Statements**▶ Complete if the organization answered "Yes" on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017Open to Public
Inspection

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC**13-5644916****Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts.**

Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

	(a) Donor advised funds	(b) Funds and other accounts
1 Total number at end of year		
2 Aggregate value of contributions to (during year)		
3 Aggregate value of grants from (during year)		
4 Aggregate value at end of year		
5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control?		<input type="checkbox"/> Yes <input type="checkbox"/> No
6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit?		<input type="checkbox"/> Yes <input type="checkbox"/> No

Part II Conservation Easements.

Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).

<input type="checkbox"/> Preservation of land for public use (e.g., recreation or education)	<input type="checkbox"/> Preservation of a historically important land area
<input type="checkbox"/> Protection of natural habitat	<input type="checkbox"/> Preservation of a certified historic structure
<input type="checkbox"/> Preservation of open space	

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

	Held at the End of the Tax Year
a Total number of conservation easements	2a
b Total acreage restricted by conservation easements	2b
c Number of conservation easements on a certified historic structure included in (a)	2c
d Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register	2d

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year ▶

4 Number of states where property subject to conservation easement is located ▶

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds?

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ \$

8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(i)?

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i) Revenue included on Form 990, Part VIII, line 1

(ii) Assets included in Form 990, Part X

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

a Revenue included on Form 990, Part VIII, line 1

b Assets included in Form 990, Part X

Part VII Investments—Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely-held equity interests		
(3) Other		
(A)		
(B)		
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.) ▶		

Part VIII Investments—Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Column (b) must equal Form 990, Part X, col. (B) line 13.) ▶		

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col. (B) line 15.) ▶	

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col. (B) line 25.) ▶	

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII. ☒

Part XIII Supplemental Information (continued)

Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years Ended June 30, 2018 and 2017.

Part XI, Line 2d - Revenue Amounts Included in Financials - Other

LLS Canada Revenue \$ 9,320,767

Pearlpoint Cancer Support Revenue \$ 134,361

Part XI, Line 4b - Revenue Amounts Included on Return - Other

Pearlpoint Management Fees \$ 70,000

Part XII, Line 2d - Expense Amounts Included in Financials - Other

LLS Canada Expenses \$ 9,952,411

Pearlpoint Cancer Support Expenses \$ 276,316

Rounding \$ 2,642

Part XII, Line 4b - Expense Amounts Included on Return - Other

LLS Canada Foreign Currency Adj \$ -99,169

Schedule F (Form 990) 2017 **THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916**

Page **2**

Part II Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
(1)			North America	Research Grant	60,000	Check			Accrual
(2)			Europe	Research Grant	199,758	Wire			Accrual
(3)			Europe	Research Grant	200,000	Wire			Accrual
(4)			North America	Research Grant	200,000	Check			Accrual
(5)			North America	Research Grant	200,000	Check			Accrual
(6)			North America	Research Grant	75,000	Check			Accrual
(7)			East Asia & Pacific	Research Grant	200,000	Wire			Accrual
(8)			East Asia & Pacific	Research Grant	199,996	Check			Accrual
(9)			East Asia & Pacific	Research Grant	67,000	Wire			Accrual
(10)			East Asia & Pacific	Research Grant	100,000	Check			Accrual
(11)			North America	Research Grant	1,000,000	Check			Accrual
(12)			North America	Research Grant	75,000	Check			Accrual
(13)			North America	Research Grant	300,000	Check			Accrual
(14)			Europe	Research Grant	333,333	Wire			Accrual
(15)			East Asia & Pacific	Research Grant	60,000	Wire			Accrual
(16)			East Asia & Pacific	Research Grant	199,176	Wire			Accrual

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter

0

3 Enter total number of other organizations or entities

16

Schedule F (Form 990) 2017

Schedule F (Form 990) 2017 **THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916**

Page **3**

Part III Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)
(1)							
(2)							
(3)							
(4)							
(5)							
(6)							
(7)							
(8)							
(9)							
(10)							
(11)							
(12)							
(13)							
(14)							
(15)							
(16)							
(17)							
(18)							

Schedule F (Form 990) 2017

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

Part I, Line 2 - Procedures for Monitoring the Use of Grant Funds

FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.

Part I, Line 3 - Activities per Region

Region	Expenditures	Investments
NORTH AMERICA	\$ 1,910,000	\$ 0
EUROPE	\$ 1,550,926	\$ 0
EUROPE	\$ 0	\$ 3,576,257
EAST ASIA	\$ 2,826,172	\$ 0

SCHEDULE G
(Form 990 or 990-EZ)Department of the Treasury
Internal Revenue Service**Supplemental Information Regarding Fundraising or Gaming Activities**

Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than \$15,000 on Form 990-EZ, line 6a.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to www.irs.gov/Form990 for the latest instructions.

OMB No. 1545-0047

2017Open to Public
Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Employer identification number

13-5644916**Part I Fundraising Activities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 17.
Form 990-EZ filers are not required to complete this part.

1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.

- a ☒ Mail solicitations
 b ☒ Internet and email solicitations
 c ☒ Phone solicitations
 d ☒ In-person solicitations
 e ☒ Solicitation of non-government grants
 f ☐ Solicitation of government grants
 g ☒ Special fundraising events

2a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

☒ Yes ☐ No

b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least \$5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
		Yes	No			
RESOURCE ONE 1 2900 EAST APACHE STREET TULSA OK 74110	DIRECT MAI		X	0	6,070,357	-6,070,357
2 MAIL AMERICA COMMUNICATIONS INC. PO BOX 870 FOREST VA 24551	DIRECT MAI		X	0	919,630	-919,630
3 THOMPSON, HABIB & DENISON 80 HAYDEN AVENUE, SUITE 300 LEXINGTON MA 02421	DIRECT MAI		X	0	656,233	-656,233
4 THE HERITAGE COMPANY, INC PO BOX 16325 LITTLE ROCK AR 72231-6325	DIRECT MAI		X	0	225,963	-225,963
5 COINSTAR 1800 114th Avenue SE BELLEVUE WA 98004	COIN COLLE		X	0	40,147	-40,147
6						
7						
8						
9						
10						
Total					7,912,330	-7,912,330

3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

All states as well as the District of Columbia and Puerto Rico

Schedule G (Form 990 or 990-EZ) 2017

THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916Page **3**

- 11 Does the organization conduct gaming activities with nonmembers? ☐ Yes ☒ No
- 12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? ☐ Yes ☒ No
- 13 Indicate the percentage of gaming activity conducted in:
- | | | |
|-------------------------------|-----|---------|
| a The organization's facility | 13a | 25.00 % |
| b An outside facility | 13b | 75.00 % |
- 14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name ▶ **GORDON MILLER, JR**
3 International Drive, Suite 200
 Address ▶ **RYE BROOK** **NY 10573**

- 15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? ☐ Yes ☒ No
- b If "Yes," enter the amount of gaming revenue received by the organization ▶ \$ and the amount of gaming revenue retained by the third party ▶ \$
- c If "Yes," enter name and address of the third party:

Name ▶
 Address ▶

16 Gaming manager information:

Name ▶ **SEE SCHEDULE G, PART IV**

Gaming manager compensation ▶ \$

Description of services provided ▶

☐ Director/officer ☐ Employee ☐ Independent contractor

17 Mandatory distributions:

- a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? ☐ Yes ☒ No
- b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year ▶ \$

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

See Schedule G Supplemental Information Worksheet

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**Part I General Information on Grants and Assistance**1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☒ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	University of Alabama at Birmingham 1530 3rd Avenue, South Suite 1170 Birmingham AL 35294-0111	63-6005396	3	67,000		Accrual		Research Grant
(2)	University of Alabama at Birmingham 1530 3rd Avenue, South Suite 1170 Birmingham AL 35294-0111	63-6005396	3	60,000		Accrual		Research Grant
(3)	University of Alabama at Birmingham 1530 3rd Avenue, South Suite 1170 Birmingham AL 35294-0111	63-6005396	3	200,000		Accrual		Research Grant
(4)	University of Alabama at Birmingham 1530 3rd Avenue, South Suite 1170 Birmingham AL 35294-0111	63-6005396	3	200,000		Accrual		Research Grant
(5)	University of Alabama at Birmingham 1530 3rd Avenue, South Suite 1170 Birmingham AL 35294-0111	63-6005396	3	200,000		Accrual		Research Grant
(6)	The University of Arizona 1303 E. University Blvd., Box 3 Tucson AZ 85721	74-2652689	3	200,000		Accrual		Research Grant
(7)	Banner MD Anderson Cancer Center 2946 E. Banner Gateway Drive Gilbert AZ 85234	74-6001118	3	250,000		FMV		Therapy Acceleration
(8)	University of Arkansas for Medical 4301 W. Markham, slot 545 Little Rock AR 72205	71-6056774	3	300,000		Accrual		Research Grant
(9)	Forty Seven Inc. 1490 O'Brien Drive Suite A Menlo Park CA 94025	47-4065674		2,925,000		FMV		Therapy Acceleration

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table

▶ 78

3 Enter total number of other organizations listed in the line 1 table

▶ 6

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

DAA

Schedule I (Form 990) (2017)

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection****THE LEUKEMIA & LYMPHOMA SOCIETY, INC**Employer identification number
13-5644916**Part I General Information on Grants and Assistance****1** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No**2** Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.**Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments.** Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	65,000		Accrual		Research Grant
(2)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	67,000		Accrual		Research Grant
(3)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	55,000		Accrual		Research Grant
(4)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	60,000		Accrual		Research Grant
(5)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	60,000		Accrual		Research Grant
(6)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	60,000		Accrual		Research Grant
(7)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	200,000		Accrual		Research Grant
(8)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	200,000		Accrual		Research Grant
(9)	Board of Trustees of the Leland Sta PO Box 44253 San Francisco CA 94144-4253	94-1156365	3	200,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶**3** Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017
**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General Information on Grants and Assistance**1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	The Scripps Research Institute 10550 North Torrey Pines Road TPC-7 La Jolla CA 92037	33-0435954	3	60,000		Accrual		Research Grant
(2)	The Scripps Research Institute 10550 North Torrey Pines Road TPC-7 La Jolla CA 92037	33-0435954	3	75,000		Accrual		Research Grant
(3)	University of California, San Francisco Box 0897 1855 Folsom Street, Suite Los Angeles CA 90074-4872	94-6036493	3	55,000		Accrual		Research Grant
(4)	University of California, San Francisco Box 0897 1855 Folsom Street, Suite Los Angeles CA 90074-4872	94-6036493	3	60,000		Accrual		Research Grant
(5)	Yale University P.O. Box 208327 New Haven CT 06520-1873	06-0646973	3	62,500		Accrual		Research Grant
(6)	Yale University P.O. Box 208327 New Haven CT 06520-1873	06-0646973	3	67,000		Accrual		Research Grant
(7)	Yale University P.O. Box 208327 New Haven CT 06520-1873	06-0646973	3	60,000		Accrual		Research Grant
(8)	Yale University P.O. Box 208327 New Haven CT 06520-1873	06-0646973	3	200,000		Accrual		Research Grant
(9)	Nemours Alfred I. duPont Hospital for Children PO Box 414876 Wilmington DE 19803	59-0634433	3	117,181		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**

Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.

▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017

**Open to Public
Inspection**

Employer identification number
13-5644916

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Part I General Information on Grants and Assistance

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No
- 2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	University of Miami PO BOX 405803 Atlanta GA 30384-5803	59-0624458	3	100,000		Accrual		Research Grant
(2)	University of Miami PO BOX 405803 Atlanta GA 30384-5803	59-0624458	3	2,000,000		Accrual		Research Grant
(3)	University of Miami PO BOX 405803 Atlanta GA 30384-5803	59-0624458	3	150,000		Accrual		Research Grant
(4)	Northwestern University 633 Clark - Room G547 Evanston IL 60208	36-2167817	3	110,000		Accrual		Research Grant
(5)	The University of Chicago 5841 S Maryland Ave, MC6092 Chicago IL 60637	36-2177139	3	67,000		Accrual		Research Grant
(6)	The University of Chicago 5841 S Maryland Ave, MC6092 Chicago IL 60637	36-2177139	3	60,000		Accrual		Research Grant
(7)	The University of Chicago 5841 S Maryland Ave, MC6092 Chicago IL 60637	36-2177139	3	200,000		Accrual		Research Grant
(8)	The University of Chicago 5841 S Maryland Ave, MC6092 Chicago IL 60637	36-2177139	3	200,000		Accrual		Research Grant
(9)	The Board of Trustees of the University 1901 South First Street, Suite A Champaign IL 61801	37-6000511	3	52,457		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

SCHEDULE I
(Form 990)Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General information on Grants and Assistance****1** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance?☐ Yes ☐ No**2** Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.**Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments.** Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	109,999		Accrual		Research Grant
(2)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	110,000		Accrual		Research Grant
(3)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	67,000		Accrual		Research Grant
(4)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	55,000		Accrual		Research Grant
(5)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	55,000		Accrual		Research Grant
(6)	Boston Children's Hospital PO Box 414413 Boston MA 02241-4413	04-2774441	3	200,000		Accrual		Research Grant
(7)	Brigham and Womens Hospital PO Box 3149 Boston MA 02241-4413	04-2774441	3	110,000		Accrual		Research Grant
(8)	Brigham and Womens Hospital PO Box 3149 Boston MA 02241-4413	04-2774441	3	67,000		Accrual		Research Grant
(9)	Brigham and Womens Hospital PO Box 3149 Boston MA 02241-4413	04-2774441	3	200,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table**3** Enter total number of other organizations listed in the line 1 table

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service
Name of the organization**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection****THE LEUKEMIA & LYMPHOMA SOCIETY, INC**Employer identification number
13-5644916**Part I General Information on Grants and Assistance**

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No
- 2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraised, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	67,000		Accrual		Research Grant
(2)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	29,991		Accrual		Research Grant
(3)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	55,000		Accrual		Research Grant
(4)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	60,000		Accrual		Research Grant
(5)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	60,000		Accrual		Research Grant
(6)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	60,000		Accrual		Research Grant
(7)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	200,000		Accrual		Research Grant
(8)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	200,000		Accrual		Research Grant
(9)	Dana-Farber Cancer Institute BP437 450 Brookline Avenue Boston MA 02215	04-2263040	3	199,999		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**

Department of the Treasury
Internal Revenue Service

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017

**Open to Public
Inspection**

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Employer identification number

13-5644916

Part I General Information on Grants and Assistance

1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Massachusetts General Hospital PO Box 414876 Boston MA 02241-4876	04-1564655	3	200,000		Accrual		Research Grant
(2)	Massachusetts General Hospital PO Box 414876 Boston MA 02241-4876	04-1564655	3	200,000		Accrual		Research Grant
(3)	Massachusetts General Hospital PO Box 414876 Boston MA 02241-4876	04-1564655	3	75,000		Accrual		Research Grant
(4)	Massachusetts Institute of Technology 77 Massachusetts Ave NE18-901 Cambridge MA 02139	04-2103594	3	200,000		Accrual		Research Grant
(5)	New York University School of Medicine P.O. BOX 415026 Boston MA 02241-4150	13-5562308	3	110,000		Accrual		Research Grant
(6)	New York University School of Medicine P.O. BOX 415026 Boston MA 02241-4150	13-5562308	3	93,712		Accrual		Research Grant
(7)	New York University School of Medicine P.O. BOX 415026 Boston MA 02241-4150	13-5562308	3	60,000		Accrual		Research Grant
(8)	New York University School of Medicine P.O. BOX 415026 Boston MA 02241-4150	13-5562308	3	200,000		Accrual		Research Grant
(9)	University of Massachusetts Medical Center 55 Lake Avenue North Worcester MA 01655-0002	04-3167352	3	110,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General Information on Grants and Assistance**1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Washington University in St. Louis 1 Brookings Dr St. Louis MO 63112	43-0653611	3	109,281		Accrual		Research Grant
(2)	Washington University in St. Louis 1 Brookings Dr St. Louis MO 63112	43-0653611	3	110,000		Accrual		Research Grant
(3)	Washington University in St. Louis 1 Brookings Dr St. Louis MO 63112	43-0653611	3	110,000		Accrual		Research Grant
(4)	Washington University School of Med 700 Rosedale Avenue Campus Box 1034 St. Louis MO 63112-1408	43-0653611	3	110,000		Accrual		Research Grant
(5)	Washington University School of Med 700 Rosedale Avenue Campus Box 1034 St. Louis MO 63112-1408	43-0653611	3	200,000		Accrual		Research Grant
(6)	Washington University School of Med 700 Rosedale Avenue Campus Box 1034 St. Louis MO 63112-1408	43-0653611	3	200,000		Accrual		Research Grant
(7)	Hackensack Meridian Health 40 Prospect Avenue Hackensack NJ 07601	54-1774039	3	110,000		Accrual		Research Grant
(8)	Hackensack Meridian Health 40 Prospect Avenue Hackensack NJ 07601		3	149,985		Accrual		Research Grant
(9)	Albert Einstein College of Medicine 1300 Morris Park Ave, Belfer 1108 Bronx NY 10461	47-2209056	3	109,622		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**

Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017

**Open to Public
Inspection**

Employer identification number
13-5644916

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Part I General Information on Grants and Assistance

1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	67,000		Accrual		Research Grant
(2)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	60,000		Accrual		Research Grant
(3)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	60,000		Accrual		Research Grant
(4)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	200,000		Accrual		Research Grant
(5)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	200,000		Accrual		Research Grant
(6)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	400,000		Accrual		Research Grant
(7)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	300,000		Accrual		Research Grant
(8)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	1,000,000		Accrual		Research Grant
(9)	Joan & Sanford I. Weill Medical Col 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	300,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

DAA

Schedule I (Form 990) (2017)

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017
**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General Information on Grants and Assistance**

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No
- 2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	67,000		Accrual		Research Grant
(2)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	67,000		Accrual		Research Grant
(3)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	55,000		Accrual		Research Grant
(4)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	59,999		Accrual		Research Grant
(5)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	60,000		Accrual		Research Grant
(6)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	200,000		Accrual		Research Grant
(7)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	333,333		Accrual		Research Grant
(8)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	200,000		Accrual		Research Grant
(9)	Sloan Kettering Institute for Cancer Research PO Box 026338 New York NY 10087	13-1924236	3	1,000,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017**Open to Public
Inspection****THE LEUKEMIA & LYMPHOMA SOCIETY, INC**

Employer identification number

13-5644916**Part I General Information on Grants and Assistance**1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	The Trustees of Columbia University P.O. Box 29789 New York NY 10087-9789	13-5598093	3	50,000		Accrual		Research Grant
(2)	Atrium Health Foundation 208 East Boulevard Attn: Electa McP Charlotte NC 28203	56-6060481	3	110,000		Accrual		Research Grant
(3)	Columbia University 615 West 131st Street - Mail Code B New York NY 10027	13-5598093	3	120,000		FMV		Therapy Acceleration
(4)	Weill Cornell Medicine 575 Lexington Ave, 9th FL New York NY 10022	13-1623978	3	900,000		FMV		Therapy Acceleration
(5)	Stemline Therapeutics, Inc 750 Lexington Avenue, 11th Floor New York NY 10022	45-0522567		500,000		FMV		Therapy Acceleration
(6)	Cincinnati Children's Hospital Medi 3333 Burnet Avenue Cincinnati OH 45229	31-0833936	3	110,000		Accrual		Research Grant
(7)	Cincinnati Children's Hospital Medi 3333 Burnet Avenue Cincinnati OH 45229	31-0833936	3	67,000		Accrual		Research Grant
(8)	Cincinnati Children's Research Foun 3333 Burnet Avenue Cincinnati OH 45229	31-0833936	3	200,000		Accrual		Research Grant
(9)	The Ohio State University 1960 Kenny Road Columbus OH 43210-1016	31-6025986	3	110,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table

3 Enter total number of other organizations listed in the line 1 table

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

DAA

Schedule I (Form 990) (2017)

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General Information on Grants and Assistance**

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No
- 2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	Regents of the University of Michigan Box 223131 Pittsburgh PA 15251-2131	38-6006309	3	200,000		Accrual		Research Grant
(2)	Temple University P.O. Box 824242 Philadelphia PA 19182-4242	23-1365971	3	200,000		Accrual		Research Grant
(3)	The Children's Hospital of Philadelphia Lockbox # 1457 PO Box 8500 Philadelphia PA 19178-1457	23-1352166	3	200,000		Accrual		Research Grant
(4)	The Children's Hospital of Philadelphia Lockbox # 1457 PO Box 8500 Philadelphia PA 19178-1457	23-1352166	3	200,000		Accrual		Research Grant
(5)	The Trustees of the University of P 3451 Walnut Street Franklin Bldg P Philadelphia PA 19104-6205	23-1352685	3	51,895		Accrual		Research Grant
(6)	The Wistar Institute 3601 Spruce Street Philadelphia PA 19104	23-6434390	3	60,000		Accrual		Research Grant
(7)	University of Pittsburgh 500 Ross Street 154-0455 Pittsburg PA 15262-0001	25-0965591	3	65,000		Accrual		Research Grant
(8)	The Children's Hospital of Philadel 1901 South First Street, Suite A Philadelphia PA 19178-1457	23-1352166	3	100,000		Accrual		Research Grant
(9)	St. Jude Children's Research Hospit PO Box 1000 Dept #949 Memphis TN 38148-0949	62-0646012	3	110,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) (2017)

DAA

**SCHEDULE I
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for the latest information.

OMB No 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I General Information on Grants and Assistance**1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ☐ Yes ☐ No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1	(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1)	The University of Texas MD Anderson PO Box 4266 Houston TX 77210-4266	74-6001118	3	2,000,000		Accrual		Research Grant
(2)	Vanderbilt University Medical Center Dept 1236, PO Box 121236 Dallas TX 75312	62-0476822	3	125,000		Accrual		Research Grant
(3)	The University of Utah 201 S. Presidents Circle, Rm. 145 Salt Lake City UT 84112-9003	87-6000525	3	110,000		Accrual		Research Grant
(4)	The University of Utah 201 S. Presidents Circle, Rm. 145 Salt Lake City UT 84112-9003	87-6000525	3	67,000		Accrual		Research Grant
(5)	University of Virginia PO Box 400195 Charlottesville VA 22904-4195	23-7173411	3	110,000		Accrual		Research Grant
(6)	Virginia Commonwealth University PO Box 843039 Richmond VA 23284-3039	54-6001758	3	300,000		Accrual		Research Grant
(7)	Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, J6-300 Seattle WA 98109-1024	23-7156071	3	110,000		Accrual		Research Grant
(8)	Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, J6-300 Seattle WA 98109-1024	23-7156071	3	110,000		Accrual		Research Grant
(9)	Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, J6-300 Seattle WA 98109-1024	23-7156071	3	67,000		Accrual		Research Grant

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ▶

3 Enter total number of other organizations listed in the line 1 table ▶

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

DAA

Schedule I (Form 990) (2017)

Schedule I (Form 990) (2017) **THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916**Page **2****Part III Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance
1 COPAY ASSISTANCE CLL	5608	18,808,624			
2 COPAY ASSISTANCE LYMPHOMA	8925	13,193,314			
3 COPAY ASSISTANCE MDS	1976	5,960,480			
4 COPAY ASSISTANCE MYELOMA	10351	56,804,404			
5 COPAY ASSISTANCE MANTEL	982	4,262,012			
6 COPAY ASSISTANCE WALDENST	1246	5,695,359			
7 COPAY ASSISTANCE ALL	106	310,000			

Part IV Supplemental Information. Provide the information required in Part I, line 2, Part III, column (b); and any other additional information.

See Schedule I Supplemental Information Worksheet

SCHEDULE I (Form 990)	Supplemental Information		2017
	For calendar year 2017, or tax year beginning 07/01/17, and ending 06/30/18		
Name of the organization THE LEUKEMIA & LYMPHOMA SOCIETY, INC			Employer identification number 13-5644916

Part I, Line 2 - Procedures for Monitoring the Use of Grant Funds

FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.

PATIENT FINANCIAL AID:

THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES.

IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT

SCHEDULE 1 (Form 990)	Supplemental Information		2017
	For calendar year 2017, or tax year beginning 07/01/17 , and ending 06/30/18		
Name of the organization THE LEUKEMIA & LYMPHOMA SOCIETY, INC			Employer identification number 13-5644916

ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS
AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM
GUIDELINES AND PROGRAM CRITERIA.

Schedule J (Form 990) 2017 **THE LEUKEMIA & LYMPHOMA SOCIETY, INC 13-5644916**Page **2****Part II Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title	(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
	(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
LOUIS J. DEGENNARO	(i) 531,927	(ii) 78,000	(iii) 24,754	17,010	21,596	673,287	0
1 PRESIDENT & CEO	(ii) 0	0	0	0	0	0	0
ROSEMARIE A. LOFFREDO	(i) 326,256	(ii) 31,059	(iii) 23,124	9,450	11,161	401,050	0
2 EVP - CFO	(ii) 0	0	0	0	0	0	0
GORDON MILLER, JR	(i) 239,086	(ii) 26,600	(iii) 4,406	13,500	25,012	308,604	0
3 SVP FINANCE	(ii) 0	0	0	0	0	0	0
ANDREW S. COCCARI	(i) 325,696	(ii) 29,689	(iii) 1,702	9,450	29,167	395,704	0
4 EVP CHIEF PROD OFFIC	(ii) 0	0	0	0	0	0	0
ALICE O'ROURKE	(i) 319,848	(ii) 28,994	(iii) 4,797	6,596	32,841	393,076	0
5 EVP CHIEF DEV OFFICE	(ii) 0	0	0	0	0	0	0
GWEN NICHOLS	(i) 313,116	(ii) 60,000	(iii) 3,988	0	22,429	399,533	0
6 EVP CHIEF MED OFFICE	(ii) 0	0	0	0	0	0	0
KATHY GRISENBECK	(i) 289,432	(ii) 28,726	(iii) 6,055	12,633	22,371	359,217	0
7 EVP CHIEF REL OFFICE	(ii) 0	0	0	0	0	0	0
LEE M. GREENBERGER	(i) 287,763	(ii) 33,056	(iii) 8,870	9,450	32,950	372,089	0
8 SVP CHIEF SCIEN OFFI	(ii) 0	0	0	0	0	0	0
CLAUDE EDKINS - END 3/31/2017	(i) 61,216	(ii) 73,100	(iii) 220,070	6,786	7,537	368,709	0
9 VP INFORMATION TECHN	(ii) 0	0	0	0	0	0	0
MARCIE KLEIN	(i) 243,153	(ii) 20,865	(iii) 2,270	9,386	21,573	297,247	0
10 EVP, COMMUNICATIONS	(ii) 0	0	0	0	0	0	0
ELISA WEISS	(i) 231,652	(ii) 24,344	(iii) 1,151	9,073	17,583	283,803	0
11 SVP PAT ACCESS AND O	(ii) 0	0	0	0	0	0	0
CARSON JACOBI	(i) 217,117	(ii) 23,243	(iii) 10,644	12,709	18,330	282,043	0
12 SVP, HEALTHCARE PART	(ii) 0	0	0	0	0	0	0
13	(i) 0	0	0	0	0	0	0
14	(i) 0	0	0	0	0	0	0
15	(i) 0	0	0	0	0	0	0
16	(i) 0	0	0	0	0	0	0

Schedule J (Form 990) 2017

SCHEDULE L
(Form 990 or 990-EZ)Department of the Treasury
Internal Revenue Service

Name of the organization

Transactions With Interested Persons

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V, line 38a or 40b.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No 1545-0047

2017Open To Public
Inspection

Employer identification number

13-5644916

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Part I Excess Benefit Transactions (section 501(c)(3), section 501(c)(4), and 501(c)(29) organizations only).

Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.

1	(a) Name of disqualified person	(b) Relationship between disqualified person and organization	(c) Description of transaction	(d) Corrected?	
				Yes	No
(1)					
(2)					
(3)					
(4)					
(5)					
(6)					

2 Enter the amount of tax incurred by the organization managers or disqualified persons during the year under section 4958 ▶ \$

3 Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ▶ \$

Part II Loans to and/or From Interested Persons.

Complete if the organization answered "Yes" on Form 990-EZ, Part V, line 38a or Form 990, Part IV, line 26, or if the organization reported an amount on Form 990, Part X, line 5, 6, or 22.

(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	(d) Loan to or from the org?		(e) Original principal amount	(f) Balance due	(g) In default?		(h) Approved by board or committee?		(i) Written agreement?	
			To	From			Yes	No	Yes	No	Yes	No
(1)												
(2)												
(3)												
(4)												
(5)												
(6)												
(7)												
(8)												
(9)												
(10)												

Total ▶ \$

Part III Grants or Assistance Benefiting Interested Persons.

Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of assistance	(d) Type of assistance	(e) Purpose of assistance
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				
(7)				
(8)				
(9)				
(10)				

**SCHEDULE M
(Form 990)**Department of the Treasury
Internal Revenue Service

Name of the organization

Noncash Contributions

- ▶ Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
 ▶ Attach to Form 990.
 ▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open To Public
Inspection****THE LEUKEMIA & LYMPHOMA SOCIETY, INC**

Employer identification number

13-5644916**Part I Types of Property**

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art — Works of art				
2 Art — Historical treasures				
3 Art — Fractional interests				
4 Books and publications				
5 Clothing and household goods				
6 Cars and other vehicles				
7 Boats and planes				
8 Intellectual property				
9 Securities — Publicly traded	X	312	3,082,490	Market Value
10 Securities — Closely held stock				
11 Securities — Partnership, LLC, or trust interests				
12 Securities — Miscellaneous				
13 Qualified conservation contribution — Historic structures				
14 Qualified conservation contribution — Other				
15 Real estate — Residential				
16 Real estate — Commercial				
17 Real estate — Other				
18 Collectibles				
19 Food inventory	X	114		
20 Drugs and medical supplies				
21 Taxidermy				
22 Historical artifacts				
23 Scientific specimens				
24 Archeological artifacts				
25 Other ▶ (Printed Items)	X	30		
26 Other ▶ (Various)	X	80	1,483,566	
27 Other ▶ ()				
28 Other ▶ ()				
29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part IV, Donee Acknowledgement			29	0

- 30a During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period?
- b If "Yes," describe the arrangement in Part II.
- 31 Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?
- 32a Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions?
- b If "Yes," describe in Part II.
- 33 If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.

	Yes	No
30a		X
31	X	
32a		X

SCHEDULE O
(Form 990 or 990-EZ)Department of the Treasury
Internal Revenue Service**Supplemental Information to Form 990 or 990-EZ**Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.

▶ Attach to Form 990 or 990-EZ.

▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection**

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

Employer identification number

13-5644916**Form 990, Part III, Line 4a - First Accomplishment**

We will continue to support research through our innovative and integrated funding programs, until every patient has a safe and effective therapy. In fiscal year 2018, LLS supported research in the U.S., Canada and 7 other countries with a total research disbursement of approximately \$47 million. Research funding was distributed across all blood cancers.

Beat AML Master Trial

Beginning November 2016, LLS launched the Beat AML Master Trial, a collaborative clinical trial testing several novel targeted therapies for patients with acute myeloid leukemia (AML) designed to facilitate FDA approval of new drugs and change the treatment paradigm for patients diagnosed with AML by developing more individualized, effective treatment approaches. The Master Trial involves collaborations with multiple medical institutions, drug companies, a genomic provider, a clinical research organization, and the FDA, all of whom have committed to working collaboratively. LLS expects up to 500 patients to enroll in the trial.

OUR CRITICAL ROLE

LLS programs accelerate relevant research outcomes by:

- Building a focused research work-force: Assuring the next round of breakthroughs requires that young investigators be encouraged to work in blood cancer research fields.
- Turning discoveries into new therapies: Fundamental new findings can be translated into safe and effective treatments that can ultimately prolong

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

cancer cells versus normal cells. Many of these new treatments benefit not only blood cancer patients, but also patients with other diseases. For example:

- Gleevec® is FDA-approved for patients of all ages with chronic myeloid leukemia (CML), and is also approved for patients with one form of acute lymphoid leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative disorders and rare forms of stomach and skin cancers. Related drugs, Sprycel® and Tasigna®, are approved for patients who do not benefit from Gleevec. One or more of these drugs are also showing promise for patients with various lymphomas, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other cancers, including brain, breast, head-and-neck, lung, pancreatic, and prostate cancers, and patients with other diseases including Alzheimer's, asthma and pulmonary hypertension.
- Rituxan® was the first FDA-approved, anti-cancer antibody drug, developed for patients with forms of B-cell non-Hodgkin lymphoma (NHL). It is now also approved for CLL patients and as a "maintenance" therapy for follicular lymphoma patients, and showing promise for patients with ALL and after stem cell transplantation. In addition, it is approved for treating patients with severe rheumatoid arthritis and two other types of autoimmune diseases. A related antibody drug, Arzerra®, is approved for CLL patients and showing wider promise.
- Velcade®, Thalidomid® and Revlimid® are FDA-approved for patients with myeloma and are also helping some patients with Hodgkin lymphoma and NHL. Krypoxis® was recently approved for myeloma patients for whom at least two prior therapies were insufficient. One or more of these drugs are now being tested for patients with T-cell and B-cell forms of lymphoma, acute leukemias, as well as AIDS-related Kaposi sarcoma and brain, breast,

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

least one prior treatment. Additionally, it received further expansion to treat 17p deletion in CLL with or without prior therapy.

- Zydelig® is an oral small molecule inhibitor that blocks the delta isoform of the enzyme phosphoinositide 3-kinase. It was approved by the FDA in July 2014 to treat relapsed/refractory CLL in combination with rituxan. It was also approved to use as a monotherapy for relapsed mantle cell lymphoma and follicular lymphoma.

OTHER ACTIVE RESEARCH DIRECTIONS

LLS-funded researchers are also exploring other areas of research that hold promise for patients:

- Novel Stem Cell Transplantation Procedures: These include so-called "mini" transplants that use less toxic pre-transplant treatments and engineered donor cells that help reduce post-transplant complications, making these potentially curative treatments available to more patients.
- Immunotherapies: Including antibodies, vaccines and engineered immune cells, these targeted therapies help a patient's immune system fight infections and kill residual cancer cells, prolonging remissions, and perhaps one day replacing toxic chemotherapies.
- Diagnostics: New technologies make it possible to characterize the abnormalities in individual cancer cases in molecular detail. This information can be used to help choose the best possible treatment for each patient, especially as more targeted therapies become available.
- Quality of Life Research: These studies increase our understanding of how specific treatments can cause debilitating side-effects, including late-effects, and which patients are at risk for developing these complications, so that they can be better managed or even prevented.

Schedule O (Form 990 or 990-EZ) (2017)

Page 2

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

- The Academic Concierge Division identifies especially promising LLS-funded grant projects and supports further development to gain clinical proof of concept.
- The Biotechnology Accelerator Division partners LLS with companies to combine scientific and financial resources and accelerate the development of potential blood cancer therapies that otherwise might not be prioritized by the company.
- The Clinical Trials Division brings clinical trials to blood cancer patients in their communities, including under-represented populations, and with the ultimate goal of increasing patient enrollment in blood cancer trials.

Form 990, Part III, Line 4b - Second Accomplishment

provided by professionals or rigorously trained peer volunteers. All resources are provided through a variety of media - print, online, by phone, and face-to-face in communities. A number of resources are available in Spanish for patients, caregivers and healthcare professionals.

Print Publications:

An extensive catalog of education materials is offered free-of-charge to patients and healthcare professionals. Each year, LLS distributes disease and support booklets and fact sheets through the Information Resource Center, LLS website and LLS chapters. Each year, LLS publishes an annual compilation of data available for blood cancers, including the estimated numbers of new blood cancer cases and deaths, the most recent statistics available for incidence, mortality and survival. In 2018, 621,651 free printed disease and support booklets and 7,449 fact sheets were ordered.

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

qualifying blood cancer patients with travel and lodging expenses related to treating their blood cancer diagnosis. Travel Assistance is subject to funding availability.

In 2018, \$2,007,419 was provided to patients through the LLS Susan Lang Travel Program 4,772 patients received LLS Travel Assistance in 2018.

Community Programs

Services are provided in communities to patients and their families, caregivers and healthcare professionals by Patient Access staff and trained volunteers who have specific support and outreach roles. Staff are healthcare and allied healthcare professionals, often with a background in oncology nursing, public health or social work; volunteers are typically patients or caregivers who undergo rigorous background checks and training.

Staff and volunteers serve as liaisons with community and regional oncology/hematology healthcare professionals and treatment centers, and provide community-based outreach, education, and support in a variety of forms.

Regional Blood Cancer Conferences:

LLS works to elevate our visibility in communities we serve by hosting larger-scale conferences, geared for patients, caregivers and healthcare professionals. These events are a catalyst for bringing many dedicated people together to focus on blood cancer awareness, information and the latest advances in medical science. They are designed for patients and caregivers but are attended by some local healthcare professionals (nurses and social workers) as well. In 2018, 10 BCC conferences were held with 3,220 attendees.

Schedule O (Form 990 or 990-EZ) (2017)

Page 2

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

individuals participated in these chats.

Patti Robinson Kaufmann First Connection Program:

First Connection is a program that links newly diagnosed patients and caregivers to a peer volunteer who has experienced a similar diagnosis. A trained patient/caregiver- volunteer currently in remission contacts the patient/caregiver to share information and support. This program is available through LLS chapters; referral is also provided by LLS's Information Resource Center.

-Over 1,300 First Connections were made across the US in FY 2018.

Form 990, Part III, Line 4c - Third Accomplishment

caregivers with comprehensive navigation to find and enroll in an appropriate clinical trial. As part of this process, the nurses work closely with Information Specialists to address resource barriers to clinical trial enrollment.

Patients, families and healthcare professionals may speak to an Information Specialist at (800) 955-4572 Monday through Friday, 9 a.m. to 9 p.m., ET, email infocenter@LLS.org or chat one-on-one via the LLS website. The Information Resource Center

offers translation services in more than 165 languages.

In FY 2018:

- 18,453 inquiries were made to our Information Specialists.

- 12,643 households received information and/or support from Information Specialists via emails, phone, and answer chats.

- 562 patients worked with a nurse in the Clinical Trial Support Center to receive comprehensive assistance with clinical trial enrollment; over 60%

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

experts. Upcoming and archived programs are posted at www.LLS.org/webcasts.

In FY 2018:

-LLS conducted 16 live national telephone-web education programs, with 5,572 participants

-There were 29,756 page views for archived web programs; 12,004 virtual lecture views; 6,801 podcast downloads; and 32,708 video views.

-LLS launched a new podcast, "The Bloodline with LLS," which reached more than 7,000 listeners and covered a range of topics that matter most to patients and caregivers, from cancer-related fatigue to communicating effectively with cancer care teams.

Form 990, Part III, Line 4d - All Other Accomplishment

D) PROFESSIONAL EDUCATION:

LLS serves the educational needs of the medical and research community through a number of professional education symposia offered throughout the year. The educational program offers varying formats to facilitate the exchange of information and ideas on the newest developments in cancer research and treatment. Upcoming and archived CE/CME programs are available at www.LLS.org/CE.

In FY 2018:

-LLS provided 11 CME/CE-granting in-person educational programs, with 1,981 healthcare professionals in attendance.

--There were 18,503 page views for archived web programs; 12,919 virtual lecture views; and 3,775 online video views for professionals.

Form 990, Part V, Line 4b - Financial Accounts in Foreign Countries

Canada

Name of the organization

Employer identification number

THE LEUKEMIA & LYMPHOMA SOCIETY, INC

13-5644916

basis and submit a signed form acknowledging that they have reviewed the policy and disclosed any conflicts of interest.

All forms are collected and the audit committee reviews any forms disclosing a possible conflict of interest and determines whether or not a conflict exists.

Part VI, Line 12 C:

All employees, Board of Directors members, Board of Representatives are recused from any discussion where a Conflict of Interest exists. Any questions regarding COI will go to the Audit Committee.

Form 990, Part VI, Line 15a - Compensation Process for Top Official

The Executive Committee comprised of independent members of the Board of Directors reviews, monitors, and approves the Chief Executive Officer's performance and compensation.

In 2018 the Executive Committee, through an independent third party, obtained a market study comprised of similar not-for-profit organizations to review their compensation market levels and set the Chief Executive's salary commensurately. The committee met, approved and documented the process in the Committee minutes.

Form 990, Part VI, Line 15b - Compensation Process for Officers

In 2018, the Executive Committee, through an independent third party, obtained a market study comprised of similar not-for-profit organizations to review the compensation market levels of other officers and Key Employees and to approve the President and CEO's recommendations on their compensation levels.

**SCHEDULE R
(Form 990)**Department of the Treasury
Internal Revenue Service
Name of the organization**Related Organizations and Unrelated Partnerships**▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
▶ Attach to Form 990.▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017**Open to Public
Inspection**Employer identification number
13-5644916**THE LEUKEMIA & LYMPHOMA SOCIETY, INC****Part I Identification of Disregarded Entities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1) BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573	Research	NY	9,963,492	12,544,354	LLS
(2)					
(3)					
(4)					
(5)					

Part II Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?	
						Yes	No
(1) THE LLS RESEARCH PROGRAMS, INC. 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 13-3470494	PART VII	DE	501C3	12a	LLS, INC	X	
(2) THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 13-3709252	PART VII	DE	501C3	12a	LLS, INC	X	
(3) THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8	PART VII	CA			N/A		X
(4) PEARLPOINT CANCER SUPPORT 2817 WEST END AVENUE NASHVILLE TN 37203 58-1747771	PART VII	TN	501C3	7	LLS, INC	X	
(5)							

For Paperwork Reduction Act Notice, see the Instructions for Form 990.
DAA

Schedule R (Form 990) 2017

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?**a** Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity**b** Gift, grant, or capital contribution to related organization(s)**c** Gift, grant, or capital contribution from related organization(s)**d** Loans or loan guarantees to or for related organization(s)**e** Loans or loan guarantees by related organization(s)**f** Dividends from related organization(s)**g** Sale of assets to related organization(s)**h** Purchase of assets from related organization(s)**i** Exchange of assets with related organization(s)**j** Lease of facilities, equipment, or other assets to related organization(s)**k** Lease of facilities, equipment, or other assets from related organization(s)**l** Performance of services or membership or fundraising solicitations for related organization(s)**m** Performance of services or membership or fundraising solicitations by related organization(s)**n** Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)**o** Sharing of paid employees with related organization(s)**p** Reimbursement paid to related organization(s) for expenses**q** Reimbursement paid by related organization(s) for expenses**r** Other transfer of cash or property to related organization(s)**s** Other transfer of cash or property from related organization(s)

	Yes	No
1a		X
1b		X
1c		X
1d		X
1e		X
1f		X
1g		X
1h		X
1i		X
1j		X
1k		X
1l	X	
1m		X
1n		X
1o	X	
1p		X
1q	X	
1r		X
1s		X

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (1a-1s)	(c) Amount involved	(d) Method of determining amount involved
(1) The LLS of Canada	q	260,005	COST
(2) PEARLPOINT CANCER SUPPORT	l	70,000	COST
(3) PEARLPOINT CANCER SUPPORT	o	90,967	COST
(4)			
(5)			
(6)			

Part VII Supplemental Information.

Provide additional information for responses to questions on Schedule R. See Instructions.

Schedule R - Group Exemption Relationships

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY
ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA.

THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH
FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY,
INC.

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IS THE 100% CONTROLLING MEMBER OF
PEARLPOINT CANCER SUPPORT, INC.